Apparatus and method for simulating inhalation efforts

Description

TECHNICAL FIELD

Described herein are an interactive apparatus and methods for recording, transferring and displaying key physical measurements based on physiological conditions generated by a subject during an inhalation maneuver, for instance, in real-time. In particular, the apparatus can be used alone and/or combined with an inhalation simulation system which can record and reproduce, or simulate a patient inhalation effort.

BACKGROUND

Inhaler devices for dispensing therapeutic substances via the respiratory tract, in particular, for pulmonary delivery in treating local or systemic diseases are commercially available. For example, nebulizers, devices containing propellants, and dry powder inhalers have been used for the treatment of diseases, such as asthma, respiratory tract infections and systemic disease such as diabetes.

The efficiency of delivering a required dosage of a therapeutic substance to a patient in treating a disease depends on the efficiency of the device, and overall delivery can be enhanced by providing proper feedback mechanisms to a patient during use of the device to teach, for example, proper inhalation techniques to a patient. Improper use of the devices and poor inhalation techniques can lead to lack of efficacy in treating a disease, for example, by administering lower dosages of a therapeutic substance than intended or higher dosages of a therapeutic substance which can be harmful to a patient. To effectively deliver therapeutic substances to the respiratory tract, a patient or user can be trained or coached to use the device in an appropriate manner.

Dry powder inhalers used to deliver medicaments to the lungs contain a dosing system for a powder formulation usually either in bulk supply or quantified into individual doses stored in unit dose compartments, like hard gelatin capsules, cartridges, or blister packs. Dosing reproducibility requires that the drug formulation is uniform and that the dose can be delivered to the patient with consistent and reproducible results. Therefore, dosing can be improved by optimizing discharge of a formulation, which is effectuated, for example, by having patients perform proper inhalation maneuvers.

Devices for training patients to properly deliver therapeutic substances by the pulmonary tract are described, for example, in U.S. Pat. No. 5,333,106, which discloses an apparatus for interactive training of a patient in use of an aerosol inhaler, including a feedback display based upon air flow versus volume data using a proper sequence of inhalation steps. Further, U.S. patent application Ser. No. 10/759,859 (Publication No. US 2004/0187869) discloses a training device for medicament inhalers, for example, dry powder inhalers, which is based on measuring pressure differential and displaying a single value corresponding to both inhalation rapidity and inhalation flow rate peak, and includes a dry powder inhaler simulator.

Dry powder inhaler and cartridge systems such as those describe in U.S. Pat. Nos. 7,305,986 and 7,464,706, the disclosures of which are incorporated herein by reference in their entirety for all they teach regarding dry powder inhalers, can generate primary drug particles or suitable inhalation plumes during an inspiratory maneuver by deagglomerating a powder formulation within the inhaler and capsule or cartridge. The benefits of delivering drugs via pulmonary circulation are numerous including rapid entry into arterial circulation, avoidance of first pass drug degradation by liver metabolism, and ease of use, for example, lack of discomfort compared to other routes of administration such as by injection. These devices have been in use in clinical settings and patients have been properly trained on the use of such inhalers.

There is a need in the art for improvements in design and manufacture of a device for training subjects in proper use of an inhalation system; monitoring patients during use of an inhalation system, monitoring the performance of an inhalation system, such as presence of leakage or defects, and capable of being coupled to a system for reproducing a patient's inhalation profile. The present disclosure presents apparatus and methods to achieve these goals.

SUMMARY

Described herein are apparatus for measuring key inspiratory characteristic parameters during use of an inhalation system. The apparatus and methods for using the apparatus can be useful, for example, in training and/or monitoring a subject requiring the use of an inhaler, for example, a high resistance, dry powder inhaler system for delivery of pharmaceuticals, active ingredients or medicaments to the lungs and pulmonary circulation. The apparatus can simultaneously measure and replicate the parameters of a patient's inhalation profile, or store the inhalation profile obtained and replicate the stored information at a later time.

Exemplary embodiments of the inhalation systems disclosed herein comprise a display means for visual cues to facilitate training and/or monitoring a subject in achieving an optimal or appropriate inspiratory or inhalation maneuver for the effective delivery of a therapy via the respiratory system. The system facilitates the training of subjects for the proper use of an inhalation device in order to achieve a preferred flow rate and/or pressure drop profiles for that individual so that maximal delivery of a medicament can be attained. The devices and methods can also be used to monitor inhalation systems performance, for example, detection of the dose being delivered; quantification of the drug being delivered, duration of discharge of a dose being delivered; number of doses administered to the subject, and to monitor the mechanical integrity of the inhalation system.

In an exemplary embodiment, the apparatus can perform interactively, for example, the apparatus comprises a wireless communication interface allowing remote acquisition of data, which can be sent to a computer/microprocessor based-system providing an interactive display of data, storage of data and/or web-based transfer of information. Alternatively, other exemplary embodiments can comprise a wired communication interface.

In one exemplary embodiment, the apparatus or device can be adapted, for example, to a high resistance dry powder inhalation system, such as those described in U.S. Pat. Nos. 7,305,986 and 7,464,706, and U.S. patent application Ser. Nos. 12/413,405 and 12/484,125; the disclosures all of which are incorporated herein by reference in their entirety for all they disclose regarding dry powder inhalers. However, any type of inhaler can be used. The device can comprise an inhaler with or without a cartridge containing a pharmaceutical formulation, one or more transducers including, electrical, electronic, electro-mechanical, electromagnetic, photonic or photovoltaic; such as pressure sensors, temperature sensors, electroacoustic or sound sensors, and optical sensors; a signal conditioning circuitry and/or a software program, a means for electronic signal communication and an output display. In such an exemplary embodiment, the apparatus can be used with an analog or digital sensor, appropriate signal conditioners such as amplification, signal filtering, analog to digital conversion, a microprocessor for onboard processing, a wireless communicator in communication with a remote computer or personal data assistant (PDA) for subsequent signal processing and/or real-time output display. The device can be used to deliver pharmaceutical compositions housed in pre-metered unit dose cartridges containing an active ingredient for delivering to the pulmonary circulation. In alternative exemplary embodiments, the sensing and monitoring device can be adapted onto or within an inhalation system comprising a dry powder inhaler with a cartridge that can be empty, or can contain a dry powder suitable for pulmonary delivery.

In one embodiment, the apparatus can be used to deliver the measured parameters to a system which recreates a patient's measured profile and which system can recreate or simulate a patient's inhalation maneuver at the same time as the patient inhales or at a later time. In this embodiment, the simulation inhalation system includes a computer with a microprocessor and a set of machine-readable instructions that are executable by a processing device to implement an algorithm, wherein the algorithm comprises instructions for manipulating the data including the steps of: receiving the data from at least one sensor; filtering the data; transforming the data; analyzing the data; and displaying a patient's stored information profile. In a particular embodiment, the algorithm activates the motor controller to actuate a syringe pump creating a vacuum thereby simulating a subject's inhalation. In one embodiment, the apparatus for reproducing a patient's inhalation profiles comprises a closed loop system that automatically produces pressure drop, volume and flow measurements in a controlled chamber, which resultant pressure drop and flow rate produced evacuates a powder contained in an inhaler adapted to the system using an anatomical model having an artificial substantially accurate upper respiratory tract or airway. In one embodiment, the apparatus can replicate previously measured inhalation profiles from a subject enabling characterization of inhalation parameters, including, peak inspiratory pressure, pressure increase rate or speed at which the pressure is changing, volume, and time to peak pressure or flow rate.

Dry powders comprising microparticles suitable for pulmonary delivery are well known in the art including, for example, those disclosed in U.S. Pat. Nos. 6,428,771 and 6,071,497, the disclosures of which are incorporated herein by reference in their entirety for all they disclose regarding microparticles. In respective exemplary embodiments, the dry powders, the active ingredient can be a protein, a peptide, or a polypeptide and combinations thereof, for example, and endocrine hormone such as insulin, glucagon-like peptide-1 (GLP-1), parathyroid hormone or analogs thereof.

In certain embodiments, a dry powder formulation for delivery to the pulmonary circulation comprises an active ingredient or agent, including a peptide, a protein, a hormone, analogs thereof or combinations thereof, wherein the active ingredient is insulin, calcitonin, growth hormone, erythropoietin, granulocyte macrophage colony stimulating factor (GM-CSF), chorionic gonadotropin releasing factor, luteinizing releasing hormone, follicle stimulating hormone (FSH), vasoactive intestinal peptide, parathyroid hormone (including black bear PTH), parathyroid hormone related protein, glucagon-like peptide-1 (GLP-1), exendin, oxyntomodulin, peptide YY, triptans such as sumatriptan, interleukin 2-inducible tyrosine kinase, Bruton's tyrosine kinase (BTK), inositol-requiring kinase 1 (IRE1), or analogs, active fragments, PC-DAC-modified derivatives, or O-glycosylated forms thereof. In particular embodiments, the pharmaceutical composition or dry powder formulation comprises fumaryl diketopiperazine and the active ingredient is one or more selected from insulin, parathyroid hormone 1-34, GLP-1, oxyntomodulin, peptide YY, heparin, PTHrP, analogs thereof and combinations thereof.

In one exemplary embodiment described herein are dry powder inhalers comprising: a sensor in communication with the dry powder inhaler, wherein the sensor can detect at least one signal type, including pressure, temperature, and acoustic or sound signals generated from the dry powder inhalation system, and the sensors can send signals to at least one device for analysis, storage, printing or display, including in real-time. In such an exemplary embodiment, the sensor is configured within the dry powder inhaler or adaptable to the dry powder inhaler and the sensor can be a microphone.

In an exemplary embodiments, the inhalation systems comprise a dry powder inhaler having high resistance to airflow and a resistance value between about 0.065 (√kPa)/liter per minute and about 0.200 (√kPa)/liter per minute. High resistance inhalation systems can be provided with the sensing and monitoring apparatus described herein, although low resistance or other types of inhalers can also be adapted with the present system. In one embodiment, the sensor can detect intrinsic characteristic signals generated by the inhalation system in use. In another exemplary embodiment, the sensor is a sound sensor which includes a sound detecting device or a microphone, configured to transmit the sound signal by wire or wireless communication mode to at least one other device in the system. The sensing and monitoring apparatus for dry powder inhalers described herein can further be associated with an analog to digital converter which communicates at least one signal such as a sound signal to a microprocessor configured to analyze and process the signal. In another exemplary embodiment, at least one device is an analog to digital converter.

In one exemplary embodiment, monitoring systems are described for a dry powder inhaler comprising: a monitoring device comprising at least one sensor; an analog to digital converter; a data storage medium, wherein the data storage medium includes a set of machine-readable instructions that are executable by a processing device to implement an algorithm, wherein the algorithm comprises instructions for manipulating and analyzing data including the steps of: receiving the data from at least one sensor; filtering the data; transforming the data; analyzing the data; and monitoring a patient using the data obtained.

In an exemplary embodiment wherein at least one sensor is a microphone, the monitoring device is provided any place within the inhaler, for example, within the airflow conduits, within the wall of the inhaler, or outside of the inhaler as a separate piece. In another exemplary embodiment, the monitoring device can also be a detachable device that can be configured to be mounted on, or attachable to the inhaler, for example, a jacket or similar structure for adapting dry powder inhaler. In yet another exemplary embodiment, the monitoring device provides a graphical display which is a real-time graphical representation of an inhalation performed by a subject using the device.

In another exemplary embodiment, the signal is an amplitude of sound signal, a frequency of sound signal or combinations thereof. In yet other exemplary embodiments, the sensor further measures at least one sound signal at different frequencies. In another exemplary embodiment, the dry powder inhalers further comprise a cartridge and the cartridge can comprise a dry powder for pulmonary delivery. In one embodiment, the dry powder can comprise, for example diketopiperazine microparticles, including, substituted-diketopiperazine microparticles, for example, fumaryl diketopiperazine, and at least one active ingredient. In still another embodiment, at least one medicament comprises insulin, GLP-1, parathyroid hormone, sumatriptan, calcitonin, analogs thereof, or combinations thereof.

In a further embodiment, the sensing and/or monitoring device is configured to detect signals from a dose being delivered to a subject. In this embodiment, the sensing and monitoring system can detect movement of particles, for example, powder particles within the inhaler and optionally, within a cartridge system in use, from initiation of powder delivery to the end of delivery of the powder particles, wherein the sensor detects variations in the intrinsic characteristics of inhaler sound and powder particles sound emanating from the inhalation system. Data obtained from the detection recordings can be analyzed and correlated to the amount of dose emitted or delivered out of the inhalation system, the time that elapsed for dose delivery, and the performance of the inhalation system.

In another exemplary embodiment, the sensing and monitoring apparatus can be provided as an adaptable, detachable device such as a jacket, saddle, or any structure that can be adapted to an inhaler, including, dry powder inhalers. In this embodiment, the removable device facilitates use of the inhalation system, since the structure or configuration and operation of the inhaler is not modified or compromised. Therefore, the same inhaler can be used without the jacket once the characteristic performance of the inhaler has been determined and the subject can properly use it. In embodiments herein, the sensor, such as a small microphone, can be advantageously placed in any area of the jacket, including, for example, embedded in the wall of the jacket or adaptor, or extending from the walls of the jacket. In this embodiment, the sensing and monitoring apparatus offers greater resolution of sound characteristics emanating from the inhaler and cartridge system in use.

In one exemplary embodiment, methods are described for measuring pressure differential during an inhalation maneuver, the method comprises: providing an inhaler to a subject wherein the inhaler comprises a sensor configured to detect at least one amplitude of sound signal, at least one frequency of sound signal or combinations thereof generated from the inhaler, having the subject inhale for at least one second; analyzing the at least one amplitude of sound signal and said at least one frequency of sound signal, or combinations thereof using an algorithm provided with a microprocessor in a computer system to generate a data set; and displaying, printing, or storing the data set as a function of time and pressure.

In further exemplary embodiments described herein are monitoring systems for use with dry powder inhalers comprising: a monitoring device having at least one sensor; an analog to digital converter; a data storage medium, wherein the data storage medium includes a set of machine-readable instructions that are executable by a processing device to implement an algorithm, the algorithm comprising instructions for manipulating or processing data including the steps of: receiving the data from the at least one sensor during an inhalation by a patient; filtering the data; transforming the data; analyzing the data; displaying the data obtained and monitoring a patient inhalation using the data.

Even further still, in one embodiment described herein are methods for measuring pressure differential during an inhalation maneuver, comprising: providing an inhaler to a subject wherein the inhaler comprises a sensor configured to detect at least one amplitude of sound signal, at least one frequency of sound signal or combinations thereof generated from the inhaler, having the subject inhale for at least one second; analyzing the at least one amplitude of sound signal, the at least one frequency of sound signal, or combinations thereof using an algorithm provided with a computer system to generate a data set; and displaying, printing, or storing the data set as a function of time and pressure.

In other embodiments described herein are interactive dry powder inhalation systems for monitoring an inhalation performed by a user, comprising: a dry powder inhaler comprising a cartridge and having a resistance to flow values between 0.065 (√kPa)/liter per minute and 0.200 (√kPa)/liter per minute; a transducer configured to detect a signal generated from the inhaler in use, and a display device configured to display in real-time an inhalation maneuver performed by a user. In another embodiment, the transducer senses and measures a pressure differential within the inhaler. Further still, the transducer can be a flow meter configured to detect and measure flow rate through air conduits of the dry powder inhaler. The transducer can be, for example, an electroacoustic device such as a microphone configured to detect and measure a sound signal generated from within the inhaler.

In still other embodiments described herein are sensing and monitoring devices for adapting to an inhaler such as a dry powder inhaler, comprising: a detachable device structurally configured to adapt to a dry powder inhaler; the detachable device comprising a microphone for detecting sound generated in the inhaler; and wherein the dry powder inhaler has a resistance to flow value between 0.065 (√kPa)/liter per minute and 0.200 (√kPa)/liter per minute.

Further, in one embodiment, sensing and monitoring devices are described for a dry powder inhalation system, wherein the dry powder inhalation system comprises a dry powder inhaler and a cartridge, and the sensing and monitoring device comprises a microphone configured to detect sound signals generated from a dry powder formulation emitted from the dry powder inhalation system.

In another embodiment, the sensing and monitoring devices described herein are combined with a simulating module that can generate a pressure differential such as a syringe pump, in a closed loop system. The simulating module can communicate via signals with a computer having a microprocessor with instructions for regulating or controlling the syringe pump to generate or create a desired vacuum or pressure drop to recreate a person's inhalation profile for a predetermined time of inhalation execution. In this embodiment, inhalation profiles obtained from a subject can be stored by the system and recreated or simulated in vitro to assess and determine the subject's effort needed to deliver a required dose with an inhaler. In this embodiment and other embodiments, the simulating module further comprises a substantially accurate anatomical head configured to have a mouth configured to receive an inhaler and has a substantially accurate model of a respiratory tract, for example, the benhead, which is configured to be adaptable and attachable to a connecting structure, including a cylinder or tube connected to a syringe pump. In this and other embodiments, the substantially accurate anatomical head can further be configured to adapt an artificial lungs device or a filtration device for trapping a powder dose during use of the simulating module.

In an exemplary embodiment, a dry powder inhalation simulation system is provided comprising: a dry powder inhaler; a sensor in communication with the dry powder inhaler; the sensor is configured to detect at least one type of signal generated from the powder inhaler and transmit at least one type of signal to at least one device for analysis, storage, printing and/or display; an artificial anatomical head comprising a substantially accurate upper respiratory tract including a mouth; a calibration syringe pump; a power supply; a computer comprising a microprocessor, an algorithm and a display monitor.

A method for simulating an inhalation maneuver by a subject is also provided, comprising providing a subject with a first inhaler adapted with a wireless or wired first sensor and a first radio transmitter; having the subject inhale through the first inhaler to produce a pressure differential through the first inhaler or an inhalation; wherein the subject can be positioned nearby an inhalation simulation apparatus comprising a computer with a microprocessor comprising a signal receiver and an algorithm configured to analyze and process the signal produced from the first sensor and generate a set of data that can be stored and/or simultaneously used by the computer; a motor controller, a motor, a vacuum source such as a calibrated syringe pump, and an artificial substantially accurate anatomical upper respiratory airway, and a second inhaler comprises a wired or wireless second sensor, a second radio transmitter and optionally, a dry powder formulation; collecting at least one type of signal from flow generated in the first inhaler; converting the signal to a set of data from the subject's inhalation provided by the first sensor in the computer or microprocessor with the algorithm; and generating a second set of signals in the computer to instruct the controller to activate the motor to move the syringe pump to generate a pressure differential equal to the pressure differential generated by the subject's inhalation.

In other embodiments, the simulation system is provided with an inhaler of the same type provided to a subject and comprising a sensor adapted to the inhaler and a powder formulation comprising a drug; wherein the inhaler is adapted to the artificial substantially accurate anatomical upper respiratory airway and configured to deliver the powder formulation to the artificial substantially accurate anatomical upper respiratory airway which can be connected to a clear, see through cylinder for assessing or determining the powder properties delivered by the inhaler prior to dosing a subject with the inhaler. In this manner, inhaler delivery efficiency can be assessed for individual subjects.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates an isometric view of the right side of an embodiment of a dry powder inhaler training apparatus.

FIG. 2 illustrates an isometric view of the left side of the embodiment of FIG. 1, wherein part of the housing has been removed to show internal component parts of the dry powder inhaler training device.

FIG. 3 illustrates a back view of the embodiment of FIG. 1.

FIG. 4 illustrates an isometric view of the right side of the embodiment of FIG. 1 with the device cover removed to show additional component parts in the interior of the device.

FIG. 5 illustrates a block diagram of the overall training system disclosed herein.

FIG. 6 graphically illustrates an inhalation maneuver performed by a subject without coaching.

FIG. 7 graphically illustrates an inhalation maneuver performed by a subject only coached to take a deep breath.

FIG. 8 graphically illustrates an inhalation maneuver performed by a subject properly trained to use a dry powder inhaler using the training device.

FIGS. 9A and 9B illustrate isometric views of an alternate embodiment of an inhaler with (9B) and without (9A) an integrated sensing and monitoring device.

FIG. 10 illustrates an isometric view of yet an alternate embodiment of a sensing and/or monitoring device provided as part of a jacket adapted to a dry powder inhaler.

FIG. 11 illustrates an isometric view of the sensing and/or monitoring device illustrated in FIG. 10, wherein a dry powder inhaler system is depicted in an open configuration.

FIG. 12 illustrates a back view of the sensing and/or monitor device shown mounted onto a dry powder inhaler as shown in FIGS. 10 and 11.

FIG. 13 illustrates a bottom view of the sensing and/or monitor device illustrated in FIG. 12.

FIG. 14 illustrates a side view of a dry powder inhaler in cross-section through its mid-longitudinal line with a cartridge in place and equipped with a sensing and/or monitoring device.

FIG. 15 illustrates a proximal view of a dry powder inhaler equipped with a sensing and/or monitoring device.

FIG. 16 illustrates an isometric view of the embodiment of the sensing and/or monitoring device depicted in FIGS. 10-15.

FIG. 17 illustrates an isometric view of an alternate embodiment of a sensing and/or monitoring device for adapting to a dry powder inhaler.

FIG. 18 illustrates a block diagram of the overall exemplary sensing and/or monitoring system disclosed herein.

FIG. 19 graphically illustrates an inhalation maneuver performed by a subject trained to take a deep breath and illustrating profiles with and without a dry powder dose tested at the same pressure differential.

FIG. 20 graphically illustrates an alternate embodiment of a dry powder inhaler training or monitoring and sensing apparatus used in combination with a system for reproducing or simulating a patient's inhalation maneuver.

FIG. 21 illustrates a block diagram of the overall exemplary sensing and/or monitoring device combined with the inhalation simulator system disclosed herein.

FIG. 22 graphically illustrates an inhalation maneuver performed by a subject (A) using a dry powder inhaler adapted with a sensing and monitoring device as described herein, the graph also illustrates the subject's maneuver recreated by the inhalation stimulation device (B) in real-time.

DETAILED DESCRIPTION

Disclosed herein are inhalation simulation systems and methods for using the systems for various applications. In an exemplary embodiment, the inhalation simulation system is a closed loop system comprising two components: a first component comprising an inhalation apparatus comprising an inhaler, and an interactive system which measures or monitors changes in pressure or pressure drop and/or flow rate characteristics from a subject during an inhalation maneuver, and a second component, which receives and converts the information such as an inhalation profile obtained from a subject's inhalation using the first component data, and recreates the information to replicate the patient inhalation in vitro.

In particular embodiments described herein, the first inhalation apparatus comprises and inhaler and an interactive system configured to detect or sense, and output information obtained during an inhalation in real-time or substantially instantaneously as the subject inhales, which information or data can be stored and/or displayed simultaneously as the information is obtained. The inhalation apparatus can be used for training a subject to maximize efficiency of their respiratory maneuvers in conjunction with an inhalation device, and can also be used for monitoring inhalation during delivery of a medicament to detect proper dose delivery, timing of dose delivery and proper performance of the inhaler in use. In one exemplary embodiment, the sensing and monitoring apparatus can be used with any inhaler type. However, in particular embodiments describe herein, the system can be applied in conjunction with a high resistance inhaler, including dry powder inhalers.

The inhalation apparatus comprises a transducer or sensor which can convert at least one measurand, including, pressure, air flow, air volume, humidity, and temperature, to an electrical signal. The device further includes appropriate signal conditioning circuitry, such as signal filtering, amplification and analog to digital conversion, and processing circuitry such as a microprocessor, wired or wireless communication interface and the like to transfer the generated signal in real-time to a receiving computer or personal data assistant (PDA) for display of the signal. In one embodiment, the output display can be an interactive display so that the display device provides a visual aid for teaching a subject to perform repeatable inhalation maneuvers in real-time, thereby facilitating proper inhalation delivery of medicament. In another exemplary embodiment, the data can be stored to be analyzed at a later time, or used in other applications.

In one embodiment, the sensing and monitoring can be adapted to transmit signals to or communicate with an inhalation simulating device comprising a chamber, a vacuum source such as a syringe pump or piston driven device which can generate pressure differentials and/or flow rates through the chamber. The syringe pump can comprise a microprocessor which can be actuated by signals from a computer which can be transmitted wireless or wired to a controller. Computer signals can be generated from a subject's inhalation profile which is being analyzed by an algorithm simultaneously during an inhalation maneuver, or from information obtained from a subject's inhalation profile stored in the computer system components.

FIGS. 1 through 4 illustrate an exemplary inhalation apparatus comprising a dry powder inhaler training device. The training device describe herein comprises an interactive system adapted to a high resistance dry powder inhaler as disclosed in U.S. Pat. Nos. 7,305,986 and 7,464,706, U.S. patent application Ser. No. 11/934,643 (US 2008/0053437), Ser. No. 11/949,707 (US 2008/0127970), Ser. No. 12/102,625; and other high resistance dry powder inhalers are disclosed in U.S. patent application Ser. Nos. 12/413,405; 12/484,125, the disclosures each of which are incorporated herein by reference herein for all they disclose regarding dry powder inhalers.

Training device 100 comprises activator button 102, housing 104, mouthpiece 106, mixing section 108, a cap or lid 110 over mixing section 108, air inlet port 112 and air outlet port 114. An air conduit is established between air inlet port 112 and air outlet port 114. FIG. 2 illustrates training device 100 with left panel (not shown) of housing 104 removed showing the position of signal processing/interface board 116 and sensor 118 within housing 104. FIG. 3 illustrates a back view of training device 100 showing housing 104 having a compartment with cover 120 on the right side for accommodating a power source.

In one exemplary embodiment, sensor 118, in an analogue form, is placed within housing 104 and detects pressure differential from training device 100 when training device 100 is turned on by depressing activator button 102 which is connected to a power source, such battery 122 illustrated in FIG. 4, that also provides power to the system. Sensor 118 can be placed at any point within the air conduit of training device 100. In some exemplary embodiments, sensor 118 can be placed in the air conduit within housing 104. In other exemplary embodiments, sensor 118 can be placed within the mixing chamber (not shown) or the air conduit of mouthpiece 106.

FIG. 5 illustrates a block diagram for an inhalation apparatus, such as training device 100, showing its various operational component parts. In FIG. 5, system 500 comprises two components, inhaler training device 502 and processing system 504. Processing system 504 can include a PDA or computer 506, display 508, wireless communicator 510 and output 512 which can be in the form of digital storage, a web interface, a print out or the like. In this exemplary embodiment, a user can activate inhaler training device 502 by depressing a power button, for example button 102 on training device 100, with processing system 504 also activated. When the software program integrated with computer 506 is ready, a start signal appears on display 508. With the system activated, inhalation 514 generates a pressure drop in inhaler training device 502 which is transduced to an electrical signal by sensor 118. In this embodiment, the sensor 118 can be a pressure, flow, sound, optical, gas, humidity, or temperature transducer that is either analogue or digital. Electrical signal 516 from sensor 118 is then transmitted to signal conditioner 518 to remove unwanted signals, such as signal noise. Conditioned electrical signal 520 is then transmitted to signal amplifier 522 wherein conditioned electrical signal 518 can be amplified to a predetermined voltage range, and transmitted as amplified signal 524. Amplified signal 524 is then converted to digital signal 526 through analog to digital converter 528. Digital signal 526 then passes through microprocessor 530 and into second wireless communicator 532 through connection 534 for transmission to computer 506, having wireless communicator 510 for receiving wireless signal 536. A software program built into/programmed into microprocessor 530 or computer 506 converts electrical signal 516 to a pressure value which can be displayed graphically. In certain embodiments, a baseline curve for inhaler training device 502 is provided as a reference standard to guide the user's inhalation maneuver. Therefore, during an inhalation, a user can visually compare his/her inhalation maneuver to the baseline standard. In this manner, the user can alter his/her inhalation effort to conform to the requirements of the standard. The displayed data for each inhalation performed by a subject can be saved via second connection 538 to output 512 wherein the data can be stored or transferred accordingly. For example, output 512 can be in the form of a flash drive or printer, or transmitted via email to a physician for review or further training as needed. In one embodiment, signals from the inhalation training device can be transmitted to the computer/PDA and signals from the computer/PDA can be received by the inhalation training device, thereby establishing a two way communication between the two components.

Further, other on-board devices 540 can send and receive data from microprocessor 530 through one or more cable 542. For example, other on-board devices can include digital output sensors, temperature sensors, light emitting diodes (LEDs), sound warning devices, and other on-board sensors.

Other configurations of block diagram 500 can also be configured, for example, following the signal amplification amplified signal 524 can be directly sent to computer 506 via second wireless communicator 532 and the computer can do the analog to digital conversion and other required analysis steps.

Exemplary data from training sessions with a subject are illustrated in FIGS. 6 through 8. Each figure depicts a graph (600, 700, 800) of data displayed by the training systems described herein after an inhalation maneuver. The graphs are plotted as pressure in kilopascals (kPa) on the y-axis and time in milliseconds on the x-axis. A baseline inhalation performance standard for training device 100 is shown as region 602 which is bordered by a warning region 604 and an acceptable or preferred region 606. Regions 602, 604 and 606 can be provided in different colors facilitating discernment of regions in monitoring an individual's performance during an inhalation. Region 602 can be, for example, depicted in red, indicating that the inhalation maneuver did not meet the baseline requirement. Therefore, the delivery system would not be optimal to deliver a medicament effectively. Warning region 604 can be depicted in yellow indicating a warning that the inhalation maneuver is nearing the unacceptable performance effort. Preferred region 606 can be depicted in green indicating that the inhalation performance is in the acceptable efforts to effectively deliver a medicament.

FIG. 6 graphically illustrates an example of an inhalation maneuver performed by a subject who has received no training and is not allowed to see the screen display of the computer during the inhalation maneuver. The results of this inhalation are plotted as curve 608. As graphically illustrated in FIG. 6, the inhalation effort by the subject falls in the unacceptable region 602 during the entire inhalation procedure.

FIG. 7 graphically illustrates results of an inhalation maneuver of a subject who has received some guidance on the use of a device and is allowed to look at a computer screen displaying the inhalation effort during the maneuver. In this maneuver and as shown by curve 610, the subject inhaled for an acceptable period of time, as indicated by end point 612 falling within preferred region 606, but did not inhale quickly enough or with enough effort to attain acceptable values, as indicated by regions 614 and 616 which fall within region 602.

FIG. 8 graphically illustrates an example of an inhalation maneuver performed by a subject who has received complete training and is allowed to see the display screen on a computer while performing the inhalation. As can be seen by curve 618, the subject performed entirely within acceptable values in region 606.

The graphs illustrated in FIGS. 6-9 and 19 can be incorporated into a computer program and captured as a screenshot therefrom. Other features of the devices and systems described herein can be controlled using a computer or microprocessor and visualized through an onscreen display.

In some exemplary embodiments disclosed herein, one or more key parameters can define an acceptable inhalation maneuver, including, total inhalation time, peak inspiratory pressure, time to peak inspiratory pressure and average pressure from peak to about 75% of the total inhalation time. In certain embodiments, the total inhalation time can be greater than 5 seconds, the peak inspiratory pressure can be greater than about 6 kPa, time to peak inspiratory pressure can be less than about 1.1 seconds and the average pressure from peak inhalation to 75% of total inhalation time is about 4 kPa. These values are representative of values for training device 100, and can be modified for alternate inhaler training devices, depending on the performance parameters required for optimal delivery of the medicament of the inhaler, including resistance.

In another exemplary embodiment illustrated in FIGS. 9A and B, dry powder inhaler 900 can be provided with a sensing and/or monitoring device 902 which can monitor and/or sense signals generated by or within dry powder inhaler 900 during an inhalation maneuver by a patient. FIG. 9A illustrates dry powder inhaler 900 without a sensor device either integrated into the device or attached thereto. Alternatively, in an exemplary embodiment depicted in FIG. 9B, monitoring device 902 can be provided as an integral part of dry powder inhaler 900 on mouthpiece 904 or housing 906 as desired. Dry powder inhaler 900, as depicted in FIG. 9B, has monitoring device 902 adapted within the inhaler, which comprises mouthpiece 904 and housing 906. In one embodiment, the sensor can be integrated within the component walls of inhaler 900, including the mouthpiece, housing, or sled to project into one of the flow pathways of the inhaler. Dry powder inhaler 900 comprises an air conduit with an air inlet 908, air outlet 910 and optional mouthpiece cover 912 (FIG. 10). Monitoring device 902 including a small or miniature microphone is provided within dry powder inhaler 900 configured with mouthpiece 904 and is provided with leads 914 (FIG. 13), which can be connected to an analog to digital converter, a display device, and/or a computer.

FIGS. 10-16 depict alternate embodiments, wherein dry powder inhaler 900 includes detachable sensing and monitoring device 1000 presented as a jacket or cap, wherein detachable sensing and monitoring device 1000 can be provided as a detachable part that can adapt to a dry powder inhaler. In this embodiment, the jacket is manufactured as a separate, detachable device comprising sensors, for example, a microphone which can detect signals and being capable of storing, transmitting or displaying the signals. In one embodiment, the sensor is placed in the bottom portion of the jacket as depicted in FIG. 12 so that the sensor is placed in an air conduit of the inhaler. In other example embodiments, a wireless device can also be provided in connection with the sensor. Sound waves emanating from the inhaler in use with or without a dry powder are detected by the microphone and the signals can be analyzed and correlated to time of powder discharge in the presence of a dry powder, airflow rate, end of powder discharge during an inhalation maneuver, temperature within the inhaler pathway, and the like, depending on the type of sensor used. For example, an increase in sound can be correlated to an increase in flow rate through the device, and/or powder particles collisions in the air stream during delivery.

A sensor such as a microphone, as a result of its small size, can be placed anywhere in the inhaler. In embodiments wherein the sensor is a pressure transducer, the sensor can be placed within an air conduit passing through one of the inhaler compartments. The sensors can be provided, for example, in an air conduit on or within the inhaler or provided as a separate, detachable part as an accessory to the inhaler with a shape or configuration that can be adapted to the inhaler to which it is to be adapted, and can include a cap, a jacket, sleeve or a saddle-like configuration that can be adapted or mounted to the inhaler. For the detachable embodiments, the sensing and monitoring apparatus is easy and inexpensive to manufacture and can be made from plastics, and works well with high resistance dry powder inhalers. In the embodiment illustrated in FIG. 10, for example, sensor 1202, depicted in FIG. 12, is provided within the air conduit of mouthpiece 904. The sensor can be any sensor, for example, a thermocouple wire, a pressure transducer, an analog sensor, a microphone, an optical sensor, a gas sensor, or any sensor that can detect signals generated within an inhaler. Sensor 1202, for example is a microphone. The sensors described herein can be adapted to communicate or transmit signals with a wireless device or the signals can be transmitted or stored using wire connection 916 to an analog to digital converter.

Alternatively, an analog to digital converter is provided within the inhaler device and resulting digital data is transferred out of the device directly. The signals provided by the sensors described herein can be in the form of sound generated in an inhaler by airflow passing through the air conduits and/or powder particles collisions entrained in the air flow pathway. Signals generated from the inhaler can be detected by the sensors and stored, transmitted or displayed. Data can be generated from the signals and qualitatively and/or quantitatively analyzed. In this manner, measurements can be made including time of dose release.

FIG. 11 depicts an isometric view of the sensing and/or monitoring device illustrated in FIG. 10, wherein dry powder inhaler 900 is depicted in an open configuration. Dry powder inhaler 900 comprises mouthpiece 904, housing 906, and a hinge mechanism, including a gear, for opening and closing dry powder inhaler 900. Movement of mouthpiece 904 to an open configuration as shown in FIG. 11 permits mounting of cartridge 1102 for dosing. Movement of mouthpiece 904 onto housing 906 into a closed or dosing position, as illustrated in FIG. 9, of dry powder inhaler 900 which comprises a slide tray attached to the hinge mechanism, reconfigures cartridge 1102 to a dosing position forming an air pathway through cartridge 1102 and mouthpiece 904.

In one example embodiment, detachable sensing and monitoring device 1000 (FIGS. 12, 13, and 16) can be used as needed by a patient or a health provider in training or gathering information from the patient's inhalation maneuvers and then removed from dry powder inhaler 900, at which point dry powder inhaler 900 remains functional. FIG. 11 depicts an example embodiment wherein detachable sensing and monitoring device 1000 is adapted to mouthpiece 904 so that it fits securely and cannot move during loading or unloading cartridge 1102 with repeated use. Detachable sensing and monitoring device 1000 can be removed after use and remounted onto another inhaler as needed. In this embodiment, the detachable system provides a simple device that does not interfere with, or affect with the characteristic resistance values of the inhalation system.

FIG. 12 illustrates a back view of detachable sensing and monitoring device 1000 shown mounted onto dry powder inhaler 900 in FIGS. 10 and 11, removed from an inhaler. As illustrated in FIG. 12, detachable sensing and monitoring device 1000 is configured to have first flange 1204 and second flange 1206 both of which can engage mouthpiece 904 so that a secure fit can be obtained and can clear housing 906 by sitting within corresponding first groove 918 and second groove 920 on dry powder inhaler 900 when in a closed position. In such an example embodiment, dry powder inhaler 900 can comprise wire connection 916 or at least one lead which can couple to an analog to digital converter so that signals detected by sensor 1202 on traversing portion 1208 of detachable sensing and monitoring device 1000 can be transformed into data. In an alternate example embodiment, detachable sensing and monitoring device 1000 can be adapted to a wireless transmitter to send measured signals to a receiver.

FIGS. 12 and 16 illustrate detachable sensing and monitoring device 1000 configured in the shape of a saddle to correspond to different dry powder inhaler configurations. Detachable sensing and monitoring device 1000 has top surface 1210, bottom surface 1212 and sensor 1202 configured on bottom surface 1212 of detachable sensing and monitoring device 1000 in a mid-longitudinal axis. Detachable sensing and monitoring device 1000 can also comprise at least one detent or at least one protrusion 1214 in addition to first flange 1204 and second flange 1206 to engage and adapt to dry powder inhaler 900. In one example embodiment, detachable sensing and monitoring device 1000 comprises a raised area 1216 with a hollow undersurface configured to hold sensor wires 1302 so as to avoid any obstruction of airflow in the air conduit of dry powder inhaler 900. FIG. 13 depicts a bottom view of detachable sensing and monitoring device 1000 illustrating sensor 1202 coupled to sensor wires 1302 and wire connection 916 for connecting to a digital to analogue converter.

FIG. 14 illustrates a cross-sectional side view of dry powder inhaler 900 equipped with detachable sensing and monitoring device 1000 shown in FIG. 11. The cross-section is through its mid-longitudinal line with cartridge 1102 in place and showing the position of sensor 1202 within the jacket. FIGS. 14 and 15 also show the position of sensor 1202, for example a microphone, in the air pathway of mouthpiece 904. In some embodiments, the sensor within the jacket for adapting to an inhaler's air pathways can be configured in different places depending on the inhaler. In this manner, the jacket can be configured to have the sensor integrated so when adapted to the inhaler it is positioned upstream, downstream or in the middle of the inhaler's air conduit so that the sound signals or vibrations can be detected through the wall of the inhaler or directly on the air pathway.

FIG. 17 depicts an isometric view of alternate detachable monitoring device 1700 configured to be adapted to a dry powder inhaler such as dry powder inhaler 900. In this example embodiment, first side panel 1702 and second side panel 1704 can adapt to first inhaler side panel 922 and second inhaler side panel 924 of mouthpiece 904 to form a tight fit with dry powder inhaler 900. Alternate detachable monitoring device 1700 further comprises first bottom flange 1706, second bottom flange 1708, first front flange 1710 and second front flange 1712 used to engage with dry powder inhaler 900. First bottom flange 1706 and second bottom flange 1708 grasp the bottoms of first inhaler side panel 922 and second inhaler side panel 924 while first front flange 1710 and second front flange 1712 grasp the sides of mouthpiece 904 and fit within first groove 918 and second groove 920 on dry powder inhaler 900. Alternate detachable monitoring device 1700 further includes raised area 1714 for housing a sensor and accompanying wires (not illustrated) in its undersurface. Grasping area 1718 facilitates handling of the jacket.

FIG. 18 illustrates block diagram 1800 for an exemplary configuration of an overall sensing and/or monitoring device and system as disclosed herein. In such an example embodiment, inhaler 1802 comprises microphone 1804 to detect user inhalation 1806 and provide analog signal 1808. During user inhalation 1806, sound waves generated by the airflow as it enters the air conduits of inhaler 1802 are detected by microphone 1804. Microphone 1804 can detect sound signals generated from alteration in pressure, stress, particle displacement and particle velocity of an inhaler in use, the range from 15 to 20,000 Hertz. Microphone 1804 uses the signal pattern resulting from the changing or variations in frequency emissions intrinsically being generated from the inhaler in use with and without powder to determine the flow rate or pressure within the device that when analyzed can be correlated to user and/or device performance. These vibratory signals in microphone 1804 are then converted into analog signal 1808 (e.g. voltage) and transmitted to analog to digital converter 1810. Signals from the analog/digital converter 1812 are communicated to computer/PDA 1814 provided with a microprocessor which uses an algorithm for analyzing the signals received from the analog/digital converter 1812. The processed data is presented with frequency, time and amplitude parameters, and provided on display 1816 or provided to an output means 1818 for storage for future use, communication to a web based digital storage, and/or printing out. In such an example embodiment, by monitoring the signal frequency versus time, the amplitude of analog signal 1808 can be determined. Each dry powder inhaler type can have a typical acoustical pattern, or fingerprint, which develops for the inhaler in use, and the pattern can then be detected and converted to specific signals, analyzed and stored or displayed in a display device such as a computer monitor.

In another embodiment, a sensing and monitoring system for an inhaler includes a sensing and/or monitoring device structurally configured to be adapted to an inhaler; an analog to digital converter; and a data storage medium. The data storage medium includes a disc drive, a CD-ROM, a server, a flash card or drive, memory card, and the like and includes a set of machine-readable instructions that are executable by a microprocessor or other processing device to implement an algorithm. The algorithm, when run, initiates the steps of generating a logical sub-system generation number derived from detected signals; saving the logical sub-system generation number to a data track within a logical sub-system, wherein the logical sub-system generation number and a cluster generation number in the processing device are compared; and storing and/or displaying information from the algorithm as the results from an inhalation maneuver.

FIG. 19 illustrates an exemplary graphic display 1900 of an inhalation maneuver performed using a dry powder inhaler system in response to a pressure differential, wherein the dry powder inhaler system comprised a microphone sensor. Similar to FIGS. 6-9, graphic display 1900 has acceptable region 1902 and unacceptable region 1904. These regions can be colored red and green or any other combination of colors that aid in learning the inhalation maneuver. The subject is coached to take a deep breath with the inhaler for about a period of 4 to 5 seconds and allowed to exhale normally. The graph illustrates inspiratory profiles from the subject showing measurements using a sensing and monitor device described in FIGS. 10-16. FIG. 19 illustrates the data as time in the x-axis and pressure differential in the y-axis.

The inhalation maneuvers were performed using the inhaler with a cartridge without a dry powder formulation, depicted by first curve 1906, and with a dry powder formulation, depicted by second curve 1908. The results show that the sensing and monitoring device can detect the presence of powder emitted from the system, the time of powder emission and the amount of powder emitted from the system. Curve 1906 is the signal produced by the microphone during an inhalation without powder in the system and curve 1908 is the signal produced by the microphone during the same inhalation with powder in the system. The difference of the curves 1908 and 1906 represents the presence and magnitude of powder emitted from the system and time of emission. The data in FIG. 19 illustrate that the sensing and monitoring device is effective for measuring the amount of dose emitted from the inhaler cartridge system.

In one exemplary embodiment, each component of the inhalation simulation system can be used independent of the other. In one embodiment, the second component of the inhalation simulation system can be used alone or with stored information from an inhalation profile performed by a patient and stored in the computer analyzed with algorithm and programmed software in the computer which can replicate the patient's inhalation effort in vitro using several additional devices. The inhalation simulation system can comprise individual patient profiles and the system can be programmed with specific parameters simulating or replicating the patient inhalations, which can be used, for example, to test the inhaler performance given for use, design and develop inhalers for the individual's need at specific inhalation efforts, and determine the powder performance of the inhaler.

In an exemplary embodiment, the inhalation simulation system 1910 is illustrated in FIG. 20 and FIG. 21. FIG. 20 is a graphic illustration of an embodiment of the inhalation simulation system showing aspects of the first and second components. Inhalation simulation system 1910 comprises a first inhalation apparatus 1919 comprising a dry powder inhaler with an attachable sensing and monitoring system which is part of the first component. The second component of system 1910 comprises an identical inhalation apparatus 1918, which reproduces a patient's inspiratory profile data stored or acquired simultaneously by computer 1921.

FIG. 20 depicts a dry powder inhaler training or monitoring and sensing apparatus 1918 used in combination with a system for reproducing or simulating a patient's inhalation maneuver of the first apparatus 1919. Data obtained from the inhalation maneuver by the sensing and monitoring system 1919 is transmitted to a receiver wherein the simulation system can store or reproduce the inhalation parameters generated by the patient either simultaneously or at a later time. In this embodiment and as illustrated in FIG. 20, the simulation module system 1910 comprises a sensing and monitoring device 1918, which comprises: a housing, a battery (not shown), a sensor and a radio transmitter, which as shown, is a wireless jacket adapted to an inhaler. The monitoring and sensing device 1919 as used by a patient can sense at least one aspect of an inhalation device's performance, for example, flow, pressure differential, and/or sound, during an inhalation. Signals detected can be converted into data signals and transmitted by a wired or wireless transmitter to a computer 1921 comprising a receiver and microprocessor implementing an algorithm for controlling the simulation system 1910. In particular embodiments the data can be displayed in real-time, for example on a monitor 1922. The data that is relayed to a computer comprising the algorithm can be displayed in real time, or stored for use in simulation runs at a later time or for further analysis.

In one embodiment, the inhalation simulation system 1910 comprises an artificial, substantially accurate anatomical head 1911 comprising a model of the upper respiratory tract/airway, the benhead, which is substantially accurate and a representative model of a male upper airway, bisected into two halves in the longitudinal axis through the center, which halves make a tight seal in use. The benhead can be made from an epoxy resin having a mouth and an opening in the opposing end which can be adapted to various devices, for example, a filtration system, artificial lungs, flow meter, and to the a vacuum source, such as a calibrated syringe pump. The inhalation simulation system also comprises a monitoring and sensing device 1918 which can be an integral part of an inhaler or coupled to an inhaler, a power source (not shown), a motor controller, a motor, a piston/cylinder assembly 1920 which works as a syringe pump, a computer comprising a microprocessor 1921 with an algorithm and in particular embodiments a display monitor 1922 for visualizing output data gather by the simulation system. The simulation system can also comprise a filter adaptor and sample tube 1925 and filter such as glassfiber filters provided by Pall Life Sciences, for preventing powder from entering the simulation system 1910 other components, valves 1023, 1924 for controlling flow. Powder can be recovered from the filter and sample tube for quantitation of a dose delivery and quality of dose.

In operation, the motor controller receives motion specific input from a computer based on the information stored or simultaneously received in the system. Once the controller is activated to control the motion of an electrical motor, which is mechanically coupled to a piston such that rotational motion of the motor is translated into linear motion of the piston. As the piston moves, the volume in the cylinder changes thereby creating flow into the cylinder which creates a vacuum in the conduits of inhaler device adapted with monitoring and sensing device 1918. Sound generated as a result of the pressure differential/airflow generated in inhaler 1918 is then captured by the sensor in the device or attached to the device. In an alternate embodiment, the sensor can be integrated within the dry powder inhaler. If a powder formulation is contained in inhaler with sensor 1918, the pressure drop generated in the device can cause the powder to be emitted from the inhaler and flow, pressure differential and/or sound can be detected by the sensing and monitoring device 1918 and transmitted to the computer 1921.

In one embodiment, sensing and monitoring device 1919 is coupled with inhalation simulation system 1910 to provide an apparatus that can be configured to measure flow in a patient's inhaler in use, without dose, and which can reproduce the same flow characteristics, for example, rate, magnitude, duration of an inhalation maneuver in a second device, with dose. In this embodiment, a patient can inhale without exposure to an active drug, and inhaler and patient's performance measurements can be ascertained, including, for example, amount of dose emitted from an inhaler, particle size distribution, and the like can be made on the resulting discharge. In alternative embodiments, 1918 can comprise only an inhaler from which the dose can be delivered to the simulator system, or it can further comprise monitoring and sensing means so that the fidelity of the simulation of the patient's inhalation maneuver can be assessed. In some embodiments, the filter adaptor 1925 further comprises a transparent tube (not shown) to allow visual observation of the “inhaled” bolus of powder, for example by eye or by high speed video camera. In alternate embodiments, a laser diffraction device can be used to measure the plume emitted from the dry powder inhaler containing the powder composition. The laser diffraction system can be adapted to measure the particle size distribution of the plume as it crosses by the transparent tube.

FIG. 21 illustrates a block diagram of the overall exemplary embodiment of the inhalation simulation system 1910 components interact with one another. In operation, an inhaler 1926, such as a dry powder inhaler, can be coupled with a removable monitoring and sensing device 1919, such that the monitoring and sensing device 1919 is positioned on the inhaler near a position of moving flow. Upon inhalation, flow is generated through the device 1926 and sensed by a sensor within the sensing and monitoring apparatus 1919. In one embodiment, the sensor can comprise a microphone, which can be used to measure the sound generated by the flow moving through the conduits of the inhaler 1926. Experiments have shown that the amplitude of the sound correlates well with the magnitude of the pressure drop across the inhaler 1926. In other embodiments, the sensor can comprise a pressure transducer or a flow meter. The sensed flow is converted to an electrical signal which is characteristic of the inhaler 1928 by the sensor and relayed to a radio device 1930 operating, for example, wireless protocols such as Bluetooth or Zigbee, within the housing. The radio device 1930 then transmits the data to a computer or microprocessor 1932 for analysis, display 1940 and/or storage. As the data is received by the computer 1930, the data signals are scaled and correlated to pressure, and ultimately converted to a rotational speed used by the motor controller to drive the motor 1934 so that the information received is reproduced by the simulation system 1910 to generate a pressure differential in the piston/cylinder device 1936 creating a flow in inhaler-monitoring and sensing system 1918. Sound signals generated from the inhaler adapted to the Benhead in the simulation system are detected from the flow by the sensing and monitoring device 1918, which sound signals are characteristic of the inhaler 1926′ and converted to electrical signal by the sensor and relayed to a radio device 1929 operating, for example, wireless protocols such as Bluetooth or Zigbee, within the housing. The radio device 1929 then transmits the data to the computer or microprocessor 1932 for analysis, display 1940 and/or storage.

In one embodiment, the inhalation simulation system 1910 is configured to be unidirectional so that the flow is in one direction. Valves 1923 and 1924 are provided to allow the system to return to the start position after use. In one embodiment, the respiratory tract of an anatomical artificial head 1911 can be used with or without artificial mucous to mimic in vivo affects of powder deposition during dose delivery. In an embodiment, the inhalation simulation system can comprise a camera for recording the quality of a plume emitted from a powder contained in the inhalation device 1918 during use.

Example 1
Using an Integrated Training Device

A 57 year old Type II diabetic is instructed to receive inhaled insulin from a dry powder inhalation system, because she has an elevated hemoglobin A1c and is considered out of control. The patient is trained for inhalation using a device as illustrated in FIG. 9B with an integrated sensor. The patient is given the device and asked to take a deep rapid breath in using the training device.

The data is collected on a computer and the patient is able to view the data in real-time on a display screen. The patient's first inhalation attempt is too slow and is indicated on-screen as entering a red “unacceptable region.” The patient is instructed to take another rapid breath in that is slightly faster than the previous attempt. Upon completion of the inhalation, the graph illustrates that the patient's inhalation maneuver was acceptable and entirely in the green region of the graph. Upon being comfortable with the training, the patient is clear for use of a similar device.

The patient is prescribed a dry powder inhaler similar to the type that illustrated in FIG. 9A and cartridges filled with an inhalable insulin for treatment of the patient's diabetes. Six months after prescribing the inhaled insulin, the patient's diabetes is diagnosed as under control.

Example 2
Using an Attachable Training Device

A 59 year old Type II diabetic is instructed to receive inhaled insulin from a dry powder inhalation system. The patient has requested the inhalation system for convenience reasons. The patient is trained for inhalation using a device as illustrated in FIG. 9A. The patient is given the device fitted with an attachable sensor similar to that if FIG. 12 and asked to take a deep rapid breath in using the training device.

The data is collected on a computer and the patient is able to view the data in real-time on a display screen. The patient's first attempt is acceptable as indicated by the software. Upon being comfortable with the training, the patient is clear for use of the device.

The patient attachable sensor is removed from the dry powder inhaler. The patient is given the dry powder inhaler and cartridges filled with inhalable insulin for treatment of the patient's diabetes. Six months after prescribing the inhaled insulin, the patient's diabetes is diagnosed as under control and the patient comments on the great convenience of the device.

Example 3
Using an Attachable Training Device and a Dry Powder Inhaler to Assess Inhaler Performance with an Inhalation Simulation System

A 45 year old Type II diabetic is instructed to receive inhaled insulin from a dry powder inhalation system. The patient has requested the inhalation system for convenience reasons. The patient is trained for proper inhalation maneuvers using a device illustrated in FIG. 9A. The patient is given the device fitted with an attachable, wireless sensor device configured in a jacket attachable to the inhaler similar to that illustrated in FIG. 12. The patient is asked to inhale deeply while using the inhaler with the training device until the patient attains his preferred inhalation profile when compared to a standard profile provided with the system and displayed in a monitor while performing the inhalation.

Once the patient feels comfortable attaining his preferred inhalation profile, the patient is asked to inhale in proximity to an actuated simulation inhalation apparatus as described above. The patient's training device system can communicate with a computer to actuate the simulation system. The simulation inhalation apparatus is adapted with an inhaler of the same type as the one use by the patient, which inhaler is adapted with its own attachable wireless sensor device as that of the patient's inhaler, and containing a dry powder formulation comprising insulin and fumaryl diketopiperazine(bis-3,6-(N-fumaryl-4-aminobutyl)-2,5-diketo-diketopiperazine; FDKP) of the prescribed dose ordered.

To assess inhaler performance and determine proper dosing for the patient, the patient is asked to inhale optimally as done previously. As the patient inhales, signals from the training device sensor are transmitted to a receiver of the simulation system in the computer. Upon receiving the signals from the inhaler and data generated from the signal are processed, the simulation inhalation program of the system sends a set of signals to instructs the motor controller of the simulation system to activate the motor and thereby the syringe pump to recreate the patient's inhalation profile which is generated by a pressure differential created in the syringe system and an airflow through the inhaler is created which discharges the powder formulation from a cartridge in the inhaler. The powder plume produced by the inhaler is collected in a filter system connected to the artificial airway, photographed and evaluated for percent dose emitted from the inhaler and the distribution of the particle sizes in the emitted dose. Powder deposition patterns are evaluated inside the artificial model of the upper respiratory tract. After determining the efficiency of dose delivered by the inhaler, the patient dosing requirements are determined for the appropriate amount of powder formulation that the patient will receive as recommended by the physician. FIG. 22 illustrates data obtained from a sensing and monitoring device without a drug as used by the patient and coupled to an inhalation simulation system in real time. As seen in FIG. 22, the patient's inhalation maneuver (curve A) is displayed by the monitor, as well as the inhalation simulation (B) recreated and displayed by the simulation system in real time. The data in FIG. 22 show that the recreated inhalation maneuver is almost identical to the simulation performed by the subject.

The present simulation system allows for an improved system to determine inhaler performance and actual dosing characteristics, attributes and properties resulting from an actual patient inhalation(s) (or those of multiple patients) without exposure to drug. The use of the system also allows for the optimization of inhaler design to meet the requirements of a patient population.

The preceding disclosures are illustrative embodiments. It should be appreciated by those of skill in the art that the techniques disclosed herein elucidate representative techniques that function well in the practice of the present disclosure. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments that are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.

The terms “a,” “an,” “the” and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.

Specific embodiments disclosed herein may be further limited in the claims using consisting of or and consisting essentially of language. When used in the claims, whether as filed or added per amendment, the transition term “consisting of” excludes any element, step, or ingredient not specified in the claims. The transition term “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s). Embodiments of the invention so claimed are inherently or expressly described and enabled herein.

Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.

Certain embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the abovedescribed elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

Furthermore, numerous references have been made to patents and printed publications throughout this specification. Each of the above-cited references and printed publications are individually incorporated herein by reference in their entirety.

In closing, it is to be understood that the embodiments of the invention disclosed herein are illustrative of the principles of the present invention. Other modifications that may be employed are within the scope of the invention. Thus, by way of example, but not of limitation, alternative configurations of the present invention may be utilized in accordance with the teachings herein. Accordingly, the present invention is not limited to that precisely as shown and described.

Claims

1. An apparatus comprising: a first acoustic sensor in communication with a first breath-powered dry powder inhaler, the first sensor configured to monitor an inhalation maneuver of a patient and transmit a signal corresponding to the inhalation maneuver;a processing device comprising a microprocessor and a storage medium having an algorithm stored therein, the device configured to receive the signal from the first sensor and processing the signal using the algorithm to generate a data set that is analyzed, stored, printed, transmitted, and/or displayed;a controller that receives the data set and in turn controls a motor that is attached to a calibrated syringe pump that upon actuation by the controller generates a pressure differential in a second breath-powered dry powder inhaler that is attached to an anatomically correct artificial airway;a display in communication with the processing device and configured to graphically display both the inhalation maneuver and data collected as a result of the pressure differential, wherein the pressure differential is modeled after the inhalation maneuver.
2. The apparatus of claim 1, wherein the first sensor is located within the first inhaler or configured to attach to the first inhaler.
3. The apparatus of claim 1, wherein the first inhaler and the second inhaler are breath-powered dry powder inhalers each comprising a sensor and a microprocessor built within the respective inhalers or provided in a device attachable to the inhalers.
4. The apparatus of claim 1, wherein the first sensor is a microphone.
5. The apparatus of claim 1, wherein the second inhaler comprises a cartridge comprising a dry powder for pulmonary delivery.
6. The apparatus of claim 5, wherein the cartridge comprises a dry powder comprising diketopiperazine microparticles.
7. The apparatus of claim 6, wherein the dry powder comprises at least one active ingredient.
8. The apparatus of claim 7, wherein the at least one active ingredient comprises insulin, GLP-1, growth hormone, sumatriptan, parathyroid hormone, or analogs thereof.
9. The apparatus of claim 6, wherein the first sensor is configured to transmit the signal by wire or wireless communication mode to the processing device.
10. The apparatus of claim 6, wherein an analog to digital converter communicates the signal to the microprocessor that is configured to analyze and process the signal.
11. The apparatus of claim 6, further comprising a signal conditioning circuitry and a wired or wireless communication interface.
12. The apparatus of claim 6, wherein data generated from the signal are processed by the microprocessor to generate a data set that recreates the patient's inhalation profile.
13. The apparatus of claim 6, wherein the first and second inhalers are structurally identical.
14. The apparatus of claim 5, wherein the dry powder comprises at least one active ingredient.
15. The apparatus of claim 14, wherein the at least one active ingredient comprises insulin, GLP-1, growth hormone, sumatriptan, parathyroid hormone, or analogs thereof.
16. A method for simulating an inhalation maneuver by a subject, the method comprising: monitoring the inhalation maneuver by way of a first acoustic sensor located in or attached to a first breath-powered dry powder inhaler;transmitting a signal generated by the first acoustic sensor to a device comprising a microprocessor and a storage medium having an algorithm stored therein;processing the signal using the algorithm to generate a data set; andperforming the following with the data set:storing the data set in the storage medium, andtransmitting the data set in the form of a second signal to a controller configured to control a motor that is attached to a calibrated syringe pump that upon actuation by the controller generates a pressure differential in a second breath-powered dry powder inhaler that is attached to an anatomically correct artificial airway,wherein the pressure differential is modeled after the inhalation maneuver.
17. The method of claim 16, wherein the airway is configured with a mouth connected to the second inhaler.
18. The method of claim 16, wherein the first inhaler is adapted with a radio transmitter.
19. The method of claim 16, wherein the first inhaler is adapted with a wireless or wired jacket comprising a microphone that can convert a sound signal generated within the first inhaler into an electrical impulse configured to communicate with a radio signal receiver that is in communication with the microprocessor.
20. The method of claim 16, wherein the first and second inhalers are structurally identical.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 13/505,729, filed Jun. 19, 2012, which is the U.S. national stage application of PCT/US2010/055323, filed Nov. 3, 2010, which claims the benefit under 35 U.S.C. §119(e) from U.S. Provisional Patent Application No. 61/257,813, filed on Nov. 3, 2009, the entire disclosures of which are incorporated herein by reference.

US Referenced Citations (1104)

Number	Name	Date	Kind
2549303	Friden	Apr 1951	A
2754276	Joseph et al.	Jul 1956	A
D189076	Altman	Oct 1960	S
3337740	Gray et al.	Aug 1967	A
3407203	Buijle	Oct 1968	A
3518340	Raper	Jun 1970	A
3622053	Ryden	Nov 1971	A
3669113	Altounyan et al.	Jun 1972	A
3673698	Guerard	Jul 1972	A
3823816	Controullis et al.	Jul 1974	A
3823843	Stephens et al.	Jul 1974	A
3856142	Vessalo	Dec 1974	A
3873651	Mosley, Jr. et al.	Mar 1975	A
3906950	Cocozza	Sep 1975	A
3921637	Bennie et al.	Nov 1975	A
3976773	Curran et al.	Aug 1976	A
3980074	Watt et al.	Sep 1976	A
3998226	Harris	Dec 1976	A
4013075	Cocozza	Mar 1977	A
4018619	Webster et al.	Apr 1977	A
4022749	Kuechler	May 1977	A
4040536	Schwarz	Aug 1977	A
4047525	Kulessa et al.	Sep 1977	A
4066756	Orr et al.	Jan 1978	A
4078128	Hoyt et al.	Mar 1978	A
4091077	Smith et al.	May 1978	A
4098273	Glenn	Jul 1978	A
4102953	Johnson et al.	Jul 1978	A
4110240	Leo et al.	Aug 1978	A
4148308	Sayer	Apr 1979	A
4153689	Hirai	May 1979	A
D252707	Besnard	Aug 1979	S
4168002	Crosby	Sep 1979	A
4171000	Uhle	Oct 1979	A
4175556	Freezer	Nov 1979	A
4187129	Bost et al.	Feb 1980	A
4196196	Tiholiz	Apr 1980	A
4206758	Hallworth et al.	Jun 1980	A
4210140	James et al.	Jul 1980	A
4211769	Okada	Jul 1980	A
4268460	Boiarski et al.	May 1981	A
4272398	Jaffe	Jun 1981	A
4275820	LeBlond	Jun 1981	A
4289759	Heavner	Sep 1981	A
4294829	Suzuki	Oct 1981	A
4300546	Kruber	Nov 1981	A
4356167	Kelly	Oct 1982	A
D269463	Young et al.	Jun 1983	S
4407525	Hoppe	Oct 1983	A
4456007	Nakao et al.	Jun 1984	A
4483922	Carpenter	Nov 1984	A
D276654	Snellman-Wasenius et al.	Dec 1984	S
4487327	Grayson	Dec 1984	A
4524769	Wetterlin	Jun 1985	A
4526804	Escallon	Jul 1985	A
4534345	Wetterlin	Aug 1985	A
D282209	Newell et al.	Jan 1986	S
4581020	Mittleman	Apr 1986	A
4592348	Waters, IV et al.	Jun 1986	A
4613500	Suzuki	Sep 1986	A
4615817	McCoy	Oct 1986	A
4624861	Yale et al.	Nov 1986	A
4637996	Konishi	Jan 1987	A
D288852	Miyoshi	Mar 1987	S
4659696	Hirai et al.	Apr 1987	A
4668218	Virtanen	May 1987	A
4681752	Melillo	Jul 1987	A
D295321	Hallworth	Apr 1988	S
4757066	Shiokari et al.	Jul 1988	A
4792451	Kim	Dec 1988	A
4811731	Newell et al.	Mar 1989	A
D301273	Leonard	May 1989	S
4835312	Itoh et al.	May 1989	A
4841964	Hurka et al.	Jun 1989	A
4847091	Illum	Jul 1989	A
4849227	Cho	Jul 1989	A
4861627	Mathiowitz	Aug 1989	A
4866051	Hunt et al.	Sep 1989	A
4873087	Morishita et al.	Oct 1989	A
4887722	Greenward, Sr.	Dec 1989	A
4900730	Miyauchi	Feb 1990	A
4907583	Wetterlin et al.	Mar 1990	A
4925673	Steiner	May 1990	A
4926852	Zoltan et al.	May 1990	A
4927555	Colarusso, Jr.	May 1990	A
4927928	Shroot et al.	May 1990	A
4946828	Markussen	Aug 1990	A
4981295	Belman et al.	Jan 1991	A
4981625	Rhim et al.	Jan 1991	A
4983402	Steiner et al.	Jan 1991	A
4984158	Hillsman	Jan 1991	A
4991605	Keritsis	Feb 1991	A
4998624	Capes et al.	Mar 1991	A
5006343	Benson	Apr 1991	A
D316902	Hoefling	May 1991	S
5017383	Ozawa et al.	May 1991	A
5019400	Gombotz et al.	May 1991	A
5021376	Nienburg et al.	Jun 1991	A
5027806	Zoltan et al.	Jul 1991	A
5042975	Chien	Aug 1991	A
D321570	Blasdell et al.	Nov 1991	S
5067500	Keritsis	Nov 1991	A
5069204	Smith et al.	Dec 1991	A
5074418	Buan et al.	Dec 1991	A
5075027	Dixit et al.	Dec 1991	A
5098590	Dixit et al.	Mar 1992	A
5105291	Matsumoto et al.	Apr 1992	A
D326517	Funai et al.	May 1992	S
5110007	Law et al.	May 1992	A
5110823	Hamaguchi et al.	May 1992	A
5118666	Habener	Jun 1992	A
5120712	Habener	Jun 1992	A
5124291	Bremer et al.	Jun 1992	A
5131539	Karita et al.	Jul 1992	A
5139878	Kim	Aug 1992	A
5145684	Liversidge et al.	Sep 1992	A
5152284	Valentini et al.	Oct 1992	A
D331106	Fuchs	Nov 1992	S
5167506	Kilis et al.	Dec 1992	A
5170801	Casper et al.	Dec 1992	A
5188837	Domb	Feb 1993	A
5196049	Coombs et al.	Mar 1993	A
5201308	Newhouse	Apr 1993	A
5203768	Haak et al.	Apr 1993	A
5204108	Ilium	Apr 1993	A
5208998	Dyler, Jr.	May 1993	A
5215739	Kamishita et al.	Jun 1993	A
D337636	Kocinski	Jul 1993	S
D338062	Yair	Aug 1993	S
D338268	Kobayashi et al.	Aug 1993	S
5239992	Bougamont et al.	Aug 1993	A
5244653	Berke et al.	Sep 1993	A
5250287	Cocozza	Oct 1993	A
D340975	Sladek	Nov 1993	S
5260306	Boardman et al.	Nov 1993	A
5270305	Palmer	Dec 1993	A
5287850	Haber et al.	Feb 1994	A
D344796	Sochon et al.	Mar 1994	S
D344797	Sochon et al.	Mar 1994	S
D345013	Huck et al.	Mar 1994	S
5301666	Lerk et al.	Apr 1994	A
5306453	Shulman	Apr 1994	A
D347057	Yair	May 1994	S
D348100	Clarke	Jun 1994	S
5320094	Laube et al.	Jun 1994	A
D348928	Ashley et al.	Jul 1994	S
D348929	Paton	Jul 1994	S
5327883	Williams et al.	Jul 1994	A
5328464	Kriesel et al.	Jul 1994	A
5331953	Andersson et al.	Jul 1994	A
5333106	Lanpher et al.	Jul 1994	A
D349572	Jagnandan et al.	Aug 1994	S
D350193	Huck et al.	Aug 1994	S
5337740	Armstrong et al.	Aug 1994	A
D350602	Hobbs et al.	Sep 1994	S
D350821	Wright et al.	Sep 1994	S
5351683	Chiesi et al.	Oct 1994	A
5352461	Feldstein et al.	Oct 1994	A
5354562	Platz	Oct 1994	A
5358734	Lenox et al.	Oct 1994	A
D352107	Meier et al.	Nov 1994	S
5360614	Fox et al.	Nov 1994	A
5363842	Mishelevich et al.	Nov 1994	A
5364838	Rubsamen	Nov 1994	A
5372128	Haber et al.	Dec 1994	A
D355029	Kinneir et al.	Jan 1995	S
5385904	Andersson et al.	Jan 1995	A
5394868	Ambrosio et al.	Mar 1995	A
5401516	Milstein et al.	Mar 1995	A
D357603	Wolff	Apr 1995	S
5404871	Goodman et al.	Apr 1995	A
D358880	Mulhauser et al.	May 1995	S
5413804	Rhodes	May 1995	A
5415162	Casper et al.	May 1995	A
D359153	Viggiano	Jun 1995	S
D359555	Funai et al.	Jun 1995	S
5424286	Eng	Jun 1995	A
5437271	Hodson et al.	Aug 1995	A
5443841	Milstein et al.	Aug 1995	A
D362500	Cook et al.	Sep 1995	S
5447150	Bacon	Sep 1995	A
5447151	Bruna et al.	Sep 1995	A
5447728	Milstein et al.	Sep 1995	A
5451410	Milstein et al.	Sep 1995	A
D363775	Hobbs	Oct 1995	S
5454871	Liaw et al.	Oct 1995	A
5455335	Kahne et al.	Oct 1995	A
5458135	Patton et al.	Oct 1995	A
5469750	Lloyd et al.	Nov 1995	A
5469971	Chilton et al.	Nov 1995	A
5476093	Laniken	Dec 1995	A
5477285	Riddle et al.	Dec 1995	A
D365876	Chawla	Jan 1996	S
5482032	Smith et al.	Jan 1996	A
5482927	Maniar et al.	Jan 1996	A
5483954	Mecikalski	Jan 1996	A
5484606	Dhaber et al.	Jan 1996	A
5487378	Robertson et al.	Jan 1996	A
5492112	Mecikalski et al.	Feb 1996	A
D368364	Reitano et al.	Apr 1996	S
5503144	Bacon	Apr 1996	A
5503852	Steiner et al.	Apr 1996	A
5505194	Adjei et al.	Apr 1996	A
5506203	Backstrom et al.	Apr 1996	A
D370255	Yamamoto et al.	May 1996	S
5514646	Chance et al.	May 1996	A
5518998	Backstrom et al.	May 1996	A
5524613	Haber et al.	Jun 1996	A
5532461	Crummenauer et al.	Jul 1996	A
5533502	Piper	Jul 1996	A
5533505	Kallstrand et al.	Jul 1996	A
5541155	Leone-Bay	Jul 1996	A
5542411	Rex	Aug 1996	A
5542539	Early	Aug 1996	A
5545618	Buckley et al.	Aug 1996	A
5547929	Anderson, Jr. et al.	Aug 1996	A
5562909	Allcock et al.	Oct 1996	A
5562918	Stimpson	Oct 1996	A
5568884	Bruna	Oct 1996	A
5570810	Lambelet, Jr. et al.	Nov 1996	A
5571795	Kahne et al.	Nov 1996	A
5574008	Johnson et al.	Nov 1996	A
5577497	Mecikalski et al.	Nov 1996	A
5578323	Milstein et al.	Nov 1996	A
5584417	Graf et al.	Dec 1996	A
D377215	Rand	Jan 1997	S
D377686	Waldeck et al.	Jan 1997	S
5595175	Malcher et al.	Jan 1997	A
5596701	Augusteijn et al.	Jan 1997	A
D377861	Jacober	Feb 1997	S
5598835	von Schrader	Feb 1997	A
5601846	Milstein et al.	Feb 1997	A
5610271	Dooley et al.	Mar 1997	A
5614492	Habener	Mar 1997	A
5615670	Rhodes et al.	Apr 1997	A
5617844	King	Apr 1997	A
5619984	Hodson et al.	Apr 1997	A
5622164	Kilis et al.	Apr 1997	A
5622166	Eisele et al.	Apr 1997	A
5623724	Gurkovich et al.	Apr 1997	A
5623920	Bryant	Apr 1997	A
D379506	Maher	May 1997	S
5629020	Leone-Bay	May 1997	A
5631224	Efendic et al.	May 1997	A
5632971	Yang	May 1997	A
5634900	Makino et al.	Jun 1997	A
5639441	Sievers et al.	Jun 1997	A
5641861	Dooley et al.	Jun 1997	A
D381416	Hansson et al.	Jul 1997	S
5642727	Datta et al.	Jul 1997	A
5642728	Andersson et al.	Jul 1997	A
5643957	Leone-Bay et al.	Jul 1997	A
5645051	Schultz	Jul 1997	A
5651359	Bougamont et al.	Jul 1997	A
5653961	McNally et al.	Aug 1997	A
5655516	Goodman et al.	Aug 1997	A
5655523	Hodson et al.	Aug 1997	A
5657748	Braithwaite	Aug 1997	A
5658878	Backstrom et al.	Aug 1997	A
5660169	Kallstrand et al.	Aug 1997	A
5672581	Rubsamen et al.	Sep 1997	A
5673686	Villax et al.	Oct 1997	A
5679377	Bernstein et al.	Oct 1997	A
5687710	Ambrosio et al.	Nov 1997	A
5690910	Ahmed et al.	Nov 1997	A
5693338	Milstein	Dec 1997	A
5699789	Hendricks	Dec 1997	A
D389238	Kirk, III et al.	Jan 1998	S
D389570	Savolainen	Jan 1998	S
5705483	Galloway et al.	Jan 1998	A
D390651	Smith et al.	Feb 1998	S
D390653	Blasdell et al.	Feb 1998	S
5714007	Pletcher et al.	Feb 1998	A
5714167	Milstein et al.	Feb 1998	A
5727333	Folan	Mar 1998	A
5727546	Clarke et al.	Mar 1998	A
5740793	Hodson et al.	Apr 1998	A
5740794	Smith et al.	Apr 1998	A
5746197	Williams	May 1998	A
5746227	Rose et al.	May 1998	A
5747445	Backstrom et al.	May 1998	A
5752505	Ohki et al.	May 1998	A
5755218	Johansson et al.	May 1998	A
D395147	Vidgren et al.	Jun 1998	S
D395499	Eisele et al.	Jun 1998	S
5758638	Kreamer	Jun 1998	A
5763396	Weiner et al.	Jun 1998	A
5766620	Heiber et al.	Jun 1998	A
5766633	Milstein et al.	Jun 1998	A
5769073	Eason et al.	Jun 1998	A
5772085	Bryant et al.	Jun 1998	A
RE35862	Steiner et al.	Jul 1998	E
5775320	Patton et al.	Jul 1998	A
5785049	Smith et al.	Jul 1998	A
5785989	Stanley et al.	Jul 1998	A
D397435	Naumann	Aug 1998	S
5792451	Sarubbi et al.	Aug 1998	A
5794613	Piskorski	Aug 1998	A
5797391	Cook et al.	Aug 1998	A
D398992	Feret	Sep 1998	S
5799821	Lambelet, Jr. et al.	Sep 1998	A
5807315	Va Antwerp et al.	Sep 1998	A
5809997	Wolf	Sep 1998	A
5811127	Milstein et al.	Sep 1998	A
5813397	Goodman et al.	Sep 1998	A
5817343	Burke	Oct 1998	A
5824345	Milstein et al.	Oct 1998	A
5839429	Marnfeldt et al.	Nov 1998	A
5840279	Narodylo et al.	Nov 1998	A
5840340	Milstein et al.	Nov 1998	A
5846447	Beatty	Dec 1998	A
5848589	Welnetz	Dec 1998	A
5849322	Ebert et al.	Dec 1998	A
5857457	Hyppola	Jan 1999	A
5858099	Sun et al.	Jan 1999	A
5865012	Hansson et al.	Feb 1999	A
5868774	Reil	Feb 1999	A
5874064	Edwards et al.	Feb 1999	A
5875776	Vaghefi	Mar 1999	A
5877174	Ono et al.	Mar 1999	A
5881719	Gottenauer et al.	Mar 1999	A
5881721	Bunce et al.	Mar 1999	A
5884620	Gonda et al.	Mar 1999	A
5888477	Gonda et al.	Mar 1999	A
5896855	Hobbs et al.	Apr 1999	A
5901703	Ohki et al.	May 1999	A
5904139	Hauser	May 1999	A
D410541	Moulin	Jun 1999	S
D411005	Coe	Jun 1999	S
5908639	Simpkin et al.	Jun 1999	A
5912011	Makino et al.	Jun 1999	A
5918594	Asking et al.	Jul 1999	A
5919897	Dooley et al.	Jul 1999	A
5921237	Eisele et al.	Jul 1999	A
5922253	Herbert et al.	Jul 1999	A
5924419	Kotliar	Jul 1999	A
5929027	Takama et al.	Jul 1999	A
D412572	Gray	Aug 1999	S
D412744	Braithwaite	Aug 1999	S
D412978	Cameron	Aug 1999	S
D412979	Weinstein et al.	Aug 1999	S
5934273	Andersson et al.	Aug 1999	A
5942242	Mizushima et al.	Aug 1999	A
5948749	Igarashi et al.	Sep 1999	A
5952008	Backstrom et al.	Sep 1999	A
5954047	Armer et al.	Sep 1999	A
5965701	Junien	Oct 1999	A
5971951	Ruskewicz	Oct 1999	A
D416085	Forssell et al.	Nov 1999	S
D416621	Forssell et al.	Nov 1999	S
D416998	Hodson et al.	Nov 1999	S
D417271	Denyer et al.	Nov 1999	S
5975347	Lambelet, Jr. et al.	Nov 1999	A
5976569	Milstein	Nov 1999	A
5976574	Gordon	Nov 1999	A
5977071	Galloway et al.	Nov 1999	A
5980865	Ahmed et al.	Nov 1999	A
5981488	Hoffmann	Nov 1999	A
5983893	Wetterlin	Nov 1999	A
5985248	Gordon et al.	Nov 1999	A
5985309	Edwards et al.	Nov 1999	A
5990077	Drucker	Nov 1999	A
D417732	Dagsland et al.	Dec 1999	S
D417912	Dagsland et al.	Dec 1999	S
5996577	Ohki et al.	Dec 1999	A
5997848	Patton et al.	Dec 1999	A
6001336	Gordon	Dec 1999	A
6006747	Eisele et al.	Dec 1999	A
6006753	Efendic	Dec 1999	A
D418600	Haerle	Jan 2000	S
D420736	Moulin	Feb 2000	S
6026809	Abrams et al.	Feb 2000	A
6029663	Eisele et al.	Feb 2000	A
D421800	Doat	Mar 2000	S
6039208	Lambelet et al.	Mar 2000	A
6043214	Jensen et al.	Mar 2000	A
6045828	Bystorm et al.	Apr 2000	A
6051256	Platz et al.	Apr 2000	A
6051551	Hughes et al.	Apr 2000	A
6055980	Mecikalski et al.	May 2000	A
6056169	Bruna et al.	May 2000	A
6060069	Hill et al.	May 2000	A
6063910	Debenedetti et al.	May 2000	A
6071497	Steiner et al.	Jun 2000	A
6073629	Hardy et al.	Jun 2000	A
6076521	Lindahl et al.	Jun 2000	A
6077543	Gordon et al.	Jun 2000	A
6080762	Allen et al.	Jun 2000	A
D428486	Schuckmann	Jul 2000	S
6085745	Levander et al.	Jul 2000	A
6087334	Beeley et al.	Jul 2000	A
6087351	Nyce	Jul 2000	A
6089228	Smith et al.	Jul 2000	A
6095136	Virtanen	Aug 2000	A
6098618	Jennings et al.	Aug 2000	A
6098619	Britto et al.	Aug 2000	A
6099517	Daugherty	Aug 2000	A
6102035	Asking et al.	Aug 2000	A
6105571	Coffee	Aug 2000	A
6105574	Jahnsson	Aug 2000	A
6109261	Clarke et al.	Aug 2000	A
6109481	Alexander et al.	Aug 2000	A
6116237	Schultz	Sep 2000	A
6116238	Jackson et al.	Sep 2000	A
6116239	Volgyesi	Sep 2000	A
6119684	Nohl et al.	Sep 2000	A
6119688	Whaley et al.	Sep 2000	A
6131567	Gonda et al.	Oct 2000	A
6132766	Sankaram et al.	Oct 2000	A
6133235	Galloway et al.	Oct 2000	A
6142145	Dagsland	Nov 2000	A
6152130	Abrams	Nov 2000	A
6153613	Ono et al.	Nov 2000	A
6155423	Katzne et al.	Dec 2000	A
6156114	Bell et al.	Dec 2000	A
6158431	Poole	Dec 2000	A
6159360	Gerteis et al.	Dec 2000	A
RE37053	Hanes et al.	Feb 2001	E
6182655	Keller et al.	Feb 2001	B1
6187291	Weinstein et al.	Feb 2001	B1
6191102	DiMarchi et al.	Feb 2001	B1
6192876	Denyer et al.	Feb 2001	B1
6193844	McLaughlin et al.	Feb 2001	B1
6193957	Ahmed	Feb 2001	B1
D438612	Suh	Mar 2001	S
D439325	Frost	Mar 2001	S
D439656	Andersson et al.	Mar 2001	S
6198847	Washizawa	Mar 2001	B1
D441446	Dagsland et al.	May 2001	S
D441859	Pera	May 2001	S
D442685	Sladek	May 2001	S
6235725	Ahmed	May 2001	B1
D444226	Geert-Jensen et al.	Jun 2001	S
6250300	Andersson et al.	Jun 2001	B1
6254854	Edwards et al.	Jul 2001	B1
6257232	Andersson et al.	Jul 2001	B1
6258816	Singh et al.	Jul 2001	B1
6263871	Brown et al.	Jul 2001	B1
6269952	Watt et al.	Aug 2001	B1
6273084	Frid	Aug 2001	B1
6273085	Eisele et al.	Aug 2001	B1
6273086	Ohki et al.	Aug 2001	B1
6277819	Efendic	Aug 2001	B1
6279511	Loughnane	Aug 2001	B1
D448076	von Schuckmann	Sep 2001	S
6286506	MacAndrew et al.	Sep 2001	B1
6286507	Jahnsson	Sep 2001	B1
6294204	Rossling et al.	Sep 2001	B1
D449684	Christrup et al.	Oct 2001	S
6298846	Ohki et al.	Oct 2001	B1
6298847	Datta et al.	Oct 2001	B1
D450117	Braithwaite et al.	Nov 2001	S
D451597	Suh	Dec 2001	S
6328034	Eisele et al.	Dec 2001	B1
6331318	Milstein	Dec 2001	B1
D452910	Braithwaite et al.	Jan 2002	S
6335316	Hughes et al.	Jan 2002	B1
D453264	Acevedo, Jr.	Feb 2002	S
6347629	Braithwaite	Feb 2002	B1
6348447	Hellstrom et al.	Feb 2002	B1
6357442	Casper et al.	Mar 2002	B1
6358058	Strupat et al.	Mar 2002	B1
6358924	Hoffman	Mar 2002	B1
6360743	Andersson et al.	Mar 2002	B1
6360929	McCarthy	Mar 2002	B1
D455208	Bacon et al.	Apr 2002	S
6363932	Forchione et al.	Apr 2002	B1
6365190	Gordon et al.	Apr 2002	B1
6372258	Platz et al.	Apr 2002	B1
6375975	Modi	Apr 2002	B1
6380357	Hermeling et al.	Apr 2002	B2
6386195	Coffee	May 2002	B1
6388053	Galloway et al.	May 2002	B1
6394085	Hardy et al.	May 2002	B1
6395300	Straub et al.	May 2002	B1
6395744	Adams et al.	May 2002	B1
6395774	Milstein	May 2002	B1
6410513	Galloway et al.	Jun 2002	B1
D460173	Harrison et al.	Jul 2002	S
6415784	Christrup et al.	Jul 2002	B1
6418926	Chawla	Jul 2002	B1
6423344	Platz et al.	Jul 2002	B1
D461239	Cassidy	Aug 2002	S
6427688	Ligotke et al.	Aug 2002	B1
6428771	Steiner et al.	Aug 2002	B1
6428805	Dohi et al.	Aug 2002	B1
6432383	Modi	Aug 2002	B1
6436443	Edwards et al.	Aug 2002	B2
6439227	Myrman et al.	Aug 2002	B1
6440463	Feldstein et al.	Aug 2002	B1
6441172	Nefzi et al.	Aug 2002	B1
D463544	Engelberth et al.	Sep 2002	S
6443143	Ishida et al.	Sep 2002	B1
6444226	Steiner et al.	Sep 2002	B1
6446626	Virtanen	Sep 2002	B1
6446627	Bowman et al.	Sep 2002	B1
6447750	Cutie et al.	Sep 2002	B1
6447751	Weinstein et al.	Sep 2002	B1
6447753	Edwards et al.	Sep 2002	B2
6451337	Smith et al.	Sep 2002	B1
6457470	Coffee	Oct 2002	B1
6468507	Cutie et al.	Oct 2002	B1
6470884	Horlin	Oct 2002	B2
6479049	Platz et al.	Nov 2002	B1
6484715	Ritsche et al.	Nov 2002	B1
6484717	Dagsland et al.	Nov 2002	B1
D469527	Keller et al.	Jan 2003	S
6503480	Edwards et al.	Jan 2003	B1
6509006	Platz et al.	Jan 2003	B1
6509313	Smith	Jan 2003	B1
D469866	Albulet et al.	Feb 2003	S
6514482	Bartus et al.	Feb 2003	B1
6518239	Kuo et al.	Feb 2003	B1
6523536	Fugelsang et al.	Feb 2003	B2
D471273	Albulet et al.	Mar 2003	S
6528096	Musa et al.	Mar 2003	B1
6532437	Clardy et al.	Mar 2003	B1
6536427	Davies et al.	Mar 2003	B2
D473298	Bowman et al.	Apr 2003	S
D473640	Cuffaro et al.	Apr 2003	S
6540672	Simonsen et al.	Apr 2003	B1
6540982	Adjei et al.	Apr 2003	B1
6540983	Adjei et al.	Apr 2003	B1
6543448	Smith et al.	Apr 2003	B1
6546929	Burr et al.	Apr 2003	B2
6555127	Steiner	Apr 2003	B2
6555521	Hermeling et al.	Apr 2003	B2
D474536	Albulet et al.	May 2003	S
D475133	McLuckie	May 2003	S
6557549	Schmidt et al.	May 2003	B2
6561186	Casper et al.	May 2003	B2
6567686	Sexton	May 2003	B2
6568390	Nichols et al.	May 2003	B2
6569406	Stevenson et al.	May 2003	B2
6571793	Nilsson et al.	Jun 2003	B1
6572893	Gordon et al.	Jun 2003	B2
6575160	Volgyesi	Jun 2003	B1
6575162	Rand	Jun 2003	B1
6578571	Watt	Jun 2003	B1
6582728	Platz et al.	Jun 2003	B1
6583111	DiMarchi	Jun 2003	B1
D477665	Myrman et al.	Jul 2003	S
6589560	Foster et al.	Jul 2003	B2
6591832	DeJonge	Jul 2003	B1
6592904	Platz et al.	Jul 2003	B2
6595205	Andersson et al.	Jul 2003	B2
6595208	Coffee et al.	Jul 2003	B1
D478983	Whitehall et al.	Aug 2003	S
6606992	Schuler et al.	Aug 2003	B1
D479745	Albulet et al.	Sep 2003	S
6613308	Bartus et al.	Sep 2003	B2
6615987	Greenhill et al.	Sep 2003	B1
6620910	Calas et al.	Sep 2003	B1
6626173	Genova et al.	Sep 2003	B2
D480806	Engelberth et al.	Oct 2003	S
6630169	Bot et al.	Oct 2003	B1
6632258	Wheelock et al.	Oct 2003	B1
6632456	Backstrom et al.	Oct 2003	B1
6635283	Edwards et al.	Oct 2003	B2
6637431	Ekelius et al.	Oct 2003	B2
6640050	Nichols et al.	Oct 2003	B2
6644309	Casper et al.	Nov 2003	B2
6645468	Cutie et al.	Nov 2003	B2
6645504	Weiner et al.	Nov 2003	B1
6652838	Weinstein et al.	Nov 2003	B2
6652885	Steiner et al.	Nov 2003	B2
D483860	Knoch	Dec 2003	S
6655379	Clark et al.	Dec 2003	B2
6655380	Andersson et al.	Dec 2003	B1
6655381	Keane et al.	Dec 2003	B2
6660716	Yakubu-Madus et al.	Dec 2003	B1
6663898	Milstein	Dec 2003	B2
6668826	Myrman et al.	Dec 2003	B1
6672304	Casper et al.	Jan 2004	B1
6676931	Dugger, III	Jan 2004	B2
6679255	Pera	Jan 2004	B2
6681767	Patton et al.	Jan 2004	B1
6681768	Haaije de Boer et al.	Jan 2004	B2
6685967	Patton et al.	Feb 2004	B1
6698421	Attolini	Mar 2004	B2
6698422	Fugelsang et al.	Mar 2004	B2
6701917	O'Leary	Mar 2004	B2
6703361	Weiner et al.	Mar 2004	B2
6703365	Galloway et al.	Mar 2004	B2
6703381	Ekwuribe et al.	Mar 2004	B1
6705313	Niccolai	Mar 2004	B2
6715486	Gieschen et al.	Apr 2004	B2
6715487	Nichols et al.	Apr 2004	B2
6718972	O'Leary	Apr 2004	B2
6720407	Hughes et al.	Apr 2004	B1
6722363	von Schuckmann	Apr 2004	B1
D489448	Shayan	May 2004	S
6729324	Casper et al.	May 2004	B2
6729328	Goldemann	May 2004	B2
6737045	Patton	May 2004	B2
6745761	Christup et al.	Jun 2004	B2
6747006	Efendic	Jun 2004	B2
6748946	Rand et al.	Jun 2004	B1
6748947	Keane et al.	Jun 2004	B2
6752145	Bonney et al.	Jun 2004	B1
6755190	Rasmussen	Jun 2004	B2
D492769	Hatanaka	Jul 2004	S
D493220	Burge et al.	Jul 2004	S
D493519	Jonsson et al.	Jul 2004	S
6774112	Gougoutas	Aug 2004	B2
6787152	Kirby et al.	Sep 2004	B2
6790496	Levander et al.	Sep 2004	B1
6792945	Davies et al.	Sep 2004	B2
6797258	Platz et al.	Sep 2004	B2
6799572	Nichols et al.	Oct 2004	B2
6800643	Cuenoud et al.	Oct 2004	B2
6803044	Catania et al.	Oct 2004	B1
6821949	Bridon et al.	Nov 2004	B2
6823863	Huxham et al.	Nov 2004	B2
D499802	Pinon et al.	Dec 2004	S
6830046	Blakley et al.	Dec 2004	B2
6838075	Stevenson et al.	Jan 2005	B2
6838076	Patton et al.	Jan 2005	B2
6847595	Tanaka	Jan 2005	B2
6848443	Schmidt et al.	Feb 2005	B2
6849708	Habener	Feb 2005	B1
6852690	Nauck et al.	Feb 2005	B1
6858199	Edwards et al.	Feb 2005	B1
6860262	Christup et al.	Mar 2005	B2
6866037	Aslin et al.	Mar 2005	B1
6871646	Keane et al.	Mar 2005	B2
6871647	Allan et al.	Mar 2005	B2
6880554	Coffee	Apr 2005	B1
6881423	Dohi et al.	Apr 2005	B2
6884435	O'Hagan et al.	Apr 2005	B1
6887459	Haeberlin	May 2005	B1
6887849	Bridon et al.	May 2005	B2
6889687	Olsson	May 2005	B1
6892728	Helgesson et al.	May 2005	B2
6896906	Hastedt et al.	May 2005	B2
D506680	Saelzer	Jun 2005	S
6904907	Speldrich et al.	Jun 2005	B2
6906030	Milstein	Jun 2005	B2
6916354	Elliott	Jul 2005	B2
6918991	Chickering, III et al.	Jul 2005	B2
6921458	Chickering, III et al.	Jul 2005	B2
6921528	Edwards et al.	Jul 2005	B2
6923175	Poole et al.	Aug 2005	B2
D509296	Minshull et al.	Sep 2005	S
D509898	Bunce et al.	Sep 2005	S
6948496	Eason et al.	Sep 2005	B2
6949258	Zhang	Sep 2005	B2
6951215	Hoffman	Oct 2005	B1
6953812	Jorgensen et al.	Oct 2005	B2
D511208	Pardonge et al.	Nov 2005	S
D511977	Saelzer	Nov 2005	S
6962006	Chickering, III et al.	Nov 2005	B2
D512777	Beisner et al.	Dec 2005	S
6979437	Bartus et al.	Dec 2005	B2
D514222	Andersson et al.	Jan 2006	S
6981499	Andersson et al.	Jan 2006	B2
6989155	Ganderton et al.	Jan 2006	B1
6991779	Steiner et al.	Jan 2006	B2
D515696	Lucking et al.	Feb 2006	S
D515924	Grant	Feb 2006	S
D516211	Minshull et al.	Feb 2006	S
6998387	Goke et al.	Feb 2006	B1
D518170	Clarke et al.	Mar 2006	S
D518171	Anderson et al.	Mar 2006	S
7022674	DeFelippis et al.	Apr 2006	B2
7025056	Eason et al.	Apr 2006	B2
7028686	Gonda et al.	Apr 2006	B2
7030084	Ekwuribe et al.	Apr 2006	B2
7032593	Johnston et al.	Apr 2006	B2
7035294	Dove et al.	Apr 2006	B2
7047967	Knudsen	May 2006	B2
7048908	Basu et al.	May 2006	B2
7060274	Blumberg et al.	Jun 2006	B2
7067129	Blumberg et al.	Jun 2006	B2
7077130	Nichols et al.	Jul 2006	B2
7080642	Hodson et al.	Jul 2006	B2
7084243	Glaesner et al.	Aug 2006	B2
7093594	Harrison et al.	Aug 2006	B2
7093595	Nesbitt	Aug 2006	B2
D527817	Ziegler et al.	Sep 2006	S
7101843	Glaesner et al.	Sep 2006	B2
7101866	Biggadike et al.	Sep 2006	B2
7107988	Pinon et al.	Sep 2006	B2
D529604	Young et al.	Oct 2006	S
7125566	Etter	Oct 2006	B2
7128067	Byron et al.	Oct 2006	B2
7131441	Keller et al.	Nov 2006	B1
7132115	Musa et al.	Nov 2006	B2
7140365	Poole et al.	Nov 2006	B2
D533268	Olfati	Dec 2006	S
7143764	Dagsland et al.	Dec 2006	B1
7143765	Asking et al.	Dec 2006	B2
7144863	DeFelippis et al.	Dec 2006	B2
7146978	Edwards et al.	Dec 2006	B2
7151456	Godfrey	Dec 2006	B2
7163014	Nichols et al.	Jan 2007	B2
D537522	Cox et al.	Feb 2007	S
7171965	Young et al.	Feb 2007	B2
7172768	Hastedt et al.	Feb 2007	B2
7179788	DeFelippis et al.	Feb 2007	B2
D537936	Cox et al.	Mar 2007	S
D538423	Berube et al.	Mar 2007	S
7185650	Huber et al.	Mar 2007	B2
7198806	Berndt	Apr 2007	B2
7211557	DiMarchi et al.	May 2007	B2
7219664	Ruckdeschel et al.	May 2007	B2
7223728	Yakubu-Madus et al.	May 2007	B2
D544093	Eriksen	Jun 2007	S
7231919	Giroux	Jun 2007	B2
7232897	Hotamisligil et al.	Jun 2007	B2
7234459	Del Bon	Jun 2007	B2
7234460	Greenleaf et al.	Jun 2007	B2
7234464	Goede et al.	Jun 2007	B2
7238663	DeFelippis et al.	Jul 2007	B2
7246617	Harmer et al.	Jul 2007	B1
D548330	Cox et al.	Aug 2007	S
D548618	Ferguson et al.	Aug 2007	S
D548619	Ferguson et al.	Aug 2007	S
D548833	Young et al.	Aug 2007	S
D549111	Ferguson et al.	Aug 2007	S
7258118	Goede et al.	Aug 2007	B2
7259233	Dodd et al.	Aug 2007	B2
D550835	Tanaka et al.	Sep 2007	S
7270124	Rasmussen	Sep 2007	B2
D552729	Cox et al.	Oct 2007	S
7276534	Milstein	Oct 2007	B2
7278419	Gonda	Oct 2007	B2
7278426	Myrman et al.	Oct 2007	B2
7278843	Feldstein et al.	Oct 2007	B2
7279457	Pohl et al.	Oct 2007	B2
7284553	Hochrainer	Oct 2007	B2
D557799	Greenhalgh et al.	Dec 2007	S
7305986	Steiner	Dec 2007	B1
7306787	Tarara et al.	Dec 2007	B2
D560793	Pearl et al.	Jan 2008	S
7314859	Green et al.	Jan 2008	B2
7316748	Li et al.	Jan 2008	B2
7331340	Barney	Feb 2008	B2
7334577	Gumaste et al.	Feb 2008	B2
7344734	Heijerman et al.	Mar 2008	B2
7368102	Tarara et al.	May 2008	B2
7373938	Nichols et al.	May 2008	B2
7377277	Hickey et al.	May 2008	B2
7387122	Nishibayashi et al.	Jun 2008	B2
7399528	Caponetti et al.	Jul 2008	B2
7401713	Ede et al.	Jul 2008	B2
7402564	Schteingart et al.	Jul 2008	B1
7414720	Wachtel et al.	Aug 2008	B2
D577815	Gokhale et al.	Sep 2008	S
7422013	Burr et al.	Sep 2008	B2
D579549	Birath et al.	Oct 2008	S
7448375	Gonda et al.	Nov 2008	B2
7448379	Yamashita et al.	Nov 2008	B2
7451761	Hickey et al.	Nov 2008	B2
7453556	Hochrainer et al.	Nov 2008	B2
D583463	Wood et al.	Dec 2008	S
7461653	Oliva	Dec 2008	B2
7462367	Schmidt et al.	Dec 2008	B2
7464706	Steiner et al.	Dec 2008	B2
7469696	Yang et al.	Dec 2008	B2
7500479	Nichols et al.	Mar 2009	B2
7503324	Barney et al.	Mar 2009	B2
7504538	Chang et al.	Mar 2009	B2
7517874	Beckett et al.	Apr 2009	B2
7520278	Crowder et al.	Apr 2009	B2
7521069	Patton et al.	Apr 2009	B2
7533668	Widerstrom	May 2009	B1
D594753	Eadicicco et al.	Jun 2009	S
7556798	Edwards et al.	Jul 2009	B2
7559322	Foley et al.	Jul 2009	B2
D597418	Stojek	Aug 2009	S
D597657	Kinsey et al.	Aug 2009	S
D598785	Stojek	Aug 2009	S
7584846	Senter	Sep 2009	B2
7598222	Prouty, Jr. et al.	Oct 2009	B2
D604832	Smutney	Nov 2009	S
D604833	Polidoro	Nov 2009	S
D605752	Polidoro	Dec 2009	S
D605753	Smutney	Dec 2009	S
7625865	Colombo	Dec 2009	B2
7648960	Steiner et al.	Jan 2010	B2
D613849	Smutney	Apr 2010	S
D614045	Gaudenzi et al.	Apr 2010	S
D614760	Smutney et al.	Apr 2010	S
7694676	Wachtel	Apr 2010	B2
7708014	Yamashita et al.	May 2010	B2
7709639	Stevenson	May 2010	B2
7713937	Schteingart et al.	May 2010	B2
7727963	Schteingart et al.	Jun 2010	B2
7735485	Yamashita et al.	Jun 2010	B2
D620812	Gaudenzi et al.	Aug 2010	S
7794754	Feldstein et al.	Sep 2010	B2
7799344	Oberg	Sep 2010	B2
7803404	Hokenson	Sep 2010	B2
7820676	Leone-Bay et al.	Oct 2010	B2
D628090	Stuiber et al.	Nov 2010	S
7833549	Steiner et al.	Nov 2010	B2
7833550	Steiner et al.	Nov 2010	B2
7842662	Schteingart et al.	Nov 2010	B2
D629505	Adamo	Dec 2010	S
D629506	Adamo	Dec 2010	S
D629886	Adamo	Dec 2010	S
D629887	Adamo	Dec 2010	S
D629888	Adamo	Dec 2010	S
D635241	McLean	Mar 2011	S
D635242	Adamo	Mar 2011	S
D635243	Kinsey	Mar 2011	S
7913688	Cross	Mar 2011	B2
D636867	Polidoro et al.	Apr 2011	S
D636868	Kinsey et al.	Apr 2011	S
D636869	Laurenzi et al.	Apr 2011	S
7919119	Straub et al.	Apr 2011	B2
7943178	Steiner et al.	May 2011	B2
7943572	Cheatham et al.	May 2011	B2
7954491	Hrkach	Jun 2011	B2
7959609	Gaydos et al.	Jun 2011	B2
D641076	Grunstad et al.	Jul 2011	S
D643308	Bergey	Aug 2011	S
D645954	Hately	Sep 2011	S
D647195	Clarke et al.	Oct 2011	S
D647196	Clarke et al.	Oct 2011	S
8037880	Zhu et al.	Oct 2011	B2
8037881	Pentafragas	Oct 2011	B2
8039431	Wilson et al.	Oct 2011	B2
8047203	Young et al.	Nov 2011	B2
D652322	Stuiber et al.	Jan 2012	S
8109267	Villax et al.	Feb 2012	B2
8119593	Richardson	Feb 2012	B2
D655622	Sadler et al.	Mar 2012	S
8133514	Milstein	Mar 2012	B2
8146588	Steiner et al.	Apr 2012	B2
8156936	Steiner et al.	Apr 2012	B2
D659020	Kemner	May 2012	S
D659022	Kemner	May 2012	S
8166970	Poole et al.	May 2012	B2
8172817	Michaels et al.	May 2012	B2
8196576	Kriksunov et al.	Jun 2012	B2
8201555	Chawla	Jun 2012	B2
8202992	Stevenson	Jun 2012	B2
D664640	Smutney et al.	Jul 2012	S
8215300	Steiner et al.	Jul 2012	B2
8217007	Schteingart et al.	Jul 2012	B1
8227409	Kraft	Jul 2012	B2
8236766	Schteingart et al.	Aug 2012	B2
8252916	Simard et al.	Aug 2012	B2
8258095	Boss et al.	Sep 2012	B2
8278308	Leone-Bay et al.	Oct 2012	B2
8293869	Bossard	Oct 2012	B2
8314106	Kraft	Nov 2012	B2
D671842	Bergey	Dec 2012	S
D674893	Kinsey et al.	Jan 2013	S
8372804	Richardson	Feb 2013	B2
8377869	Richardson	Feb 2013	B2
8389470	Steiner	Mar 2013	B2
8394414	Steiner et al.	Mar 2013	B2
8408200	Clark et al.	Apr 2013	B2
8420604	Hokenson	Apr 2013	B2
8424518	Smutney	Apr 2013	B2
8485180	Smutney et al.	Jul 2013	B2
8486894	Schteingart et al.	Jul 2013	B2
8499757	Smutney	Aug 2013	B2
8512932	Wilson et al.	Aug 2013	B2
8522775	Malhotra et al.	Sep 2013	B2
8536131	Schteingart et al.	Sep 2013	B2
8538707	Adamo et al.	Sep 2013	B2
8539946	Esteve et al.	Sep 2013	B2
8551528	Grant et al.	Oct 2013	B2
8563101	Spallek	Oct 2013	B2
8636001	Smutney	Jan 2014	B2
8642548	Richardson et al.	Feb 2014	B2
8671937	Steiner et al.	Mar 2014	B2
8677992	Villax	Mar 2014	B2
8763606	Mosier et al.	Jul 2014	B2
8778403	Grant et al.	Jul 2014	B2
8783249	Poole et al.	Jul 2014	B2
8808786	Jinks et al.	Aug 2014	B2
8820324	Smith et al.	Sep 2014	B2
8909487	Adamo et al.	Dec 2014	B2
8925726	Bergey	Jan 2015	B2
9041925	Adamo et al.	May 2015	B2
9138407	Caponetti et al.	Sep 2015	B2
20010020147	Staniforth et al.	Sep 2001	A1
20010039442	Gorge et al.	Nov 2001	A1
20020000225	Schuler et al.	Jan 2002	A1
20020033177	Ohki et al.	Mar 2002	A1
20020052381	Bar-Or et al.	May 2002	A1
20020053344	Davies et al.	May 2002	A1
20020053347	Ziaee	May 2002	A1
20020065239	Caplan et al.	May 2002	A1
20020088462	Genova et al.	Jul 2002	A1
20020101590	Shimaoka	Aug 2002	A1
20020144680	Nilsson et al.	Oct 2002	A1
20020161001	Kanstrup et al.	Oct 2002	A1
20030000524	Andersson et al.	Jan 2003	A1
20030010794	Herdtle et al.	Jan 2003	A1
20030013641	Steiner et al.	Jan 2003	A1
20030017211	Steiner	Jan 2003	A1
20030053960	Heijerman et al.	Mar 2003	A1
20030064097	Patel et al.	Apr 2003	A1
20030068378	Chen et al.	Apr 2003	A1
20030099636	Epshtein et al.	May 2003	A1
20030136405	Goede et al.	Jul 2003	A1
20030194420	Holl et al.	Oct 2003	A1
20030235538	Zirenberg	Dec 2003	A1
20040024180	Drauz	Feb 2004	A1
20040025875	Reber et al.	Feb 2004	A1
20040034014	Kanstrup et al.	Feb 2004	A1
20040038865	Gelber et al.	Feb 2004	A1
20040053819	Dodd et al.	Mar 2004	A1
20040062722	Gonda et al.	Apr 2004	A1
20040076588	Batycky et al.	Apr 2004	A1
20040077528	Steiner et al.	Apr 2004	A1
20040096403	Steiner	May 2004	A1
20040107963	Finlay et al.	Jun 2004	A1
20040121964	Madar et al.	Jun 2004	A1
20040138099	Draeger	Jul 2004	A1
20040151059	Robert, II et al.	Aug 2004	A1
20040151774	Pauletti et al.	Aug 2004	A1
20040157928	Kim et al.	Aug 2004	A1
20040163648	Burton	Aug 2004	A1
20040182387	Steiner et al.	Sep 2004	A1
20040187869	Bjorndal et al.	Sep 2004	A1
20040204439	Staniforth et al.	Oct 2004	A1
20040204440	Staniforth et al.	Oct 2004	A1
20040211419	Eason et al.	Oct 2004	A1
20040234615	Sabetsky	Nov 2004	A1
20040234616	Sabetsky	Nov 2004	A1
20040241232	Brown et al.	Dec 2004	A1
20040247628	Lintz et al.	Dec 2004	A1
20040250812	Davies et al.	Dec 2004	A1
20050000518	Dunkley et al.	Jan 2005	A1
20050039743	Taylor	Feb 2005	A1
20050043228	DeFelippis et al.	Feb 2005	A1
20050043247	Trunk et al.	Feb 2005	A1
20050056281	Snow	Mar 2005	A1
20050070469	Bloom	Mar 2005	A1
20050080000	Thurow et al.	Apr 2005	A1
20050119604	Bonney et al.	Jun 2005	A1
20050124644	Nilsson et al.	Jun 2005	A1
20050147581	Zamiri et al.	Jul 2005	A1
20050153874	Cheatham et al.	Jul 2005	A1
20050155601	Steiner et al.	Jul 2005	A1
20050183723	Pinon et al.	Aug 2005	A1
20050187749	Singley	Aug 2005	A1
20050214251	Pohl et al.	Sep 2005	A1
20050252508	Koerner	Nov 2005	A1
20050265927	Lee	Dec 2005	A1
20050274378	Bonney et al.	Dec 2005	A1
20060000469	Tseng	Jan 2006	A1
20060003316	Simard et al.	Jan 2006	A1
20060040953	Leone-Bay et al.	Feb 2006	A1
20060041133	Stevenson et al.	Feb 2006	A1
20060099269	Cheatham et al.	May 2006	A1
20060120969	Nilsson et al.	Jun 2006	A1
20060153778	Gelber et al.	Jul 2006	A1
20060160722	Green et al.	Jul 2006	A1
20060165756	Catani et al.	Jul 2006	A1
20060239933	Nilsson et al.	Oct 2006	A1
20060239934	Cheatham et al.	Oct 2006	A1
20060243275	Ruckdeschel et al.	Nov 2006	A1
20060249419	Taylor et al.	Nov 2006	A1
20060260777	Rashba-Step et al.	Nov 2006	A1
20060283758	Pasbrig	Dec 2006	A1
20070006876	Finlay et al.	Jan 2007	A1
20070017506	Bell et al.	Jan 2007	A1
20070020191	Boss et al.	Jan 2007	A1
20070027063	Boss et al.	Feb 2007	A1
20070044793	Kleinstreuer	Mar 2007	A1
20070049576	Barlow et al.	Mar 2007	A1
20070059373	Oberg	Mar 2007	A1
20070059374	Hokenson et al.	Mar 2007	A1
20070074989	Merboth et al.	Apr 2007	A1
20070077219	Fahl et al.	Apr 2007	A1
20070086952	Steiner	Apr 2007	A1
20070099454	Gordon	May 2007	A1
20070125375	Finlay et al.	Jun 2007	A1
20070128193	O'Neil et al.	Jun 2007	A1
20070151562	Jones	Jul 2007	A1
20070191462	Hettiarachchi	Aug 2007	A1
20070196503	Wilson et al.	Aug 2007	A1
20070207958	Bridon et al.	Sep 2007	A1
20070225587	Burnell	Sep 2007	A1
20070235029	Zhu et al.	Oct 2007	A1
20070240708	Schuckmann	Oct 2007	A1
20070272763	Dunne et al.	Nov 2007	A1
20070277820	Crowder	Dec 2007	A1
20070277821	Oliva et al.	Dec 2007	A1
20070295332	Ziegler	Dec 2007	A1
20070299074	Netz et al.	Dec 2007	A1
20080008764	Milstein	Jan 2008	A1
20080015457	Silva	Jan 2008	A1
20080047550	Steiner et al.	Feb 2008	A2
20080066739	LeMahieu et al.	Mar 2008	A1
20080108554	Jackson et al.	May 2008	A1
20080108574	Barlow et al.	May 2008	A1
20080115785	Eason et al.	May 2008	A1
20080127970	Steiner et al.	Jun 2008	A1
20080127974	Lastow	Jun 2008	A1
20080129791	King et al.	Jun 2008	A1
20080168987	Denny et al.	Jul 2008	A1
20080190424	Lucking et al.	Aug 2008	A1
20080197044	Hickey et al.	Aug 2008	A1
20080216824	Ooida	Sep 2008	A1
20080217199	Burress et al.	Sep 2008	A1
20080255468	Derchak et al.	Oct 2008	A1
20080260838	Hokenson et al.	Oct 2008	A1
20080260840	Alessi	Oct 2008	A1
20080295833	Rohrschneider et al.	Dec 2008	A1
20080314384	Harris et al.	Dec 2008	A1
20080319333	Gavish	Dec 2008	A1
20090025720	Chen	Jan 2009	A1
20090068274	Edwards et al.	Mar 2009	A1
20090084379	Goeckner et al.	Apr 2009	A1
20090084380	Gieschen et al.	Apr 2009	A1
20090134051	Rapp et al.	May 2009	A1
20090149727	Truitt et al.	Jun 2009	A1
20090151720	Inoue et al.	Jun 2009	A1
20090178676	Villax et al.	Jul 2009	A1
20090205657	Barney et al.	Aug 2009	A1
20090209502	Haeberlin et al.	Aug 2009	A1
20090232891	Gelber et al.	Sep 2009	A1
20090241949	Smutney	Oct 2009	A1
20090250058	Lastow	Oct 2009	A1
20090258818	Surolia et al.	Oct 2009	A1
20090314292	Overfield	Dec 2009	A1
20090320837	Smith et al.	Dec 2009	A1
20100012120	Herder	Jan 2010	A1
20100086609	Steiner et al.	Apr 2010	A1
20100113363	Holst et al.	May 2010	A1
20100163042	Bhowmick et al.	Jul 2010	A1
20100180894	Jones et al.	Jul 2010	A1
20100181225	Spallek et al.	Jul 2010	A1
20100190701	Day et al.	Jul 2010	A1
20100193380	Sullivan et al.	Aug 2010	A1
20100197565	Smutney et al.	Aug 2010	A1
20100212667	Smith et al.	Aug 2010	A1
20100235116	Adamo et al.	Sep 2010	A1
20100238457	Adamo et al.	Sep 2010	A1
20100278924	Oberg	Nov 2010	A1
20100288276	Ganderton et al.	Nov 2010	A1
20100326438	Dunne	Dec 2010	A1
20110000482	Gumaste et al.	Jan 2011	A1
20110003004	Hokenson	Jan 2011	A1
20110011394	Edwards et al.	Jan 2011	A1
20110083667	Briant	Apr 2011	A1
20110158935	Kraft	Jun 2011	A1
20110183901	Cheatham	Jul 2011	A1
20120014999	Grant et al.	Jan 2012	A1
20120040899	Costello	Feb 2012	A1
20120071510	Leone-Bay et al.	Mar 2012	A1
20120094905	Costello	Apr 2012	A1
20120115777	Richardson	May 2012	A1
20120122775	Boss et al.	May 2012	A1
20120160241	Oliva	Jun 2012	A1
20120164186	Grant et al.	Jun 2012	A1
20120178935	Stevenson	Jul 2012	A1
20120192865	Steiner et al.	Aug 2012	A1
20120207913	Smyth	Aug 2012	A1
20120240929	Steiner et al.	Sep 2012	A1
20120247235	Adamo et al.	Oct 2012	A1
20120247465	Wachtel	Oct 2012	A1
20120328676	Leone-Bay et al.	Dec 2012	A1
20130012710	Freeman et al.	Jan 2013	A1
20130053309	Kraft	Feb 2013	A1
20130104887	Smutney et al.	May 2013	A1
20130118491	Richardson et al.	May 2013	A1
20130125886	Richardson et al.	May 2013	A1
20130143801	Steiner et al.	Jun 2013	A1
20130189365	Hokenson	Jul 2013	A1
20130199527	Smutney et al.	Aug 2013	A1
20130289278	Kraft	Oct 2013	A1
20130291866	Smutney	Nov 2013	A1
20130291867	Smutney	Nov 2013	A1
20130303445	Wilson et al.	Nov 2013	A1
20130338065	Smutney	Dec 2013	A1
20140007873	Smutney	Jan 2014	A1
20140014106	Smutney	Jan 2014	A1
20140083421	Smutney	Mar 2014	A1
20140096771	Remmelgas et al.	Apr 2014	A1
20140100158	Richardson et al.	Apr 2014	A1
20140187490	Richardson et al.	Jul 2014	A1
20140199398	Grant et al.	Jul 2014	A1
20140227359	Leone-Bay et al.	Aug 2014	A1
20140243530	Stevenson et al.	Aug 2014	A1
20140271888	Grant et al.	Sep 2014	A1
20140290654	Poole et al.	Oct 2014	A1
20140302151	Leone-Bay et al.	Oct 2014	A1
20140308358	Oberg et al.	Oct 2014	A1
20140315953	Leone-Bay et al.	Oct 2014	A1
20150031609	Steiner et al.	Jan 2015	A1
20150045295	Smutney et al.	Feb 2015	A1
20150052977	Adamo et al.	Feb 2015	A1
20150065422	Kraft	Mar 2015	A1
20150080298	Costello et al.	Mar 2015	A1
20150108023	Bergey	Apr 2015	A1
20150122258	Steiner et al.	May 2015	A1
20150150980	Leone-Bay et al.	Jun 2015	A1
20150174210	Boss et al.	Jun 2015	A1
20150226656	Adamo et al.	Aug 2015	A1
20150231067	Mann	Aug 2015	A1
20150246188	Steiner et al.	Sep 2015	A1
20150283069	Smutney et al.	Oct 2015	A1
20150283213	Costello et al.	Oct 2015	A1
20150290132	Gelber et al.	Oct 2015	A1

Foreign Referenced Citations (235)

Number	Date	Country
2536047	Mar 2005	CA
2551182	Aug 2010	CA
101851213	Oct 2010	CN
2840442	Feb 1982	DE
3639836	Jun 1988	DE
19519840	Dec 1996	DE
69715	Jan 1983	EP
122036	Oct 1984	EP
143524	Jun 1985	EP
180543	May 1986	EP
220958	May 1987	EP
237507	Aug 1987	EP
257915	Feb 1988	EP
308637	Mar 1989	EP
360340	Mar 1990	EP
364235	Apr 1990	EP
387222	Sep 1990	EP
388621	Sep 1990	EP
606486	Dec 1993	EP
581473	Feb 1994	EP
655237	May 1995	EP
666085	Aug 1995	EP
748213	Dec 1996	EP
558879	May 1997	EP
844007	Dec 1998	EP
1060741	Dec 2000	EP
1114644	Jul 2001	EP
640354	Dec 2001	EP
1364967	Nov 2003	EP
825885	Mar 2004	EP
96911738	Jun 2004	EP
1598066	Nov 2005	EP
833652	Feb 2008	EP
1923087	May 2008	EP
2060268	May 2009	EP
2314298	Apr 2011	EP
475440	Nov 1937	GB
716815	Oct 1954	GB
2072536	Oct 1981	GB
2148841	Jun 1985	GB
2240337	Jul 1991	GB
2253200	Sep 1992	GB
2262452	Jun 1993	GB
2398065	Aug 2004	GB
53-020301	Jan 1988	JP
2115154	Apr 1990	JP
2-149545	Feb 1992	JP
H07-041428	Feb 1995	JP
09-208485	Aug 1997	JP
10234827	Sep 1998	JP
2002322294	Nov 2002	JP
2003-503420	Jan 2003	JP
2004-121061	Apr 2004	JP
2006-280620	Oct 2006	JP
2007-061281	Mar 2007	JP
200505517	Feb 2005	TW
9013285	Nov 1990	WO
9104011	Apr 1991	WO
9106287	May 1991	WO
9116038	Oct 1991	WO
9116882	Nov 1991	WO
9119524	Dec 1991	WO
9204069	Mar 1992	WO
9208509	May 1992	WO
9302712	Feb 1993	WO
9314110	Jul 1993	WO
9317728	Sep 1993	WO
9318754	Sep 1993	WO
9400291	Jan 1994	WO
9408552	Apr 1994	WO
9408599	Apr 1994	WO
9419041	Sep 1994	WO
9423702	Oct 1994	WO
9425005	Nov 1994	WO
9500127	Jan 1995	WO
9505208	Feb 1995	WO
9511666	May 1995	WO
9524183	Sep 1995	WO
9531979	Nov 1995	WO
9534294	Dec 1995	WO
9601105	Jan 1996	WO
9605810	Feb 1996	WO
9613250	May 1996	WO
9622802	Aug 1996	WO
9627386	Sep 1996	WO
9632149	Oct 1996	WO
9636314	Nov 1996	WO
9636317	Nov 1996	WO
9640206	Dec 1996	WO
9701365	Jan 1997	WO
9704747	Feb 1997	WO
9725086	Jul 1997	WO
9730743	Aug 1997	WO
9735562	Oct 1997	WO
9746206	Dec 1997	WO
9749386	Dec 1997	WO
9826827	Jun 1998	WO
9839043	Sep 1998	WO
9841255	Sep 1998	WO
9843615	Oct 1998	WO
9914239	Mar 1999	WO
9918939	Apr 1999	WO
9932510	Jul 1999	WO
9933862	Jul 1999	WO
9952506	Oct 1999	WO
0012116	Mar 2000	WO
0033811	Jun 2000	WO
0059476	Oct 2000	WO
0071154	Nov 2000	WO
0100654	Jan 2001	WO
0181321	Jan 2001	WO
0107107	Feb 2001	WO
0149274	Jul 2001	WO
0151071	Jul 2001	WO
0152813	Jul 2001	WO
0166064	Sep 2001	WO
0168169	Sep 2001	WO
0197886	Dec 2001	WO
0211676	Feb 2002	WO
0212201	Feb 2002	WO
0247659	Jun 2002	WO
02058735	Aug 2002	WO
02059574	Aug 2002	WO
02067995	Sep 2002	WO
02085281	Oct 2002	WO
02098348	Dec 2002	WO
02102444	Dec 2002	WO
03000202	Jan 2003	WO
03022304	Mar 2003	WO
03055547	Jul 2003	WO
03057170	Jul 2003	WO
03061578	Jul 2003	WO
03072195	Sep 2003	WO
03080149	Oct 2003	WO
03086345	Oct 2003	WO
03094951	Nov 2003	WO
2004012672	Feb 2004	WO
2004012720	Feb 2004	WO
2004033010	Apr 2004	WO
2004035121	Apr 2004	WO
2004041338	May 2004	WO
2004050152	Jun 2004	WO
2004054647	Jul 2004	WO
2004056314	Jul 2004	WO
2004060458	Jul 2004	WO
2004064862	Aug 2004	WO
2004075919	Sep 2004	WO
2004080401	Sep 2004	WO
2004080482	Sep 2004	WO
2004103304	Dec 2004	WO
2005020964	Mar 2005	WO
2005023348	Mar 2005	WO
2005028699	Mar 2005	WO
2005067964	Jul 2005	WO
2005081977	Sep 2005	WO
2005089722	Sep 2005	WO
2005089843	Sep 2005	WO
2005102428	Nov 2005	WO
2005102429	Nov 2005	WO
2005113042	Dec 2005	WO
2005113043	Dec 2005	WO
2005120616	Dec 2005	WO
2006010248	Feb 2006	WO
2006017688	Feb 2006	WO
2006023849	Mar 2006	WO
2006023943	Mar 2006	WO
2006023944	Mar 2006	WO
2006037636	Apr 2006	WO
2006059939	Jun 2006	WO
2006061637	Jun 2006	WO
2006086107	Aug 2006	WO
2006090149	Aug 2006	WO
2006105501	Oct 2006	WO
2007007110	Jan 2007	WO
2007016600	Feb 2007	WO
2007019229	Feb 2007	WO
2007024953	Mar 2007	WO
2007030706	Mar 2007	WO
2007033316	Mar 2007	WO
2007033372	Mar 2007	WO
2007042822	Apr 2007	WO
2007068896	Jun 2007	WO
2007075534	Jul 2007	WO
2007093310	Aug 2007	WO
2007098500	Aug 2007	WO
2007100535	Sep 2007	WO
2007118342	Oct 2007	WO
2007118343	Oct 2007	WO
2007121411	Oct 2007	WO
2007132217	Nov 2007	WO
2007144607	Dec 2007	WO
2007144614	Dec 2007	WO
2008001744	Jan 2008	WO
2008008021	Jan 2008	WO
2008014613	Feb 2008	WO
2008020217	Feb 2008	WO
2008060484	May 2008	WO
2008092864	Aug 2008	WO
2008110809	Sep 2008	WO
2009005546	Jan 2009	WO
2009008001	Jan 2009	WO
2009009013	Jan 2009	WO
2009047281	Apr 2009	WO
2009055030	Apr 2009	WO
2009055740	Apr 2009	WO
2009055742	Apr 2009	WO
2009095684	Aug 2009	WO
2009121020	Oct 2009	WO
2009140587	Nov 2009	WO
2009152477	Dec 2009	WO
2009155581	Dec 2009	WO
2010021879	Feb 2010	WO
2010078373	Jul 2010	WO
2010080964	Jul 2010	WO
2010102148	Sep 2010	WO
2010105094	Sep 2010	WO
2010108046	Sep 2010	WO
2010125103	Nov 2010	WO
2010144785	Dec 2010	WO
2010144789	Dec 2010	WO
2011017554	Feb 2011	WO
2011056889	May 2011	WO
2011163272	Dec 2011	WO
2012064892	May 2012	WO
2012135765	Oct 2012	WO
2012174472	Dec 2012	WO
2012174556	Dec 2012	WO
2013063160	May 2013	WO
2014012069	Jan 2014	WO
2014036323	Mar 2014	WO
2014066856	May 2014	WO
2014144895	Sep 2014	WO
2015010092	Jan 2015	WO
2015021064	Feb 2015	WO
2015148905	Oct 2015	WO

Non-Patent Literature Citations (607)

Entry
Shields, Irritable bowel syndrome, archived Jun. 21, 2009, available at: https://web.archive.org/web/200906211 00502/http://www.gastroenterologistpaloalto.com/conditions-diseases-irritable-bowelsyndrome-palo-alto-ca. html.
Smith et al., Evaluation of novel aerosol formulations designed for mucosal vaccination against infleunza virus. Vacine, vol. 21, pp. 2805-2812 (2003).
U.S. Appl. No. 14/873,041, filed Oct. 1, 2015.
Design U.S. Appl. No. 29/504,212, filed Oct. 2, 2014.
U.S. Appl. No. 14/774,311, filed Sep. 10, 2015.
U.S. Appl. No. 14/746,656, filed Jun. 22, 2015.
Young et al., Encapsulation of lysozyme in a biodegradable polymer by preparation with a vapor-over-liquid antisolvent. Journal of Pharmaceutical Sciences, 88:640-650 (1999).
Hazard Prevention and Control in the Work Environment: Airborne Dust WHO/SDE/OEH/99. 14 Chapter 1—Dust: Definitions and Concepts [retrieved from internet by Examiner in European case on Sep. 22, 2015]. <URL: http://www.who.int/occupational—health/publications/airdust/en/> published on Oct. 29, 2004 as per Wayback Machine.
Owens et al., Blood glucose self-monitoring in type 1 and type 2 diabetes: reaching a multidisciplinary consensus. Diabetes and Primary Care, vol. 6, No. 1, pp. 8-16 (2004).
Amodeo et al., Pain peptides. Solution structure of orphanin FQ2. FEBS Letters, vol. 473, Issue 2, pp. 157-160 (2000).
Vanderah et al., FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious k opioid agonist with unprecedented selectivity. The Journal of Pharmacology and Experimental Therapeutics, vol. 310, No. 1, pp. 326-333 (2004).
Li et al. “GLP-1; a novel zinc finger protein required in somatic cells of the gonad for germ cell development.” Dev Biol 301:106, 2007.
Li, Jun. Chapter 15: Drug Therapy of Metabolic Diseases. Clinical Pharmacotherapy, People's Medical Publishing House, 1st Edition, pp. 333-335 (2007).
Lian et al. “A Self-Complimentary Self-Assembling Microsphere System: Application for Intravenous Delivery of the Antiepilpetic and Neuroprotectant Compound Felbanate.” J Pharm Sci 89:867-875, 2000.
Lim, “Microencapsulation of Living Cells and Tissues”, J. Pharm. Sci., 70: 351-354 (1981).
Linder et al., Increase in serum insulin levels is correlated with lung distribution after pulmonary delivery of Technosphere/Insulin. Diabetologia, No. 46, A277 (2003).
Liu et al., “Pulmonary delivery of free and liposomal insulin”, Pharmaceuticals Res. 10:228-232, 1993.
Lorber D, Howard CP, Ren H, et al. Reduced incidence and frequency of hypoglycemia in an integrated analysis of pooled data from clinical trials of subjects with type 2 diabetes using prandial inhaled Technosphere® insulin. AACE 2010; Poster 270.
Luque et al. “Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes.” J. Endocrinol 173:465, 2002.
Luzi, L. and DeFronzo, R.A. “Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans.” Am. J. Physiol. 257 (Endocrinol. Metab. 20):E241-E246, 1989.
Luzio, S.D., et al. “Intravenous insulin simulates early insulin peak and reduces post-prandial hyperglycaemia/hyperinsulinaemia in type 2 (non-insulin-dependent) diabetes mellitus.” Diabetes Res. 16:63-67, 1991.
Malhotra et al., Exendin-4, a new peptide from Heloderma suspectum venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini. Regulatory Peptides, 41:149-56, 1992.
Mandal “Inhaled insulin for diabetes mellitus.” Am J Health Sys Pharm 62:1359-64, 2005.
Mann “Pulmonary insulin—the future of prandial insulin therapy.” Presented at the 5th Annual Meeting of the Diabetes Technology Society, Nov. 2005, abstract A94.
Mannkind Corporation “Postprandial hyperglycemia: clinical significance, pathogenesis and treatment.” MannKind corporation Monograph. 2009.
MannKind Corporation, Pulmonary Delivery: Innovative Technologies Breathing New Life into Inhalable Therapeutics, www.ondrugdelivery.com, 2006.
Burcelin et al., Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analong of glucagon-like peptide-1. Metabolism, vol. 48, No. 2, pp. 252-258 (1999).
Marino MT, Cassidy JP, Smutney CC, et al. Bioequivalence and dose proportionality of Afrezza® inhalation powder administered using a Gen2 inhaler compared to the MedTone® inhaler. Diabetes Technology Meeting 2010; poster.
Marino MT, Cassidy JP, Smutney CC, et al. Improvement in bioavailability of FDKP with the NexGen2A device: Implications for delivery of pulmonary insulin. Third International Conference on Advanced Technologies and Treatments for Diabetes 2010; Poster 108.
Marino MT, Cassidy JP, Smutney CC, et al. Improvement in bioavailability of FDKP and insulin with the NGDSB device. Third International Conference on Advanced Technologies and Treatments for Diabetes 2010; Poster 107.
Marino MT. A pharmacokinetic/pharmacodynamic model of inhaled insulin with application to clinical trial simulation. ADA 2010; Abstract 2105-PO.
Marino MT. Cassidy JP, Baughman RA, et al. C-peptide correction method to determine exogenous insulin levels in pk studies using Afresa® (Technosphere® insulin [TI]) ADA 2009; Poster 1451.
Marshall “Preventing and detecting complications of diabetes.” BMJ 333:455, 2006.
Mastrandrea “A breath of life for inhaled insulin: severe subcutaneous insulin resistance as an indication.” Pediatric Diabetes 2010: 11: 377-379.
Mathiowitz, Morphology of Polyanhydride Microsphere Delivery Systems, Scanning Microscopy, 4: 329-340 (1990).
Mathiowitz, Novel microcapsules for delivery systems. Reactive Polymers, 6: 275-283 (1987).
Mathiowitz, Polyanhydride microspheres as drug carriers I, hot-melt microencapsulation. J. Controlled Medicine, 5: 13-22 (1987).
Mathiowitz, Polyanhydride microspheres as drug carriers II, microencapsulation by solvent removal. J. Appl. Polymer Sci., 35: 755-774 (1988).
Mathiowitz, Polyanhydride microspheres IV, morphology and characterization systems made by spray drying. J. App. Polymer Sci., 45: 125-134 (1992).
Matsui et al. “Hyperplasia of type II pheumocytes in pulmonary lymphangioleiomyomatosis. Immunohistochemical and electron microscope study.” Arch Pathol Lab Med 124:1642, 2000.
Matthews DR et al. “Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.” Diabetologia. Jul. 1985;28(7):412-9.
McElduff A et al. “Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx(R) insulin diabetes management system.” Br J Clin Pharmacol 59:546, 2005.
McMahon et al., “Effects of basal insulin supplementation on disposition of mixed meal in obese patients with NIDDM”, Diabetes, vol. 38, pp. 291-303 (1989).
Meier et al. “Absence of a memory effect for the insulinotropic action of glucagon-like peptide-1 (GLP-1) in healthy volunteers.” Horm Metab Res 35:551, 2003.
Meier et al. “Secretion, degradation, and elimination of glucagon-like peptide-1 and gastric inhibitor polypeptide in patients with chronic renal insufficiency and healthy control subjects.” Diabetes 53:654, 2004.
Meier et al. “The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.” Am J Physiol Endocrinol Metab 290:E1118, 2006.
Mendes et al., A non-dimensional functional relationship for the fine particle fraction produced by dry powder inhalers, Aerosol Science 38, pp. 612-624 (2007).
Mentlein et al., Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem., 214:829-835, 1993.
Merck Manual 17th, Japanese Edition, NIKKEI BP Corp., 1999, p. 167-179.
Mitchell et al. “Intranasal Insulin: PK Profile Designed Specifically for Prandial Treatment of Type 2 Diabetes.” Drug Development Research 69(3):143-152 (2008).
Monnier et al. “Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.” JAMA 295:1681, 2006.
Montrose-Rafizadeh et al., Diabetes, 45(Suppl. 2):152A, 1996.
Moren, Aerosols in Medicine (2nd Ed.), Elsevier, pp. 321-350 (1993).
Mudaliar et al., Insulin Therapy in Type 2 Diabetes. Endocrinology and Metabolism Clinics, vol. 30, No. 4, pp. 1-32 (2001).
Nagai et al., “Powder Dosage Form of Insulin for Nasal Administration”, J. Control Ref., 1:15-22 (1984).
Narayan et al. “Impact of recent increase in incidence on future diabetes burden.” Diabetes Care 29:2114, 2006.
Naslund E et al. “GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans.” Am J Physiol (Regulatory Integrative Comp Physiol 46):R910, 1999.
Naslund E et al. “Prandial subcutaneous injections of glucagon-like petide-1 cause weight loss in obese human subjects.” Br J Nutrition 91:439, 2004.
International Search Report mailed on Nov. 21, 2013 for International Application No. PCT/US2013/057397 filed on Aug. 29, 2013.
Eavarone et al., A voxel-based monte carlo model of drug release from bulk eroding nanoparticles. Journal of Nanoscience and Nanotechnology, vol. 10, pp. 5903-5907 (2010).
Marino MT, Cassidy JP, Smutney CC, et al. Improvement in bioavailability of FDKP with the NexGen2A device: Implications for delivery of pulmonary insulin. Diabetes Technology Meeting 2009; poster.
Rosenstock et al. “Efficacy and Safety of Technosphere Inhaled Insulin Compared With Technosphere Powder Placebo in Insulin-Naive Type 2 Diabetes Suboptimally Controlled with Oral Agents.” Diabetes Care, vol. 31, No. 11, pp. 2177-2182, 2008.
Rosenstock et al. “Inhaled Insulin Improves Glycemic Control when Substituted for or Added to Oral Combination Therapy in Type 2 Diabetes.” Ann Intern Med 143:549-558, 2005.
Rosenstock et al., “Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes”, Diabetes Care, 28(4):950-5 (2005).
Rosenstock J, Baughman RA, Ribera-Schaub T, et al. A randomized, double-blind, placebo controlled study of the efficacy and safety of inhaled Technosphere® insulin in patients with type 2 diabetes (T2DM). Diabetes 2005;54: Abstract 357-OR.
Rosenstock J, Lorber D, Petrucci R, et al. Basal/bolus with prandial inhaled Technosphere® insulin (TI) plus insuli glargine qd vs biaspart 70/30 insulin bid in T2 DM inadequately controlled on insulin with/without oral agents ADA 2009; Poster 466.
Rosenstock J, Lorger DL. Gnudi L, et al.Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet 2010;375:2244-2253.
Rossiter A, Amin N, Harris R, et al. Pulmonary safety of inhaled Technosphere® insulin therapy in adults with diabetes using high-resolution computerized tomography of the chest. Diabetologia 2009; 52 (suppl 1).
Rossiter A, Howard C, Amin N, et al. Technosphere® insulin: Safety in type 2 diabetes mellitus. ADA 2010; Poster 523.
Roumeliotis, New inhaler launched with a bag, in-Pharma Technologist.com, Decision News Media SAS (2006).
Rousseau et al. “Drug delivery by fumaryl diketopiperazine particles: evidence for passive transport.” Presented at the American Diabetes Association 64th Scientific Sessions, Jun. 2004, abstract 484-P.
Rubin RR, Peyrot M. Psychometric properties of an instrument for assessing the experience of patients treated with inhaled insulin: The inhaled insulin treatment questionnaire (INTQ) Health & Quality of Life Outcomes 2010.8:32.
Rubin RR, Peyrot M; Patient reported outcomes in adults with type 1 diabetes using mealtime Afresa® (inhaled Technosphere® insulin) or rapid acting insulin with basal insulin ADA 2009; Poster 1881.
Ryan EA et al. “Successful islet transplantation. Continued insulin reserve provides long-term glycemic control.” Diabetes 51:2148-2157, 2002.
Sajeesh et al., Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. International Journal of Pharmaceuticals, 2006, 325, pp. 147-154.
Sakagami M et al. “Respirable microspheres for inhalation: the potential of manipulating pulmonary disposition for improved therapeutic efficacy.” Clin Pharmacokinet 44(3):263-277, 2005.
Sakr, A new approach for insulin delivery via the pulmonary route: design and pharmacokinetics in non-diabetic rabbits. International Journal of Pharmaceutics, 86: 1-7 (1992).
Salib, Utilization of sodium alginate in drug microencapsulation. Pharazeutische Industrie, 40(11a): 1230-1234 (1978).
Saraceni C et al. “Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function.” Drugs R D 8:145, 2007.
Sarrach et al., “Binding and entrapment of insulin by liposomes made of lecithin-phosphotidix acid in acid solution” Pharmazie 40:642-645, 1985 (German and English Abstract).
Savage et al., “Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying healthy volunteers”, Gut, vol. 28, pp. 166-170, 1987.
Sawhney et al., Bioerodible hydrogels based on photopolymerized poly(ethylene glycol)-co-poly(a-hydroxy acid) diacrylate macromere. Macromolecules, 26: 581-587 (1993).
Schaffer et al. “Assembly of high-affinity insulin receptor agonists and antagonists from peptide building blocks.” PNAS 100:4435-4439, 2003.
Schepp et al., Eur. J. PharmacoL, 269:183-91, 1994.
Scherbaum “Unlocking the opportunity of tight glycaemic control. Inhaled insulin: clinical efficacy.” Diabetes Obesity and Metabolism 7:S9-S13, 2005.
Schirra et al. “Gastric emptying and release of incretin hormones after glucose ingestion in humans.” J Clin Invest 7:92-103, 1996.
Schluter et al., “Pulmonary Administration of Human Insulin in volunteers and Type I Diabetics”, Diabetes, 33, (Suppl) 298 (1984).
Schneider et al., “Stimulation by proinsulin of expression of plasminogen activator inhibitor type 1 in endothelial cells”, Diabetes 41(7):890-895 (1992).
Schon, Istvan et al. “Formation of Aminosuccinyl Peptides During Acidolytic Deprotection Followed by their Tranformation to Piperazine-2, 5-dione Derivatives in Neutral Media.” International Journal of Peptide & Protein Research, 14(5), 485-494, 1979.
Schroder, “Crystallized carbohydrate spheres as a slow release matrix for biologically active substances”, Biomaterials 5:100-104, 1984.
Scrocchi et al. “Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.” Nature Medicine 2:1254-1258, 1996.
Seshiah & Balaji, “Early Insulin Therapy in Type 2 Diabetics”, Int. J. Diabetes in Developing Countries, 2003, 23, 90-93.
Seville, P.C. et al., Preparation of dry powder dispersions for non-viral gene delivery by freeze-drying and spray drying. J. Gene Medicine 2002; 4:428-437.
Shah et al. “Lack of suprression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus.” J Clin Indocrinol Metab 85:4053, 2000.
Shelly et al. “Polysorbate 80 hypersensitivity.” The Lancet 345:1312, 1995.
Shimada et al. Translocation pathway of the intertracheally instilled ultrafine particles from the lung into the blood circulation in the mouse. Toxicologic Pathology pp. 949-957 (2006).
Shojania et al. “Effect of quality improvement strategies for type 2 diabetes on glycemic control.” JAMA 296:427, 2006.
Silverstein et al., “Care of Children and Adolescens with Type 1 Diabetes, a Statement of the American Diabetes Association”, Diabetes Care, Jan. 2005, vol. 28, p. 186-212.
Singh et al., Use of 125I-[Y39]exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig. Regul. Pept. 53 : 47-59 (1994).
Simms JR, Carballo I, Auge CR, et al. Assessment of immunotoxic effects on humoral and cellular immune parameters following repeated inhalation of Technosphere insulin in the rat. Diabetes 2005;54:Abstract 2078-PO.
Skyler, Pulmonary insulin: current status. Diabetes Voice, vol. 51, Issue I, p. 23-25, 2006.
Skyler “Pulmonary Insulin Delivery—State of the Art 2007” Diabetes Tecnology & Therapeutics, vol. 9, Supplement 1, pp. S1-S3. 2007.
Skyler JS et al. “Use of inhaled insulin in a basal/bolus insulin regimen in Type 1 diabetic subjects.” Diabetes Care 28:1630-1635, 2005.
Smith et al. “New-onset diabetes and risk of all-cause and cardiovascular mortality.” Diabetes Care 29:2012, 2006.
Smutney CC, Friedman EM, Amin N. Inspiratory efforts achieved in use of the Technosphere® insulin inhalation system. Diabetes Technology Meeting 2008; Poster SMUT8052.
Smutney CC, Friedman EM, Amin N. Inspiratory efforts achieved in use of the Technosphere® insulin inhalation system. Journal of Diabetes Science and Technology 2009 3(5):1175-1189.
Smutney CC, Polidoro JM, Adamo B, et al. In-vitro performance improvement realized in a next generation dry powder delivery system. Diabetes Technology Meeting 2009; poster.
Smutney CC, Polidoro JM, Adamo B, Shah S. In vitro performance improvement realized in a next generation dry powder delivery system. Third International Conference on Advanced Technologies and Treatments for Diabetes 2010; Poster 122.
Smutney CC, Polidoro JM. Easy-to-use next-generation pulmonary insulin delivery system. ADA 2010; Abstract 2093.
Smutney CC, Polidoro JM. Improvements realized in a next-generation pulmonary insulin delivery system. ADA 2010; Abstract 2097.
Sodium chloride is a natural product from http://www.wqpmag.com/potassium-chloride-vs-sodium-chloride, pp. 1-3.
Nathan DM et al. “Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy.” Diabetes Care 29:1963-1972, 2006.
Nathan DM et al. “Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy.” Diabetes Care 31:173-175, 2008.
Nathan DM et al. “Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy.” Diabetes Care 32:193-203, 2009.
Nathan et al. “Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes.” New Eng. J. Med. 353:2643-2653, 2005.
Nathan, “Initial Management of Glycemia in Type 2 Diabetes Melllitus” N. Eng. J. Med., 2002, 347, 1342-9.
Nauck “Is glucagon-like peptide 1 an incretin hormone?” Diabetologia 42:373-379, 1999.
Nauck et al. “Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.” Am J Physiol 273 (Endocrinol Metabl 36):E981, 1997.
Nauck et al. “Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.” Diabetologia 29:46-52, 1986.
Nauck et al., Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab., 87:1239-1246, 2002.
Nauck et al., Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia, 39:1546-1553, 1996.
Nauck et al., Normalization of fasting hyperglycemia by exogenous GLP-1 (7-36 amide) in type 2 diabetic patients. Diabetologia, 36:741-744, 1993.
Nemmar et al., Passage of inhaled particles into the blood circulation in humans. Circulation pp. 411-414 (2002).
Newman, Principles of metered-dose inhaler design. Respiratory Care, vol. 50, No. 9, pp. 1177-1190 (2005).
Next Generation Inhaler Nears Market, Manufacturing Chemist, Cambridge Consultants, Polygon Media Ltd. (2006).
NHS Clinical Guidelines, “Type 1 diabetes diagnosis and mangement of type 1 diabetes in children and young people”, National Collaborating Centre for Women's and Children's Health Commissioned by the National Institute for Clinical Excellence, Sep. 2004, p. 1-217.
Non-covalent interactions from UC Davis ChemWiki, pp. 1-5.
Nystrom et al. “Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetic patients with stable coronary artery disease.” Am J Physiol Endocrinol Metabl 287:E1209, 2004.
Oberdorster et al., Correlation between particle size, in vivo particle persistence, and lung injury. Environ Health Perspect 102 Suppl 5, pp. 173-179 (1994).
Oberdorster et al.,Pulmonary effects of inhaled ultrafine particles. International Archives of Occupational and Environmental Health, vol. 74, pp. 1-8 (2001).
Okumura et al., Intratracheal delivery of insulin: absorption from solution and aerosol by rat lung. Int. J. Pharmaceuticals 88: 63-73 (1992).
O'Neill, Air pollution and inflammation in type 2 diabetes: a mechanism for susceptibility. Occup Environ Med. vol. 64, pp. 373-379 (2007).
Orgsoltab et al., Division of Organic Chemistry. Ohio Northern University. Nov. 24, 2009. Available from: <http://www2.onu.edu/˜b-meyers/organic—solvents.html>.
Oshima et al. “Comparison of half-disappearance times, distribution vols. And metabolic clearance rates of exogenous glucagon-like peptide 1 and glucagon in rats.” Regulatory Peptides 21:85, 1988.
Ostrovsky, Gene. Mannkind Inhalation Insulin Going to FDA to Seek Approval [on-line]. MedGadget.com, posted on Mar. 17, 2009, Retrieved from the Internet: <URL:http://medgadget.com/2009/03mannkind—inhalation—insulin—going—to—fda—to—seek—approval.html>.
Owens et al. “Inhaled human insulin.” Nature Reviews, Drug Discovery, vol. 5, No. 5, pp. 371-372, May 2006.
Owens et al. “Alternative routes of insulin delivery.” Diabetic Medicine 20:886-898, 2003.
Ozyazgan et al. “Effect of glucagon-like peptide-1)7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats.” Pharmacology 74:119, 2005.
Pacini P, Marino MT. Evaluation of endogenous and exogenous components to peripheral insulin concentration during administration of inhaled insulin. ADA 2010; Abstract 2094-PO.
Patton “Mechanisms of macromolecule absorption by the lungs.” Advanced Drug Delivery Reviews 19:3, 1996.
Patton “Unlocking the opportunity of tight glycaemic control. Innovative delivery of insulin via the lung.” Diabetes Obesity and Metabolism 7:S5, 2005.
Patton & Platz, Routes of Delivery: Case studies: pulmonary delivery of peptides and proteins for systemic action. Adv. Drug. Del. Rev. 8: 179-196 (1992).
Patton et al. “The lungs as a portal of entry for systemic drug delivery.” Proc Am Thorac Soc 1:338, 2004.
Patton et al. “Clinical pharmacokinetics and pharmacodynamics of inhaled insulin.” Clin Pharmacokinet 43:781-801, 2004.
Patton et al., “Inhaled Insulin”, Advanced Drug Delivery Reviews, 35, Feb. 1999, p. 235-247.
Onoue et al., Dry powder inhalation systems for pulmonary delivery of therapeutic peptides and proteins. Expert Opin. Ther. Patents 18(4):429-442 (2008).
Pearson et al., Systematically Initiating Insulin, supplemental to vol. 32, No. 1, 19S-28S, 2006.
Perera et al. “Absorption and Metabolic Effect of Inhaled Insulin.” Diabetes Care, vol. 25, No. 12, Dec. 2002, p. 2276-2281.
Pesic, Inhaler delivers more drug to the deep lung, says Cambridge Consultants. in-Pharma Technologist.com, http://www/in-pharmatechnologist.com/content/view/print/344335, Dec. 1, 2010.
Petkowicz et al., “Hypoglycemic effect of liposome-entrapped insulin adminstered by various routes into normal rats”, Pol. J. Pharmacol. Pharm. 41:299-304 (1989).
Petrucci R, Amin N, Lovertin P. et al. Pulmonary function tests remain similar in patients who received Technosphere® insulin and in patients currently receiving standard antidiabetic therapy. Diabetologia 2009; 52 (suppl 1).
Peyrot et al. “Resistance to insulin therapy among patients and providers.” Diabetes Care 28:2673-2679, 2005.
Peyrot M, Rubin RR, Otterbach K. Effect of Technosphere® inhaled insulin on treatment satisfaction, glycemic control and quality of life. Diabetes 2006; 55:Abstract 423-P.
Pezron et al., Insulin aggregation and asymmetric transport across human bronchial epithelial cell monolayers (Calu-3). J. Pharmaceutical Sci. 91: 1135-1146 (2002).
Pfeiffer MA et al. Insulin secretion in diabetes mellitus. Am J Med 70:579-88, 1981.
Pfutzner et al., Abstract 812: Influence of small dose i.v.s.c. and pulmonary insulin treatment on grandial glucose control in patients with type 2 diabetes. Internet Article [Online] 2001, 37th Annual Meeting of the EASD, Glasgow, Sep. 9-13, 2001.
Pfutzner A et al. “Pulmonary insulin delivery by means of the Technosphere(TM) drug carrier mechanism.” Expert Opin Drug Deliv 2:1097-1106, 2005.
Pfützner A et al. “Technosphereelnsulin—a new approach for effective delivery of human insulin via the pulmonary route.” Diab Tech Ther 4:589-594, 2002.
Pfützner A et al. “Lung distribution of radiolabeled Technosphere™/Insulin.” Diabetes 52 Supplement, Jun. 2003, A107.
Pfützner A et al. Pilot study with Technosphere/PTH(1-34)—a new approach for effective pulmonary delivery of parathyroid hormone (1-34). Horm Metab Res 35:319-323, 2003.
Pfützner A et al. “Variability of insulin absorption after subcutaneous and pulmonary application in patients with type 2 diabetes.” Diabetes 51 Supplement, Jun. 2002, A47-48.
Bilheimer DW, Ren H, Boss AH. Analysis of cardiovascular adverse events in patients with type 1 or type 2 diabetes enrolled in selected therapeutic trials in the phase 2/3 Technosphere® insulin development program. ADA 2011. Poster 922-P.
Billings CC, Smutney CC, Howard CP, et al. Handleability and characterization of inhalation profiles using the Gen2 delivery system in a pediatric population. Diabetes Technology Meeting 2010; poster.
Biodel's Intellecutal Property position strengthened for ultra-rapid-acting insulin programs by notice of intent to grant from European Patent Office. Newswire Feed, published May 2, 2012.
Blazquez E et al. “Glucagon-like peptide-1 (7-36) amide as a novel neuropeptide.” Mol Neurobio 18:157, 1998.
Bloomgarden “Gut-derived incretin hormones and new therapeutic approaches.” Diabetes Care 27:2554, 2004.
Boer et al., Design and application of a new modular adapter for laser diffraction characterization of inhalation aerosols. International Jornal of Pharmaceutics 249, pp. 233-245 (2002).
Boer et al., Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. Part 1. Inhalation characteristics, work of breathing and volunteers' preference in dependence of the inhaler resistance. Int. J. Pharm. 130 (1996) 231-244.
Bojanowska “Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity and stress.” Med Sci Monit 11:RA271, 2005.
Bonner-Weir S et al. “New sources of pancreatic beta-cells.” Nat Biotechnol 23:857-61, 2005.
Boss AH et al. “Inhaled Technosphere®/Insulin: Glucose elimination at the right time?” Poster presented at the American Diabetes Association 65th Scientific Sessions, Jun. 2005, abstract 443-P.
Boss AH et al. “Insulin bio-effect is limited by speed of absorption and elimination: similarities between an inhaled insulin formulation that mimics first-phase kinetics and i.v. insulin.” Diabetologia 47:A314, 2004.
Boss AH et al. “Mimicry of the early phase insulin response in humans with rapidly available inhaled insulin accelerates post prandial glucose disposal compared to slower bioavailable insulin.” Presented at the American Diabetes Association 65th Scientific Sessions, Jun. 2005, abstract 1373-P.
Boss AH et al. “Does kinetics matter? Physiological consequences of the ability of Technosphere®/Insulin inhalation to mimic first phase insulin release.” Presented at the 5th Annual Meeting of the Diabetes Technology Society, Nov. 2005, abstract A14.
Boss AH et al. “Markedly reduced post prandial glucose excursions through inhaled Technosphere®/Insulin in comparison to SC injected regular insulin in subjects with type 2 diabetes.” 1st Annual Meeting of the European Association for the Study of Diabetes, Sep. 2005, abstract 816.
Boss AH et al. “The variability and time-action profile of inhaled Technosphere®/Insulin compares favorably to that of subcutaneous human regular insulin.” Presented at the American Diabetes Association 65th Scientific Sessions, Jun. 2005, abstract 358-OR.
Boss et al. “Prandial Insulin: Is Inhaled Enough?” Drug Development Research 69(3)138-142 (2008).
Boss A H, Petrucci R, Lorber D. Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin. Journal of diabetes science and technology 2012;6:773-779.
Boss AH, Baughman RA, Evans SH, et al. A 3 month comparison in type 1 diabetes of inhaled Technosphere®/Insulin (TI) to Sc administered rapid-acting insulin analogue (RAA) as prandial insulin in a basal/prandial regimen. Diabetes 2006; 55:A97.
Boss AH, Evans SH, Firsov I, et al. Technosphere® insulin as effective as sc rapid acting insulin analogue in providing glycemic control in a 6-month study of patients with type 2 diabetes. Diabetes Technology Meeting 2006; poster.
Boss AH, Evans, SH, Ren, H, et al. Superior post prandial glucose control in patients with type 1 diabetes when using prandial technosphere insulin compared to NovoLog. Diabetologia 2006; Abstract 181.
Boss AH, Marino MT, Cassidy JP, et al. C-peptide correction method to determine exogenous insulin levels in pharmacokinetic studies using Technosphere® insulin. Diabetologia 2009; 52 (suppl 1).
Boss AH, Raskin P, Philips M, et al. Glycosylated hemoglobin and hypoglycaemia in patients with Type 2 diabetes mellitus: Technosphere® insulin and usual antihyperglycaemic regimen vs usual antihyperglycaemic regimen. Diabetologia 2010;53(suppl 1).
Brandt D, Boss AH. The next generation insulin therapy. OndrugDelivery 2006 (published online).
Brange et al., “Insulin Structure and Stability”, Pharm Biotechnol, 5:315-50 (1993).
Bray “Exanatide” Am J Health-Sys Pharm 63:411, 2006.
Brownlee et al. “Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications.” JAMA 295:1707, 2006.
Bruce, D.G., et al. “Physiological importance of deficiency of early prandial insulin secretion in non-insulin-dependent diabetes.” Diabetes 37:736-44, 1988.
Bullock BP et al. “Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.” Endocrinology 137:2968, 1996.
Burcelin et al. “Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus.” Ann N Y Acad Sci. Jun. 18, 1999;875:277-85.
Calles-Escandon, J. and Robbins, D.C. “Loss of early phase insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose.” Diabetes 36:1167-72, 1987.
Camilleri, Clinical Practice: Diabetic Gastroparesis. The New England Journal of Medicine, 356: 820-829 (2007).
Campos et al. “Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon0like peptide-1 in the mouse.” Endocrinology 134:2156, 1994.
Cassidy J P, Amin N, Marino M, et al. Insulin lung deposition and clearance following Technosphere® insulin inhalation powder administration. Pharmaceutical Research 2011; 28:2157-2164.
Cassidy J, Amin N, Baughman R, et al. Insulin kinetics following Technosphere® insulin inhalation powder administration unchanged in albuterol-treated asthmatics. ADA 2010; Poster 522.
Cassidy J, Baughman RA, Tonelli G, et al. Use of rapid acting insulin analog as the baseline infusion during glucose clamping improves pharmacokinetic evaluation. ADA 2007; 56: Abstract 602-P.
Cassidy JP, Baughman RA, Schwartz SL, et al. Afresa® (Technosphere® insulin) dosage strengths are interchangeable ADA 2009; Poster 433.
Cassidy JP, Marino MT, Amin N, et al. Lung deposition and absorption of insulin from Afresa® (Technosphere® insulin) ADA 2009; Poster 425.
Cassidy JP, Potocka E, Baughman RA, et al. Pharmacokinetic characterization of the Technosphere® inhalation platform Diabetes Technology Meeting 2009. poster.
Caumo et al. “First-phase insulin secretion: does it exist in real life Considerations on shape and function.” Am J Physiol Endocrinol Metab 287:E371-E385, 2004.
Cefalu “Concept, Strategies and Feasibility of Noninvasive Insulin Delivery.” Diabetes Care 27:239-246, 2004.
Cefalu “Novel routes of insulin delivery for patients with type 1 or type 2 diabetes.” Ann Med 33:579-586, 2001.
Cefalu et al., Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann. Int. Med., 2001, 134(3): 203-207.
Ceglia et al. “Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus.” Ann Intern Med 145:665, 2006.
Cerasi, et al. Decreased sensitivity of the pancreatic beta cells to glucose in prediabetic and diabetic subjects. A glucose dose-response study. Diabetes 21(4):224-34, 1972.
Cernea et al. “Dose-response relationship of oral insulin spray in healthy subjects.” Diabetes Care 28:1353-1357, 2005.
Cernea et al. “Noninjectable Methods of Insulin Administration.” Drugs of Today 2006, 42 (6): 405-424.
Chan et al., “Pharmacological Management of Type 2 Diabetes Mellitus: Rationale for Rational Use of Insulin”, Mayo Clin Proc, 2003, 78, 459-467.
Chase et al., “Redefining the clinical remission period in children with type 1 diabetes”, Pediatric Diabetes, 2004, 5, 16-19.
Cheatham et al. “Desirable Dynamics & Performance of Inhaled Insulin Compared to Subcutaneous Insulin Given at Mealtime in Type 2 Diabetes: A Report from the Technosphere/Insulin Study Group.” Diabetes Technology and Therapeutics, vol. 6, p. 234 (2004).
Cheatham et al. “A novel pulmonary insulin formulation replicates first phase insulin release and reduces s-proinsulin levels.” Presented at the American Diabetes Association 64th Scientific Sessions, Jun. 2004, abstract 457-P.
“An inhaled insulin formulation (Technosphere Insulin) effectively improves glycaemic control in patients with type 2 diabetes mellitus.” Inpharma Weekly, vol. 1522, Jan. 28, 2006, p. 8.
ACTOS Product Insert. Aug. 2008.
Adjusting Mealtime Insulin Doses. BD Diabetes. http://www.bd.com/diabetes/page.aspx?cat=7001&id=7280 (2014).
Ahren “GLP-1 and extra-islet effects.” Horm. Med Res 36:842, 2004.
Ahren B et al. “Characterization of GLP-1 effects on b-cell function after meal ingestion in humans.” Diabetes Care 26:2860, 2003.
Ahren B., Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. BioEssays, V. 20, pp. 642-651 (1998).
Akerlund et al., Diketopiperazine-based polymers from common acids. Journal of Applied Polymer Science (2000), 78(12), 2213-2218.
Alabraba et al. Diabetes Technology & Therapeutics. Jul. 2009, 11(7): 427-430.
Alcohols limited. Alcohol speciality solvents—Go green! Jul. 24, 2010. Available from: <http://webarchive.org/web/20100724193725/http://www.alcohols.co.uk/speciality—solvents.php>.
Aljada et al. “Insulin inhibits the pro-inflammatroy transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations.” The Journal of Clinical Endocrinology and Metabolism, vol. 87, No. 3, p. 1419-1422, 2002.
Al-Showair et al., Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respiratory Medicine, vol. 101, No. 11, p. 2395-2401 (2007).
American Diabetes Association, “Standards of medical care in diabetes—2009”, Diabetes Care, Jan. 2009, 32 Suppl 1: S13-61.
Amin N, Boss AH, Petrucci R, et al. Pulmonary functions (over 2 years) in diabetic subjects treated with Afresa® or usual antidiabetic treatment ADA 2009; Poster 570.
Amin N, et al. Long-term sustained safety and efficacy of continued use of Technosphere insulin in subjects with type 2 diabetes. Abstract—Oral Presentation 215, 48th EASD Annual Meeting, Sep. 29-Oct. 2, 2009, Vienna Austria.
Amin N, Marino MT, Cassidy JP, et al. Acute pulmonary effects of Technosphere® insulin inhalation powder administered using a Gen2B inhaler compared to MedTone® C inhaler Diabetes Technology Meeting 2010; poster.
Amin N, Phillips M, Boss AH, et al. Pulmonary functions (over 2 years) in diabetic patients treated with Technosphere® insulin (TI) or usual antidiabetic treatment. Third International Conference on Advanced Technologies and Treatments for Diabetes. 2010; Poster 290.
Angelo et al., Technosphere Insulin: Defining the Role of Technosphere Particles at the Celluar Level. J. Diabetes Sci. Technol., vol. 3, Issue 3, pp. 545-554 (2009).
Angelo et al. Technosphere® insulin inhalation powder: Defining the mechanism of action. ADA 2008; 57: Poster 428-P.
Antosiewiez et al., Prediction of pH-dependent properties of proteins. J Mol. Biol., 238:415-436 (1994).
Arakawa et al., Preferential interactions determine protein solubility in three-component solutions: the MgCl2 system. Biochemistry, 29:1914-1923 (1990).
Ashwell et al. “Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.” 2006 Diabetes UK, Diabetic Medicine, 23, 879-886.
Ashwell et al., “Optimal timing of injection of once-daily insulin gargine in people with Type 1 diabetes using insulin ispro at meal-times” 2005 Diabetes UK, Diabetic Medicine, 23, 46-52.
Atherton, F. et al. “Synthesis of 2(R)-A3(S)-Acylamino-2-OXO-1-Azetidinyloxy U-Acetic Acids.” Tetrahedron, vol. 10, No. 6, Jan. 1, 1984, pp. 1039-1046.
Avandia Product Insert, Oct. 2008.
Baggio et al. “A recombinant human glucagon-like peptide (GLP)-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostatsis.” Diabetes 53:2492, 2004.
Baggio et al. “Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and noneneteral glucose clearance in mice.” Endocrinology 141:3703, 2000.
Baggio et al. “Harnessing the therapeutic potential of glucagon-like peptide-1.” Treat Endocrinol 1:117, 2002.
Drucker et al., Minireview: The glucagon-like peptides. Endocrinology, vol. 142, No. 2, pp. 521-527 (2001).
Balkan B et al. “Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms.” Am J. Physiol Regulatory Integrative Comp Physiol 279:R1449, 2000.
Barnett AH et al. “An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with Type 2 diabetes poorly controlled on metformin.” Diabetes Care 29(8):1818-1825, 2006.
Barnett et al., An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care, 29(6): 1282-1287 (2006).
Barragan et al. “Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats.” Am J. Physiol 266 (Endocrinol Metab 29):E459, 1994.
Basu A et al. “Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance.” J Clin Invest 97:2351-2361, 1996.
Bauer et al., “Assessment o beta-adrenergic receptor blockade after isamoitane, a 5-HT1-receptor active compound, in healthy volunteer”, Clin. Pharmacol Ther 53:76-83 (1993).
Bauer et al., “Pharmacodynamic effects of inhaled dry powder formulations of fenterol and colforsin in asthma”, Clin Pharmacol Ther 53:76-83, 1993.
Baughman R, Cassidy J, Amin N, et al. A phase I, open-label study of the effect of albuterol or fluticasone on the pharmacokinetics of inhaled Technosphere® insulin inhalation powder in healthy subjects. ADA 2010; Poster 528.
Baughman R, Cassidy J, Levy B, et al. Technosphere® insulin inhalation powder pharmacokinetics unchanged in subjects who smoke. Diabetes 2008; 57: A128.
Baughman R, Haworth P, Litwin J, et al. No cardiac effects found with therapeutic and suprtherapeutic doses of Technosphere® inhalation powder: results from a thorough QTc clinical study. ADA 2011. Poster 933-P.
Baughman, RA, Evans, SH, Boss, AH, et al. Technosphere insulin does not affect pulmonary function in a 6 month study of patients with type 2 diabetes. Diabetologia 2006;49:177-118.
Bayés M et al. “Gateways to clinical trials” Methods Find Exp Clin Pharmacol 24:431-455, 2002.
Beers et al., Section 2—Chapter 13—Diabetes Mellitus, The Merck Manual of Diagnosis and Therapy, Merck Research Laboratories, pp. 165-177 (1999).
Behme et al. “Glucagon-like peptide-1 improved glycemic control in type 1 diabetes.” BMC Endocrine Disorders 3:3, 2003.
Bellary et al. “Inhaled insulin:new technology, new possibilities.” Int J Clin Pract 60:728, 2006.
Belmin J et al. “Novel drug delivery systems for insulin. Clinical potential for use in the elderly.” Drugs Aging 20:303-12, 2003.
Benita, Charaterization of Drug-Loaded Poly(d,l-lactide) Microspheres. J. Pharm. Sci., 73: 1721-1724 (1984).
Benito E et al. “Glucagon-like peptide-1-(7-36) amide increases pulmonary surfactant secretion through a cyclic adenosine 3′,5′-monophosphate-dependent protein kinase mechanism in rat type II pneumocytes.” Endocrinology 139:2363, 1998.
Bensch et al., Absorption of intact protein molecules across the pulmonary air-tissue barrier, Science 156: 1204-1206 (1967).
Berge et al., “Pharmaceutical Salts”, J. Pharmaceutical Sciences, Review Article, 66(1):1-19 (1977).
Bergenstal R, Kapsner P, Rendell M, et al., Comparative efficacy and safety of Afresa® and a rapid-acting analog both given with glargine in subjects with T1 DM in a 52-week study ADA 2009; Poster 479.
Bergeron et al. “Macromolecular Self-Assembly of Diketopiperazine Tetrapeptides.” J. Am. Chem. Soc. 116, 8479-8484, 1994.
Johnson et al., “Turbuhaler a new device for dry powder terbutaline inhalation”, Allergy 43(5):392-395 (1988).
Johnson et al: RyR2 and calpain-10 delineate a novel apoptosis pathway in pancreatic islets. J Biol Chem., 279(23):24794-802, 2004.
Johnson, Keith A., Preparation of peptide and protein powders for inhalation. Advanced Drug Delivery Reviews 1997; 26:3-15.
Jones et al., An investigation of the pulmonary absorption of insulin in the rat. Third European Congress of Biopharmaceutics and Pharmacokinetics, (1987).
Joseph et al. “Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db/db mice.” Diabetologia 43:1319-1328, 2000.
Joy et al. “Incretin mimetics as emerging treatments for type 2 diabetes.” Annal Pharmacother 39:110, 2005.
Juntti-Berggren et al. “The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients.” Diabetes Care 19:1200-1206, 1996.
Kanse et al. “Identification and characterization of glucagon-like peptide-1 7-36 amide-binding sites in the rat brain and lung.” FEBS Letters 241:209, 1988.
Kapitza C et al. “Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol.” Diabetes Tech Ther 6:119, 2004.
Kapitza et al. “Dose-response characteristics for a new pulmonary insulin formulation and inhaler.” Presented at the 35th Annual Meeting of the EASD, Sep. 2000, abstract OP29 184.
Kapsner P, Bergenstal RM, Rendell M, et al. Comparative efficacy and safety of Technosphere® insulin and a rapid-acting analog both given with glargine in subjects with type 1 diabetes in a 52-week study. Diabetologia 2009; 52 (suppl 1).
Katchalski E et al. “Synthesis of lysine anhydride”, J. Amer Chem Soc 68:879-880, 1946.
Katz et al. “Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.” J. Clin. Endocrinol. Metab. 85:5402-2410, 2000.
Kaur et al. “A Delineation of Diketopiperazine Self-Assembly Processes: Understanding the Molecular Events Involved in Ne-(Fumaroyl)diketopiperazine of L-Lys (FDKP) Interactions.” Molecular Pharmaceutics, vol. 5, No. 2, 294-315, Accepted and Received 2007, published on web 2008.
Kawai et al. “Evidence that glucagon stimulates insulin secretion through its own receptor in rats.” Diabetologia 38:274, 1995.
Kawamori et al. “Does hyperinsulinemia accelerate atherosclerosis?” Department of Medicine, Juntendo University School, vol. 13, No. 12, p. 954-960, 1994.
Kelley, D. et al. “Impaired postprandial glucose utilization in non-insulin dependent diabetes mellitus.” Metabolism 13:1549-1557, 1994.
Kenny AJ et al. “Dipeptidyl peptidase IV, a kidney brush-border serin peptidase.” Biochem J. 155:169, 1976.
Kim et al. “Development and characterization of a glucagon-like peptide 1-albumin conjugate. The ability to activate the glucagon-like peptide 1 receptor in vivo.” Diabetes 52:751, 2003.
Kinzig et al. “The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness.” J Neurosci 22:10470, 2002.
Kirk et al. “Disparities in HbA1c levels between African-American and non-hispanic white adults with diabetes.” Diabetes Care 29:2130, 2006.
Kitabchi, Proinsulin and C-peptide:a review. May 26, 1977 (5):547-87, http://www/ncbi.nlm.nih.gov/pubmed/403392.
Klinger et al., Insulin-micro and nanoparticles for pulmonary delivery. International Journal of Pharmaceutics, vol. 377, pp. 173-179 (2009).
Knop et al. “No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.” Diabetes Care 26:2581, 2003.
Knop et al. “Reduced incretin effect in type 2 diabetes. Cause or consequence of the diabetic state?” Diabetes 56:1951, 2007.
Kohler D et al. Non-radioactive approach for measuring lung permeability: inhalation of insulin. Atemw Lungenkrkh 13:230-232, 1987. (English translation attached).
Kohler, “Aerosols for Systemic Treatment”, Lung (Suppl.) 677-684 (1990).
Komada et al., Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung. J. Pharm. Sci. 83(6): 863-867 (1994).
Komatsu et al. “Glucagonostatic and insulinotropic action of glucagon-like peptide-1 (7-36)-amide.” Diabetes 38:902, 1989.
Koning et al., Relationship between inspiratory flow through simulated dry powder inhalers and peak maximal inspiratory pressure. Flow Through a Simulated DPI, Chapter 3, pp. 43-56 (2001).
Labiris et al., Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. British Journal of Clinical Pharmocology 56: 588-599 (2003).
Kontny et al., Issues Surrounding MDI Formulation Development with Non-CFC Propellants), J. Aerosol Med 4(3), 181-187 (1991).
Kopple et al. “A convenient synthesis of 2,5-piperazinediones.” J Org Chem p. 962, 1967.
Kraft KS, Grant M. Preparation of macromolecule-containing drug powders for pulmonary delivery Methods in Molecular Biology 2009;480:165-174.
Kreymann B et al. “Glucagon-like peptide-1 7-36: a physiological incretin in man.” The Lancet, Dec. 5, 1987, p. 1300.
Krssak, M. et al. “Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes.” Diabetes 53:3048-3056, 2004.
Krueger et al. “Toxicological profile of pulmonary drug delivery agent.” Presented at the American Diabetes Association 64th Scientific Sessions, Jun. 2004, abstract 465-P.
Kwon et al. “Signaling elements involved in the metabolic regulation of mTOR by nutrients, incretins, and growth factors in islets.” Diabetes 53:S225, 2004.
Lankat-Buttgereit B et al. “Molecular cloning of a cDNA encoding for the GLP-1 receptor expressed in rat lung.” Exp Clin Endocrinol 102:241, 1994.
Laureano et al. “Rapid absorption and elimination of insulin from the lung following pulmonary administration of Technosphere®/Insulin: A pharmacokinetic study in a rat model.” Presented at the American Diabetes Association 65th Scientific Sessions, Jun. 2005, abstract 445-P.
Leahy et al. Beta-cell dysfunction in type II diabetes mellitus. Curr Opin Endocrinol Diabetes 2:300-306, 1995.
Lebovitz “Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies.” Endocr Pract 12:142, 2006.
Lee et al. “Synthesis, characterization and pharmacokinetic studies of PEGylated glucagon-like peptide-1.” Bioconjugate Chem 16:377, 2005.
Lee et al., “Development of an Aerosol Dosage Form Containing Insulin”, J. Pharm. Sci. 65(4), 567-572 (1976).
Leiner et al. “Particles facilitate the absorption of insulin in a primary cell culture model of alveolar epithelium without evidence of cytotoxicity.” Presented at the American Diabetes Association 64th Scientific Sessions, Jun. 2004, abstract 467-P.
Leiner et al. “The pharmacokinetic profile of insulin administered by inhalation in the rat.” Diabetes 53 Supplement, Jun. 2004, A111.
Leone-Bay et al. “Evaluation of novel particles as an inhalation system for GLP-1.” Diabetes, Obesity and Metabolism. 11:1050-1059, 2009.
Leone-Bay A, Grant M. Technosphere® Technology: A Platform for inhaled protein therapeutics. OndrugDelivery 2006 (published online).
Leone-Bay A, Grant M. Technosphere®/insulin: mimicking endogenous insulin release. In: Rathbone M, Hadgraft J, Roberts M, et al, eds. Modified Release Drug Delivery, 2e. New York, NY: Informa Healthcare USA, Inc; 2008.
Kieffer et al. “The glucagon-like peptides.” Endocrine Reviews 20:876, 1999.
Amorij et al., Development of stable infleunza vaccine powder formulations challenges and possibilities. Pharmaceutical Research, vol. 25, No. 6, pp. 1256-1273 (2008).
Audouy et al., Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization. Vaccine, vol. 29, pp. 4345-4352 (2011).
Volund “Conversion of insulin units to SI units.” American Journal of Clinical Nutrition, Nov. 1993, 58(5), pp. 714-715.
Wachters-Hagedoorn et al. “The rate of intestinal glucose absorption is correlated with plasma glucose-dependent insulinotropic polypeptide concentrations in healthy men.” J Nutr 136:1511, 2006.
Wang et al., Glucagon-like peptide-1 is a physiological incretin in rat. J. Clin. Invest., 95 : 417-421 (1995).
Wang et al., Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia, 47:478-487, 2004.
Wareham et al., “Fasting Proinsulin Concentrations Predict the Development of Type 2 Diabetes”, Diabetes Care, 1999, 22, 262-70.
Warren et al. “Postprandial versus prandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients.” Diabetes Res Clin Pract 66:23-29, 2004.
Waterhouse et al., “Comparatie assessment of a new breath-actuated inhaler in patients with reversible airways obstruction”, Respiration 59:155-158 (1992).
WebMD (retrieved from http://www.webmd.com/pain-management/tc/pain-management-side-effects-of-pain-medicines in 2012, 4 pages).
Wei et al. “Tissue-specific expression of the human receptor for glucagon-like peptide-1: brain and pancreatic forms have the same deduced amino acid sequence.” FEBS Letters 358:219, 1995.
Weir et al. “Glucagonlike peptide 1 (7-37) actions on endocrine pancreas.” Diabetes 38:338, 1989.
Weiss, SR et al. “Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents.” Arch Intern Med 163:2277-2282, 2003.
Weissberger, “Mannkind: Overlooked Biotech with Excellent Prospects (Part V),” http://www.investorvillage.com/smbd.asp?mb=2885&mn=45817&pt=msg&mid=5021385 (posted on Jun. 19, 2008, accessed on Oct. 18, 2012).
West, Solid State Chemistry and its Applications, Chp 10, Solid Solutions. Wiley, New York, 358 (1998).
Wettergren A et al. “Truncated GLP-1 (proglucagon 78-107-Amide) inhibits gastric and pancreatic functions in man.” Digestive Diseases and Sciences 38:665, 1993.
White JR et al. “Inhaled insulin: an overview.” Clinical Diabetes 19:13-16, 2001.
Wigley et al., Insulin across respiratory mucosae by aerosol delivery. Diabetes 20(8): 552-556 (1971).
Willms B et al. “Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.” J. Clin Endocrinol Metab 81:327, 1996.
Wilson BR et al. “Technospheres(TM) for pulmonary and nasal applications.” Respiratory Drug Delivery VIII, 2002,p. 545.
Wilson et al., Spray-drying, a viable technosphere formulation process option to lyophilization, http://www.aapsj.org/abstracts/AM—2004/AAPS2004-002724.PDF, 1 page, 2004.
Witchert, Low molecular weight PLA: A suitable polymer for pulmonary administered microparticles. J. Microencapsulation, 10(2): 195-207 (1993).
Wright et al., Inhaled Insulin: Breathing new life into diabetes therapy. Nursing, vol. 37, No. 1, p. 46-48 (2007).
Wong et al. “From cradle to grave: pancreatic b-cell mass and glucagon-like peptide-1.” Minerva Endocrinologica 31:107, 2006.
Wuts et al. “The Role of Protective Groups in Organic Synthesis,” John Wiley, New York, 2nd Ed. 1991.
Yan et al., Analgesic action of microinjection of neurokinin A into the lateral reticular nucleus and nucleus raphe magnus in rats. Acta Physiologica Sinica, vol. 48, No. 5, pp. 493-496 (1996)—abstract.
Yang et al., Division and differentiation of natural antibody-producing cells in mouse spleen. PNAS, 104(11): 4542-4546 (2007).
Yoshida et al., Absorption of insulin delivered to rabbit trachea using aerosol dosage form. J. Pharm. Sci. 68(5): 670-671 (1979).
Yoshioka et al., “Serum proinsulin levels at fasting and after oral glucose load in patients with Type 2 (non-insulin dependent) diabetes mellitus”, Diabetogia, 1988, 31, 355-60.
Yu W, Marino MT, Cassidy JP, et al. Insulin antibodies associated with Technosphere® insulin. ADA 2010; Abstract 216-OR.
Yusta B et al. “GLP-1 receptor activation improves b-cell function and survival following induction of endoplasmic reticulum stress.” Cell Metabolism 4:391, 2006.
Zander et al., Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet, 359:824-830, 2002.
Zethelius et al., “Proinsulin is an Independent Predictor of Coronary Heart Disease”, Circulation 105:2153-2158 (2002).
Zimmerman, K., “Respiratory System: Fats, Function, and Diseases”, <www.livescience.com/22616-respiratory-system.html>, copyright 2013, p. 1.
Zisser et al. “In Patients Using Technospere Insulin. Variation in PPG Stayed Within ADA-recommended Targets Despite Large Variations in Glucose Load.” Mannkind Corporation (2010), ADA 2010; Poster 554.
Zisser H, Jovanovic L, Markova K, et al. Technosphere® insulin effectively controls postprandial glycemia in patients with type 2 diabetes mellitus. Diabetes Technology and Therapeutics 2012;14:997-1001.
Wasada, Glucagon-like peptide-1 (GLP-1). Nihon Rinsho, vol. 62, No. 6, pp. 1175-1180 (2004) (full Japanese article with English abstract).
Bosquillon et al., Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rates. Journal of Controlled Release 96: 233-244 (2004).
Cho et al., Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacology & Therapeutics 135: 247-278 (2012).
Definition of medicament from http://medical-dictionary.thefreedictionary.com/medicament.
Definition of matrix from http://medical-dictionary.thefreedictionary.com/matrix.
Diabetes Frontier, vol. 10, No. 5, p. 647-657 (1999) (full Japanese article with translated English portion provided in separate attachment, portion translated in English is the bottom of p. 655 and the left column of p. 656).
Ely et al., Effervescent dry powder for respiratory drug delivery. European Journal of Pharmaceutics and Biopharmaceutics 65: 346-353 (2007).
European Search report for European Application 14192154.4 mailed on Mar. 19, 2015.
Extended European Search report for European Application 14187552.6 mailed on Mar. 2, 2015.
Gillespie et al., Using carbohydrate counting in diabetes clinical practice. Journal of the American Diabetic Association, vol. 98, No. 8, p. 897-905 (1998).
Yamamoto et al., Engineering of Poly (DL-lactic-co-glycolic acid) Nano-composite particle for dry powder inhalation dosage forms of insulin with spray fludized bed granulating system. J. Soc. Powder Technol., Japan, 41: 514-521 (2004).
Standl et al. “Good Glycemic Control With Flexibility in Timing of Basal Insulin Supply.” Diabetes Care, vol. 28, No. 2, Feb. 2005.
Stanley et al. “Gastrointestinal satiety signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY and pacretic peptide.” Am J Physiol Gastrointest Liver Physiol 286:G693, 2004.
Steinberg et al. “A new approach to the safety assessment of pharmaceutical excipients.” Reg Toxicol Pharmacol 24:149, 1996.
Steiner et al. “A novel glucagon delivery system for the management of hyperinsulinemia.” Diabetes 49 Supplement 1, Abstract 1545-PO, A368, 2000.
Steiner et al. “Bioavailability and pharmacokinetic properties of inhaled dry powder Technosphere®/Insulin” Diabetes 49 Supplement, May 2000, A126.
Steiner et al. “Technosphere®, a novel drug delivery system for oral administration of calcitonin.” Pharmaceutical Res 11:S299, 1994.
Steiner et al. Technosphere(TM)/Insulin—proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes, 110:17-21, 2002.
Steiner, K. et al. “The relative importance of first- and second-phase insulin secretion in countering the action of glucagon on glucose turnover in the conscious dog.” Diabetes 31:964-972, 1982.
Steiner S, Rave K, Heise T, et al. Pharmacokinetic properties and bioavailablility of inhaled drug powder Technosphere™/insulin. Exp Clin Endocrinol Diabetes 2000; 108:S161.
Steiner S, Rave K, Heise T, et al. Technosphere™/insulin: Bioavailability and pharmacokinetic properties in healthy volunteers. Diabetologia 2000;43:Abstract 511-P.
Steiner SS, Burrell BB, Feldstein R, et al. Pulmonary delivery of Technosphere™/insulin: Increased bioefficacy and bioavailability in clinical trials using the PDC Medtone™ inhaler. Proceed Int'l Symp Control Rel Bioact Mater 2000; 27: 1000-1001.
Stowell et al. “Development of GLP-1 Technosphere(TM) powder: an inhaled GLP-1 product.” Diabetes Technology Meeting, San Francisco, Oct. 2007.
Strack “Inhaled Human Insulin.” Drugs of Today 2006, 42 (4): 207-221.
Sturis et al., GLP-1 deriative liraglutide in rats with beta-cell deficiences: influence of metabolic state on beta-cell mass dynamics. British Journal of Pharmacology, 140: 123-132 (2003).
Svartengren et al., Added External Resistance Reduces Oropharyngeal Deposition and Increases Lung Deposition of Aerosol Particles in Asthmatics. Am. J. Respir. Crit. Care Med., vol. 152, pp. 32-37, 1995.
Sympatecs. Dry Dispersion for Laser Diffraction and Image Analysis, 2011. XP-002586530.
Leone-Bay et al., Innovation in drug delivery by inhalation. Ondrugdelivery, No. 7, pp. 4-8 (2010).
Tack CJ, Boss AH, Baughman RA, et al. A randomized, double blind, placebo controlled study of the forced titration of prandial Technosphere®/Insulin in patients with type 2 diabetes mellitus. Diabetes 2006;55:Abstract 428-P.
Tack CJ, Christov V, deGalan BE, et al. Randomized forced titration to different doses of Technosphere® insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes. J Diabetes Sci Technol 2008; 2(1) :47-57.
Tang-Christensen et al. “Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats.” Am J Physiol 271 (Regulatory Integrative Comp Physiol 40):R848, 1996.
Taylor et al. “Aerosols for macromolecule delivery. Design challenges and solutions.” Am J Drug Deliv 2:143-155, 2004.
Teeter et al. “Dissociation of lung function changes with humoral immunity during inhaled human insulin therapy.” Am J Resp Crit Care Med 173:1194, 2006.
Telko et al., Dry Powder Inhaler Formulation. Respiratory Care, Sep. 2005, vol. 50, No. 9, 1209-1227.
The American Diabetes Association “Insulin Administration” Diabetes Care, vol. 27, Supplement 1, S106-S109 (2004).
The Lancet. 1989, vol. 333, p. 1235-1236.
Thorens “Expression cloning of the pancreatic b-cell receptor for the gluco-incretin hormone glucagon-like peptide-1.” PNAS 89:8641, 1992.
Thorens B et al. “Cloning and function expression of the human islet GLP-1 receptor: demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor.” Diabetes 42:1678, 1993.
Todd et al. “Glucagon-like peptide-1 (GLP-1: a trial of treatment in non-insulin-dependent diabetes mellitus.” Eur J Clin Invest 27:533, 1997.
Todd et al. Subcutaneous glucagon-like peptide-1 improves postprandial glucaemic control over a 3-week period in patients with early type 2 diabetes. Clinical Science 95:325, 1998.
Toft-Nielson et al. “Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes.” J Clin Endocrinol Metab 86:3853, 2001.
Toft-Nielson et al. “Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglcaemia.” Diabetologia 41:1180, 1998.
Toft-Nielson et al. “The effect of glucagon-like peptide-1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones” Diabetes 45:552, 1996.
Tornusciolo D.R. et al., Biotechniques 19(5):800-805, 1995. Simultaneous detection of TDT-mediated dUTP-biotin nick end-labeling (TUNEL)-positive cells and multiple immunohistochemical markers in single tissue sections.
Triantafyllidis et al., Structural, compositional and acidic characteristics of nanosized amorphous or partially arystalline ZSM-5 zeolite based materials. Microporous and Mesoporous Materials, 75:89-100 (2004).
Tu N, Kramer DA, Baughman RA. Inhaled Technosphere® Insulin improves glycemic control without weight gain. Diabetes 2007;56:Abstract 471-P.
Tuley et al., Experimental observations of dry powder inhaler dose fluidisation. International Journal of Pharmaceutics, 358, pp. 238-247 (2007).
Utah Valley University. Saponification. © 2009. Available from: <http://science.uvu.edu/ochem/index.php/alphabetical/s-t/saponification/printpage/>.
Vaczek, Accelerating drug delivery firms exploring new drug-delivery routes and devices intently awaiting the commmercial launch of Exubera. Pharmaceutical & Medical Packaging News, vol. 14, No. 6 (2006).
Vahl et al. “Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1-(9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans.” J Clin Endocrinol Metabol 88:1772, 2003.
Van Alfen-Van Der Velden et al. “Successful treatment of severe subcutaneou insulin resistance with inhaled Insulin therapy”, Pediatric Diabetes 2010: 11:380-382.
Vara E et al. “Glucagon-like peptide-1 (7-36) amide stimulates surfactant secretion in human type II pneumocytes.” Am J Resp Crit Care Med 163:840-846, 2001.
Vella A et al. “Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.” Diabetes 49:611, 2000.
Vella A et al. “The gastrointestinal tract and glucose tolerance.” Curr Opin Clin Nutr Metab Care 7:479, 2004.
Vendrame et al. “Prediabetes: prediction and prevention trials.” Endocrinol Metab Clin N Am, 2004, vol. 33, pp. 75-92.
Verdich C, et al., A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab., 86:4382-4389, 2001.
Vilsboll et al. “Reduced postprandial concentrations of intact biologically active glucagon-like peptide-1 in type 2 diabetic patients.” Diabetes 50:609, 2001.
Vilsboll et al. “Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.” J Clin Endocrinol Metab 88:220, 2003.
Vilsboll et al., “Evaluation of β-Cell Secretary Capacity Using Glucagon-Like Peptide 1”, Diabetes Care, vol. 23, No. 6, pp. 807-812, Jun. 2000.
Vilsboll et al., “Incretin secretion in Relation to Meal Size and Body Weight in Healthy Subjects and People with Type 1 and Type 2 diabetes Mellitus”, The Joumal of Clinical Endrocronology & Metabolism, vol. 88, No. 6, pp. 2706-2713, 2003.
Pfutzner et al. “Inhaled Technosphere/Insulin Shows a Low Variability in Metabolic Action in Type 2 Diabetic Patients.” Diabetes 49 Supplement, May 2000, A121.
Pfuetzner A, Rave K, Heise T, et al. Inhaled Technosphere™/insulin results in low variability in metabolic action in type 2 diabetic patients. Exp Clin Endocrinol Diabetes 2000; 108:S161.
Pfuetzner A, Rave K, Heise T, et al. Low variability in metabolic action in type 2 diabetic patients with inhaled Technosphere/insulin. Diabetologia 2000; 43:Abstract 774.
Phillips M, Amin N, Boss AH, et al. Pulmonary functions (over 2 years) in diabetic subjects treated with Technosphere® insulin or usual antidiabetic treatment. Diabetologia 2009; 52 (suppl 1).
Pohl R, Muggenberg BA, Wilson BR, et al. A dog model as predictor of the temporal properties of pulmonary Technosphere/insulin in humans. Respiratory Drug Delivery 2000; VII: 463-465.
Polonsky et al. “Abnormal Patterns of Insulin Secretion in Non-insulin-Dependent Diabetes Mellitus.” N Eng J Med 318:1231-39, 1988.
Potocka E, Amin N, Cassidy J, et al. Insulin pharmacokinetics following dosing with Technosphere® insulin in subjects with chronic obstructive pulmonary disease. Current Medical Research and Opinion 2010; 26:2347-2353.
Potocka E, Baughman R A, Derendorf H. Population pharmacokinetic model of human insulin following different routes of administration. Journal of Clinical Pharmacology 2011;51:1015-1024.
Potocka E, Baughman R, Derendorf H. Population Pharmacokinetic Model of Regular Human Insulin Following Different Routes of Administration. AAPS Journal. 2009; 11(S1). Available from: http://www.aapsj.org. Presented at the 2009 AAPS (American Association of Pharmaceutical Scientists) National Biotechnology Conference, Jun. 21-24, Seattle, WA.
Potocka E, Baughman RA, Derendorf J. A population PK/PD model of Technosphere® insulin administered to healthy and type 2 diabetics. ADA 2010; Poster 624.
Potocka E, Baughman RA, Schwartz SL, et al. Pharmacokinetics of Afresa® unchanged in patients with chronic obstructive pulmonary function ADA 2009; Poster 437.
Potocka E, Cassidy J P, Haworth P, et al. Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. Journal of diabetes science and technology 2010;4:1164-1173.
Potocka E, Cassidy JP, Haworth P, et al. Pharmacokinetic characterization of fumaryl diketopiperazine. Third International Conference on Advanced Technologies and Treatments for Diabetes 2010; Poster 291.
Potocka E, Hovorka R, Baughman R, et al. Characterization of metabolism parameters following Technosphere® insulin and insulin Lispro. ADA 2010; Poster 1561.
Potocka E, Hovorka R, Baughman RA, et al. Afresa™ supresses endogenous glucose production earlier than a rapid-acting analog (Lispro) and inhaled Exubera® ADA 2009; Oral 232.
Potocka E, Hovorka R, Baughman RA, et al. Technosphere® insulin suppresses endogenous glucose production earlier than a rapid-acting analog (lispro) and an inhaled insulin (exubera). Diabetologia 2009; 52 (suppl 1).
Prabhu et al. “A study of factors controlling dissolution kinetic of zinc complexed protein suspensions in various ionic species”, Int. J. Pharm. 217(1-2):71-8 (2001).
Laube et al., The lung as an alternative route for delivery for insulin in controlling postrprandial glucose levels in patients with diabetes. Chest, Preliminary Report 114 (6) : 1734-1739 (1998).
Quattrin et al. “Efficacy and Safety of Inhaled Insulin (Exubera) Compared with Subcutaneous Insulin Therapy in Patients with Type 1 Diabetes.” Diabetes Care, vol. 27, No. 11, Nov. 2004, p. 2622-2627.
Quddusi et al. “Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.” Diabetes Care 26:791, 2003.
Rachman et al. “Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.” Diabetes 45:1524, 1996.
Raju et al., Naseseazines A and B: a new dimeric diketopiperazine framework from a marine-derived actinomycete, Streptomyces sp. Organic letters, vol. 11, No. 17, pp. 3862-3865 (2009).
Raskin et al. “Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes.” Diabetes Care, vol. 26, No. 9, pp. 2598-2603, Sep. 2003.
Raskin P, Heller S, Honka M, et al. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere® Insulin or usual antidiabetes treatment: A randomized trial. Diabetes, Obesity and Metabolism 2012;14:163-173.
Raskin P, Phillips M, Amin N, et al. Hypoglycemia in patients with type 1 diabetes incorporating prandial inhaled Technosphere® insulin into their usual diabetes treatment regimen vs continuing their usual diabetes management. AACE 2010; Poster 283.
Raskin P, Phillips MD, Rossiter A, et al. A1C and hypoglycemia in patients with type 2 diabetes mellitus incorporating prandial inhaled Technosphere® insulin into their usual antihyperglycemic regimen vs continuing their usual antihyperglycemic regimen. ADA 2010; Abstract 359-OR.
Raufman et al., Exendin-3, a novel peptdie from Heloderma horridum venom, interacts with vasoactive intestinal peptide receptors and a newly described receptor on dispersed aciin from guinea pig pancreas. J. Biol. Chem. 266(5) : 2897-2902 (1991).
Raufman et al., Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guina pig pancreas. J. Biol. Chem. 267(30) : 21432-21437 (1992).
Raun et al. “Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, where as a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.” Diabetes 56:8, 2007.
Rave et al. “Coverage of Postprandial Blood Glucose Excursions with Inhaled Technosphere Insulin in Comparison to Subcutaneously Injected Regular Human Insulin in Subjects with Type 2 Diabetes.” Diabetes Care, vol. 30, No. 9, pp. 2307-2308, Sep. 2007.
Rave et al. “Dose Response of Inhaled Dry-Powder Insulin and Dose Equivalence to Subcutaneous Insulin Lispro.” Diabetes Care 28:2400-2405, 2005.
Rave et al. “Inhaled Technosphere Insulin in Comparison to Subcutaneous Regular Human Insulin: Time Action Profile and Variability in Subjects with Type 2 Diabetes.” Journal of Diabetes Science and Technology, vol. 2, Issue 2, pp. 205-212, Mar. 2008.
Rave et al. “Results of a Dose-Response Study with a New Pulmonary Insulin Formulation and Inhaler.” Diabetes 49, Supplement, May 2000, A75.
Rave et al. “Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin.” Diabetes Care 28:1077, 2005.
Rave K, Heise T, Pfuetzner A, et al. Assessment of dose-response characteristics for a new pulmonary insulin formulation and inhaler. Exp Clin Endocrinol Diabetes 2000; 108:S161.
Rave K, Potocka E, Boss AH, et al. Pharmacokinetics and linear exposure of Afresa™ compared with the subcutaneous injection of regular human insulin Diabetes, Obesity and Metabolism 2009; 11:715-720.
Raz et al. “Pharmacodynamics and Pharmacokinetics of Dose Ranging Effects of Oralin versus S.C. Regular Insulin in Type 1 Diabetic Patients.” Fourth Annual Diabetes Technology Meeting, Philadelphia PA, 2004.
Razavi et al. “TRPVI+ sensory neurons control beta cell stress and islet inflammation in autoimmune disease.” Cell 127:1123, 2006.
Retrieved from website: http://groups.molbiosci.northwestern.edu/holmgren/Glossary/Definitions/Def-P/placebo.html, 1 page, Retrieved on Mar. 12, 2013.
Rhodes et al. “Technosphere: Microspherical Particles from Substituted Diketopiperazines for Use in Oral Drug Delivery.” 208th ACS National Meeting, Aug. 1994.
Richardson et al. “Technosphere Insulin Technology.” Diabetes Technology & Therapeutics, vol. 9, Supplement 1, pp. S65-S72, 2007.
Richardson PC, Potocka E, Baughman RA, et al. Pharmacokinetics of Technosphere® insulin unchanged in patients with chronic obstructive pulmonary disease. Diabetologia 2009; 52 (suppl 1).
Richter et al. “Characterization of glucagon-like peptide-1(7-36)amide receptors of rat membranes by covalent cross-linking.” FEBS Letters 280:247, 1991.
Richter et al. “Characterization of receptors for glucagon-like peptide-1 (7-36)amide on rat lung membranes.” FEBS Letters 267:78, 1990.
Riddle “Combining Sulfonylureas and Other Oral Agents.” Am J Med, 2000, vol. 108(6A), pp. 15S-22S.
Riddle et al. “Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1.” Diabetes Care 29:435, 2006.
Ritzel et al. “Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 (7-36 amide) after subcutaneous injection in healthy volunteers. Dose-response-relationships.” Diabetologia 38:720, 1995.
Rosen et al., Substance P microinjected into the periaqueductal gray matter induces antinociception and is released folloing morphine administration. Brain Research, 1001: 87-94 (2004).
Rosenmund et al., Diketopiperazines from Leuchs Anhydrides. Angew Chem Intern. Edit. Vol. , No. 2 (1970).
Rosenstock “Dual therapy with inhaled human insulin (Exubera(R)) as add-on to metformin (with stopping sulfonurea) is better than triple therapy with rosiglitazone add-on to combination metformin and sulfonurea in poorly controlled Type 2 diabetes.” Diabetes 57:supplement 1:A557, Abstract 2018-PO, 2008.
Heine “Unlocking the opportunity of tight glycaemic control. Promise ahead: the role of inhaled insulin in clinical practice.” Diabetes, Obesity and Metabolism 7:S19, 2005.
Heinemann “Variability of Insulin Absorption and Insulin Action.” Diabetes Technology & Therapeutics, vol. 4, No. 5, pp. 673-682. 2002.
Heinemann et al. “Current status of the development of inhaled insulin.” Br. J. Diabetes Vasc. Dis. 4:295-301, 2004.
Heinemann L et al. “Time-action profile of inhaled insulin.” Diabetic Med 14:63-72, 1997.
Heinemann, L. “Intra-individual Variability of the Metabolic Effect of Inhales Insulin Together with an Absorption Enhancer”, Diabetes Care, vol. 23, No. 9, Sep. 2000, p. 1343-1347.
Heise et al. “The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin.” Diabetes Care 28:2161, 2005.
Herbst et al., Insulin Strategies for Primary Care Providers. Clinical Diabetes, vol. 20, No. 1, pp. 11-17 (2002).
Heubner et al. “On inhalation of insulin” Klinische Wochenschrift 16:2342, 1924. (Original and English translation provided in one document).
Heyder “Particle Transport onto Human Airway Surfaces”, Eur. J. Respir. Dis, Suppl. 119, 29-50 (1982).
Heyder, “Alveolar deposition of inhaled particles in humans”, Am. Ind. Hyg. Assoc. J. 43(11): 864-866 (1982).
Hirsch IB “Insulin analogues.” N Engl J Med 352:174-83, 2005.
Hirsch, “Type 1 Diabetes Mellitus and the Use of Flexible Insulin Regimens” American Family Phyician, Nov. 15, 1999, p. 1-16.
Hirshberg B et al. “Islet transplantation: where do we stand now?” Diabetes Metab Res Rev 19:175-8, 2003.
Hite et al. “Exhuberance over Exubera.” Clin Diabetes 24(3):110-114, 2006.
Hoet et al., Review: Nanoparticles—known and unknown health risks. Journal of Nanobiotechnology, vol. 2, No. 12, (15 pages) (2004).
Hollander et al. “Efficacy and Safety of Inhaled Insulin (Exubera) Compared with Subcutaneous Insulin Therapy in Patients with Type 2 Diabetes.” Diabetes Care, vol. 27, No. 10, Oct. 2004, p. 2356-2362.
Holst “Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1.” Diabetes Metab Res Rev 18:430, 2002.
Holst et al. “On the effects of glucagon-like peptide-1 on blood glucose regulation in normal and diabetic subjects.” Ann N Y Acad Sci. Dec. 26, 1996;805:729-36.
Howard C, Ren H, Rossiter A, et al. Reduced incidence and frequency of hypoglycemia in an integrated analysis of pooled data from clinical trials of subjects with type 1 diabetes using prandial inhaled Technosphere® insulin. Diabetologia 2009; 52 (suppl 1).
Howard CP, Gnudi L, Loiter D, et al. Prandial inhaled Technosphere® insulin plus insulin glargine vs. biaspart 70/30 insulin in type 2 diabetes inadequately controlled with/without oral agents. Third International Conference on Advanced Technologies and Treatments for Diabetes. 2010; Poster 300.
Howard CP, Loiter D, Ren H, et al. Reduced incidence and frequency of hypoglycemia in pooled data from trials of type 2 diabetics using prandial inhaled Technosphere® insulin. Third International Conference on Advanced Technologies and Treatments for Diabetes 2010; Poster 304.
Howard CP, Petrucci R,Amin N, et al. Pulmonary function test remain similar in patients who received Technosphere® insulin and in patients currently receiving standard antidiabetic therapy. AACE 2010; Poster 267.
Howard CP, Ren H, Rossiter A, Boss AH. Reduced incidence and frequency of hypoglycemia in pooled data from trials of type 1 diabetics using prandial inhaled Technosphere® insulin. Third International Conference on Advanced Technologies and Treatments for Diabetes. 2010; Poster 302.
Howard CP, Ren H, Rossiter A, et al. Reduced incidence and frequency of hypoglycemia in an integrated analysis of pooled data from clinical trials of subjects with type 1 diabetes using prandial inhaled Technosphere® insulin. AACE 2010; Poster 269.
Howard CP, Rubin RR, Peyrot. M. Patient reported outcomes in adults with type 2 diabetes using mealtime Afresa® (inhaled Technosphere® insulin) and basal insulin versus premixed insulin ADA 2009; Poster 551.
http://www.bilcaresolutions.com/en/products/pharma-packaging-innovations-pvc-aclar-films <URL:http://web.archive.org/web/20110127102552/http://www.bilcaresolutions.com/en/products/pharma-packaging-innovations-pvc-aclar-films> published on Jan. 27, 2011 as per “Wayback Engine”.
http://www.pmpnews.com/article/blister-packaging-materials (May 26, 2009).
Huda et al. “Gut peptides and the regulation of appetite.” Obesity Reviews 7:163, 2006.
Hui et al., The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. European Journal of Endocrinology, 146: 863-869 (2002).
Hussain et al. “State of insulin self-association does not affects its absorption from the pulmonary route.” Eur. J. Pharm. Sciences 25:289-298, 2005.
Ikeda, Kuniki et al. “Peptide Antibiotics. XXVI. Syntheses of Cyclodipeptides Containing N. delta.-p-aminobenzenesulfonyl Ornithine Residue.” Chemical & Pharmaceutical Bulletin, 20(9), 1849-55, 1972.
Imeryuz et al. “Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms.” Am J Physiol 273 (Gastrointest Liver Physiol 36):G920, 1997.
Insulin inhalation NN 1998, Drugs R & D, 2004, pp. 46-49, Adis Data Information BV.
Insulin is a natural product from http://www.levemir.com/startingoninsulin/whatisinulin.aspx, pp. 1-3.
International Search Report for PCT International Application No. PCT/US2010/055323 filed on Nov. 3, 2010.
Written Opinion mailed on Jul. 1, 2013 for International Application No. PCT/US2013/032162 filed on Mar. 15, 2013.
International Search Report mailed on Jun. 21, 2010 for International Application No. PCT/US2010/027038 filed on Mar. 11, 2010.
Written Opinion for International Application No. PCT/US2011/060057 filed on Nov. 9, 2011.
International Search Report mailed Mar. 18, 2013 for International Application No. PCT/US2012/061749 filed on Oct. 24, 2012.
International Search Report mailed on Jun. 20, 2012 for International Applicaion No. PCT/US2012/031695 filed on Mar. 30, 2012.
International Search Report mailed on Nov. 19, 2014 for International Application No. PCT/US2014/049817 filed on Aug. 5, 2014.
International Search Report for International Application No. PCT/US2010/020448 filed on Jan. 8, 2010.
International Search Report mailed on Mar. 11, 2010 for International Application No. PCT/US2009/069745 filed on Dec. 29, 2009.
International Search Report mailed on Oct. 17, 2011 for International Application No. PCT/US2010/026271 filed on Mar. 4, 2010.
International Search Report for International Application No. PCT/US2010/038287 filed on Jun. 11, 2010.
Ishibashi, Norio et al. “Studies on Flavord Peptides. Part V. A Mechanism for Bitter Taste Sensibility in Peptides.” Agricultural and Biological Chemistry, 52(3), 819-27, 1988.
Iwanij et al., Characterization of the Glucagon Receptor and its Functional Domains Using Monoclonal Antibodies. The Journal of Biological Chemistry, vol. 265, No. 34, pp. 21302-21308, 1990.
Jain et al. “Insulin Therapy in Type 2 Diabetic Subjects Suppresses Plasminogen Activator Inhibitor (PAI-1) Activity and Proinsulin-like Molecules Independently of Glycaemic Control.” Diabetic Medicine, vol. 10, No. 1, p. 27-32, 1993.
Johnson et al., Peptide turn mimetics. Biotechnology and Pharmacy, p. 366-378 (1993).
International Search Report for International Application No. PCT/US2013/050392 filed on Jul. 12, 2013.
Cheatham et al. “Prandial Technosphere®/Insulin inhalation provides significantly better control of meal-related glucose excursions than prandial subcutaneous insulin.” Presented at the Diabetes Technology Society meeting, Oct. 2004.
Chelikani et al., Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. Am J Physiol. Regul. Integr. Comp. Physiol., 288(6):R1695-706, 2005.
Chemical Abstracts, vol. No. 114(22), Abstract No. 214519x (1990).
Chemicaland21.com. Solvents. Dec. 12, 2008. Available from: <http://web.archive.org/web20081212035748/http://www.chemicalland21.com/info/SOLVENTS.htm.
Chow et al., Particle Engineering for Pulmonary Drug Delivery. Pharmaceutical Research, vol. 24, No. 3, pp. 411-437 (2007).
Clee et al. Nature Genetics 38:688-693, 2006.
Cobble “Initiating and Intensifying Insulin Therapy for Type 2 Diabetes: Why, When, and How.” Am J Ther. Jan. 8, 2009.
Coffey et al. “Valuing heath-related quality of life in diabetes.” Diabetes Care 25:2238, 2002.
Colagiuri et al., Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? Diabetes Care, vol. 25, pp. 1410-1417 (2002).
Combettes and Kargar, C, Newly Approved and Promising Antidiabetic Agents. Therapie, Jul.-Aug. 2007: 62 (4): 293-310.
Coors et al., Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann. Allergy Astha Immunol., 95(6): 593-599 (2005).
Costello et al., “Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism in prostate epithelial cells”, Journ. Biol. Chem. 272(46):28875-28881 (1997).
Cricket TM Single-Use Inhalers [on-line]. MannKind Technologies Website, posted in 2011, [retrieved on Jul. 30, 2012]. Retrieved from the Internet. <URL:mannkindtechnologies,com/DeviceTechnology/CricketSingleUseInhalers.aspx>.
Crosby, J. “Dog Normals”, <http://vetmedicine.about.com/od/diseasesconditionsfaqs/tp/TP—dogfacts.htm>, copyright 2013.
Cruetzfeldt et al. “Glucagonostatic actions and reduction of fasting hyerglycemia by exogenous glucagon-like peptide i(7-36) amide in type 1 diabetic patients.” Diabetes Care 19:580, 1996.
D'Alessio et al., Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J. Clin. Invest., 97:133-38 (1996).
Database adisinsight, “Gucagon-like peptide-1 inhalation-MannKind Corporation”, Database accession No. 2009:1048 Abstract.
Davis “Postprandial Physiology and the Pathogenesis of Type 2 Diabetes Mellitus.” Insulin, vol. 3, Apr. 1, 2008, pp. 132-140.
De Heer et al. “Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide-1.” Diabetes 56:438, 2007.
Deacon “Therapeutic strategies based on glucagon-like peptide 1.” Diabetes. Sep;53(9):2181-9, 2004.
Deacon et al., “Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig”, Am. J. Physiol. 271 (Endocrino. Metab. 34): E458-E464, 1996.
Decode study group. “Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. ” Lancet. Aug. 21, 1999;354(9179):617-21.
DedicatedPhase, “Preclinical Trials and Research”, <http://www.dedicatedphase1.com/preclinical-research.html>, copyright 2006-2011, p. 1.
Definition of analog from http://cancerweb.ncl.ac.uk/omd/about.html, pp. 1-5.
Del Prato S “Unlocking the opportunity of tight glycemic control” Diabetes Obesity and Metabolism 7:S1-S4, 2005.
Delgado-Aros et al. “Effect of GLP-1 on gastric volume, emptying, maximum volume ingested and postprandial symptoms in humans.” Am J Physiol Gastrointest Liver Physiol 282:G424, 2002.
Diabetes: Counting Carbs if You Use Insulin, WedMD, http://diabetes.webmd.com/carbohydrate-counting-for-people-who-use-insulin#m Oct. 1, 2010.
Diez et al. “Inhaled insulin—a new therapeutic option in the treatment of diabetes mellitus” Expert Opin. Pharmacother, 2003, 4, 191-200.
Dorwald, F.A. Side reactions in organic synthesis. Wiley, (2005).
Doyle et al. “Glucagon-like peptide-1.” Recent Prog Horm Res. 2001;56:377-99.
Dreamboat TM Reusable Inhalers [on-line]. MannKind Technologies Website, posted in 2011, Retrieved from the Internet: <URL: mannkindtechnologies.com/Device Technology/Dream Boat Reuseable Inhalers.aspx>.
Drucker “Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.” Curr Pharma Design 7:1399, 2001.
Drucker et al., “The incretin system:glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes”, www.thelancet.com, vol. 368, pp. 1696-1705, Nov. 11, 2006.
Drug Delivery, Easing the drug delivery route, Jun. 2006, Pharmaceutical & Medical Packaging News, Canon Communications.
Dungan et al., Glucagon-like peptide 1-based therapies for type 2 diabetes: a focus on exntadtide. Clinical Diabetes, 23: 56-62 (2005).
Dunn, “Zinc-ligand interactions modulate assembly and stability of the insulin hexamer”, Biometals, 18(4):295-303 (2005).
Edelman “Type II Diabetes Mellitus.” Adv Int Med, 43:449-500, 1998.
Edited by Fukushima, Masanori, “Arterial Sclerosis,” Merck Manual 17th, Japanese Edition, NIKKEI BP Corp., p. 1659-1663, 1999.
Edwards CMB et al. “Cardiovascular and pancreatic endocrine response to glucagon-like peptide-1(7-36) amide in the conscious calf.” Exp Physiol 82:709, 1997.
Edwards CMB et al. “Subcutaneous glucagon-like peptide-1(7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects.” Clinical Science 96:719, 1998.
Edwards et al., Recent advances in pulmonary drug delivery using large, porous inhaled particles. Journal of Applied Physiology, pp. 379-385 (1998).
Eggers et al., Molecular confinement influences protein structure and enhances thermal protein stability. Protein Sci., 10:250-261 (2001).
Ehlers et al. “Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.” Horm Metab Res 35:611, 2003.
Eissele et al., Rat gastric somatostatin and gastrin relase: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide. Life Sci., 55(8):629-634 (1994).
Elliot et al., Parenteral absorption of insulin from the lung in diabetic children. Austr. Paediatr. J. 23: 293-297 (1987).
Elrick et al. “Plasma insulin response to oral and intravenous glucose administration.” J Clin Endocr 24:1076, 1964.
Engelgau MM “Screening for type 2 diabetes.” Diabetes Care 23:1563-1580, 2000.
Engwerda et al., Improved pharmackinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. Diabetes Care, vol. 34, Aug. 2011, pp. 1804-1808.
Erlanger et al., Phosphorous pentoxide as a reagent in peptide synthesis. College of Physicians and Surgeons—Columbia Univeristy, vol. 26, pp. 2534-2536 (1960).
Exubera indications, dosage, storage, stability. Http://www.rxlist.com/cgi/generic4/exubera—ids.htm, 2008.
Exubera package insert, p. 1, 2008.
Fadl et al., Effects of MDI spray angle on aerosol penetration efficiency through an oral airway cast. Journal of Aerosol Science, vol. 38, No. 8, pp. 853-864 (2007).
Falsone et al., The Biginelli dihydropyrimidone synthesis using polyphosphate ester as a mild and efficient cyclocondensation/dehydration reagent. Institute of Chemistry, Organic and Bioorganic Chemistry, Karl-Franzens-University, pp. 122-134 (2001).
Farr, S.J. et al., Pulmonary insulin administration using the AERx®system:physiological and physiochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Tech. Ther. 2:185-197, 2000.
Fehmann et al. “Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide.” Endocrine Reviews 16:390, 1995.
Ferrin et al, Pulmonary retention of ultrafine and tine particles in rats. Am. J. Repir. Cell Mol. Biol., pp. 535-542 (1992).
Festa et al., “LDL particle size in relation to insulin, proinsulin, and insulin sensitivity” Diabetes Care, 22(10):1688-1693 (1999).
Forst et al., “Metabolic Effects of Mealtime Insulin Lispro in Comparison to Glibenclamide in Early Type 2 Diabetes”, Exp. Clin. Endocrinol. Diabetes, 2003, 111, 97-103.
Fritsche et al. “Glimepiride Combined with Morning Insulin Glargine, Bedtime Neutral Protamine Hagedorm Insulin, or Bedtime Insulin Glargine in Patients with Type 2 Diabetes.” American College of Physicians 2003.
Galinsky et al., A synthesis of diketopiperazine's using polyphosphoric acid. Journal of the American Pharmaceutical Association, vol. 46, No. 7, pp. 391-393 (1957).
Garber, “Premixed insulin analogues for the treatment of diabetes mellitus”, Drugs, 66(1):31-49 (2006).
Garg et al. “Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine.” Diabetes Research and Clinical Practice 66 (2004) 49-56.
Garg SK, Kelly W, Freson B, et al. Treat-to-target Technosphere® insulin in patients with type 1 diabetes. ADA 2011; Abstract 941-P.
Garg SK, McGill JB, Rosenstock J, et al. Technosphere® insulin vs insulin lispro in patients with type 1 diabetes using multiple daily injections. ADA, Abstract 917-P (2011).
Gates BJ “Update on advances in alternative insulin therapy.” Advances in Pharmacy 1:159-168, 2003.
Glucagon for Injection (1999) glucagon for injection (rDNA origin), pp. 1-7.
Glucagon-like peptide-1; http://en.wikipedia.org/wiki/Glucagon-like peptide-1 (accessed Apr. 24, 2015).
Glucophage Product Insert. Jan. 2009.
Glucotrol Product Insert. Sep. 2006.
Gnudi L, Lorber D, Rosenstock J, et al. Basal/bolus with prandial inhaled Technosphere® insulin (TI) plus insulin glargine qd vs biaspart 70130 insulin bid in type T2 diabetes mellitus inadequately controlled on insulin with/without oral agents. Diabetologia 2009; 52 (suppl 1).
Goke et al., Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J. Biol. Chem. 268(26):19650-19655 (1993).
Golpon et al. “Vasorelaxant effect of glucagon-like peptide-(7-36) amide and amylin on the pulmonary circulation of the rat.” Regulatory Peptides 102:81, 2001.
Gonzalez et al., Actualizacion del tratamiento farmacologico de la diabetes mellitus tipo 2. Del Sistema Nacional de Salud. Volumen 32, No. 1, pp. 3-16 (2008)—full article in Spanish with English abstract.
Gotfried M, Cassidy JP, Marino MT, et al. Lung deposition and absorption of insulin from Technosphere® insulin. Diabetologia 2009; 52 (suppl 1).
Grant et al “Both insulin sensitivity and maximal glucose elimination rate are reduced in type 2 diabetes.” Presented at the American Diabetes Association 65th Scientific Sessions, Jun. 2005, abstract 2202-PO.
Grant et al. “The distribution of 14C-labeled particles following intra-tracheal liquid installation in the Sprague-Dawley rat.” Presented at the American Diabetes Association 64th Scientific Sessions, Jun. 2004, abstract 461-P.
Grant M, Harris E, Leone-Bay A, Rousseau K. Technosphere®/insulin: Method of action. Diabetes Technology Meeting 2006; Poster.
Grant ML, Greene S, Stowell GW, et al. Mimicking endogenous peptide secretion by inhalation APS 2009; poster.
Greene et al. “Effects of GLP-1 Technosphere(TM) powder: administered by pulmonary insufflation in male obese Zucker diabetic fat (ZDF) rats.” Diabetes Technology Meeting, San Francisco, Oct. 2007.
Greene et al., Greene's protective groups in organic synthesis. 4th ed., pp. 781-783 (2007).
Gupta et al. “Contemporary Approaches in Aerosolized Drug Delivery to the Lung.” J. Controlled Research, 17:129-148, 1991.
Gurrieri et al., Thermal condensation of some alpha-aminoacids with phatalic acid. Thermochimica Acta, 7 (1973) 231-239.
Gutniak et al. “Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes.” J Int Med 250:81, 2001.
Gutniak et al. “Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.” NEJM 326:1316, 1992.
Gutniak et al. “GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.” Diabetes Care 20:1874, 1997.
Gutniak et al. “Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet.” Diabetes Care 19:843, 1996.
Gutniak et al. “Subcutaneious injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.” Diabetes Care 17:1039, 1994.
Guyton et al., “Acute Control of Llocal Blood Flow”, Textbook of Medical Physiology, Chapter 17, 10th Edition, W.B. Saunders Company, pp. 176-177, 2000.
Gyore et al., Thermal Analysis, vol. 2—Proceedding Fourth ICTA Budapest 1974; 387-394.
Haak “New developments in the treatment of type 1 diabetes mellitus.” Exp Clin Endocrinol Diabetes 107:Suppl 3: S108, 1999.
Haffner et al., “Proinsulin and insulin concentrations I relation to carotid wall thickness”, Strock 29:1498-1503 (1998).
Hagedorn et al. “Protamine Insulin”, JAMA, 106:177-180 (1936).
Haino, Takeharu et al. “On-beads Screening of Solid-Attached Diketopiperzines for Calix[5]Arene-Based Receptor.” Tetrahedron Letters, 40(20), 3889-3892, 2003.
Halozyme Press Release. Jun. 6, 2009.
Hanley et al., “Cross-sectional and prospective associations between proinsulin and cardovascular disease risk factors in a population experiencing rapid cultural transition” Diabetes Care 24(7): 1240-1247 (2001).
Harsch IA “Inhaled insulins. Their potential in the treatment of diabetes mellitus.” Traat. Endicrinol 4:131-138, 2005.
Hassan et al. “A Randomized, Controlled Trial Comparing Twice-a-Day Insulin Glargine Mixed with Rapid-Acting Insulin Analogs Versus Standard Neutral Protamine Hagedom (NPH) Therapy in Newly Diagnosed Type 1 Diabetes.” Pediatrics, 121(3), e466-e472, 2008.
Hassan et al. “In vivo dynamic distribution of 131l-glucagon0like peptide-1 (7-36) amide in the rat studied by gamma camera.” Nucl Med Biol 26:413, 1999.
Hausmann et al. “Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof of concept study.” Diabetes Obesity and Metabolism 8:574, 2006.
Hayasaka et al. “Proliferation of type II pneumocytes and alteration in their apical surface membrane antigenicity in pulmonary sarcoidosis.” Chest 116:477, 1999.

Related Publications (1)

	Number	Date	Country
	20150196724 A1	Jul 2015	US

Provisional Applications (1)

	Number	Date	Country
	61257813	Nov 2009	US

Continuations (1)

	Number	Date	Country
Parent	13505729		US
Child	14667539		US

Apparatus and method for simulating inhalation efforts

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

US

CPC

International Classifications

Term Extension

Abstract